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Introduction and  
outline of the thesis
Partly based on:
Prevention, identification and treatment of vulvar squamous (pre)malignancies:  
a review focusing on quality of care
Loes C.G. van den Einden, Irene A. van der Avoort, Joanne A. de Hullu
Expert Review of Anticancer Therapy. 2013;13(7):845–859
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Introduction
Vulvar squamous cell carcinoma, its precursor lesions (usual and differentiated vulvar 
 intraepithelial neoplasia) and lichen sclerosus are rare diseases that may have large impact 
on the lives of affected women and their partners. This introduction provides an overview 
of current knowledge of these vulvar diseases.
1.  Vulvar squamous cell carcinoma
1.1  Epidemiology
Vulvar malignancies are rare with a worldwide yearly incidence of one to two per 100,000 
women.1 In The Netherlands vulvar cancer accounts for 6–8% of all gynaecological 
malignancies and 406 new cases of vulvar cancer were diagnosed in 2011.2 A rise in absolute 
numbers is expected because of aging of the population. Although no population- based 
analyses are available, studies show a tendency towards an increasing incidence of vulvar 
cancer.3-5 Typically, vulvar cancer occurs in the seventh decade. The majority of patients 
with vulvar cancer have a vulvar squamous cell carcinoma (VSCC); only a minority of 
patients suffer from basal cell carcinoma, melanoma or adenocarcinoma.6
1.2  Etiology
There are two different types of VSCCs with their own associated premalignant lesions. 
The majority of VSCCs are human papilloma virus (HPV)- unrelated and the oncogenesis is 
not exactly known. The minority of VSCCs are HPV-related: a meta-analysis7 showed that 
40% of all VSCCs are caused by HPV, but recently our group showed that HPV seems to 
play an etiological role in only 19% of all VSCCs.8 See Figure 1 for an overview of the 
oncogenesis of VSCC and Figure 2 for clinical pictures of HPV and non-HPV related VSCC.
HPV negative pathway
The most common type of VSCC is HPV negative, occurs in elderly women and leads to 
differentiated keratinizing VSCC. Differentiated vulvar intraepithelial neoplasia (dVIN) is 
presumed to be the precursor lesion and often occurs in a background of lichen sclerosus 
(LS).9, 10 LS is a chronic inflammatory skin disease with a lifetime risk of developing a VSCC 
of 4-5%.11 The oncogenesis of LS to VSCC, probably through the development of dVIN, is 
not exactly known. First of all, the aetiology of LS is unknown; based upon epidemiologic 
data, hormonal factors, genetic factors, infectious agents, the Köbner phenomenon and 
autoimmune factors have been suggested to play a role. Up until now, it is considered an 
autoimmune phenomenon, with an association with other autoimmune diseases, like 
hypothyroidism and vitiligo in 21-34% of the patients.12, 13 Squamous cell hyperplasia with 
atypia might represent a step in the carcinogenesis of the LS/dVIN pathway14, but it has 
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cervical (pre)malignancies. It is primarily affecting younger women, and usual vulvar 
 intraepithelial neoplasia (uVIN) is the precursor lesion. In the presence of high-risk HPV, 
the entire ano-genital tract is at risk for the development of premalignant lesions.16 
A higher prevalence of the latter is seen in HIV infected women17 and women after organ 
transplantation.18
1.3  Clinical characteristics
Most patients with VSCC present with a vulvar mass, although there is often a long history 
of pruritis or discomfort. Less common presenting symptoms include vulvar bleeding, 
pain or dysuria. On physical examination an ulcer, a red macule or papule or a white 
hyperkeratotic (warty) plaque can be seen. Clinically it may be difficult to distinguish early 
stage VSCC from VIN. 
1.4  Diagnostics
Biopsy is the gold standard to establish a diagnosis. A punch biopsy can be taken from the 
most suspicious part of the lesion. In case of an erosion or ulcer, the biopsy should be 
taken preferably from the edge of the lesion. When there are multiple lesions, vulvar 
mapping should be performed. A (digital) photo should be taken to note localizations of 
the biopsied areas, and to document changes during follow-up. 
Several studies have tried to explore the role of vulvar cytology as a less invasive 
replacement option for histology or a triage instrument to determine whether a biopsy of 
a clinically (pre)malignant lesion is necessary. This could be of special value in patients 
after treatment of VIN/VSCC with a high risk of recurrence and when vulvar examination is 
difficult because of scarring due to previous vulvectomy. Various techniques for vulvar 
cytology have been described with varying results.19-22 Until now, cytology is not used in 
daily practice.
1.5  Treatment
Over the past years, efforts have been made to individualise treatment of patients with 
VSCC and define subgroups of patients that may be treated by less radical procedures. 
Until 20 years ago radical vulvectomy with ‘en bloc’ bilateral inguinofemoral lymph-
adenectomy (IL) was the standard treatment for almost all patients with VSCC. Currently, 
standard treatment entails a wide local excision (WLE) with uni- or bilateral IL via separate 
incisions. This change in treatment modality has significantly improved the quality of care 
because of its less mutilating effect. Nowadays, radical vulvectomy with en bloc IL is only 
performed in case of advanced nodal involvement. More recently, sentinel lymph node 
(SLN) procedure has been introduced in early stage VSCC23 and has shown excellent 
results with a very high negative predictive value of a negative SLN, and is considered as a 
standard treatment since 2008. Strict criteria (tumour <4 cm, only unifocal lesions) and 
also been shown that LS lesions with atypia that have progressed to VSCC, were in fact 
dVIN lesions.9 
HPV positive pathway
The second type of VSCC is consisting of non-keratinising carcinomas and is caused by 
high-risk HPV, predominantly HPV 16 and 18.15 The oncogenesis is resembling that of 
Figure 1  Schematic representation of the aetiology of vulvar squamous cell carcinoma.
HPV= Human papilloma virus; VIN= Vulvar intraepithelial neoplasia; SCC= Squamous cell carcinoma
Figure 2  Clinical pictures of patients with vulvar squamous cell carcinoma. (A) 43-year-old 
renal transplant recipient (14 years after transplantation) with HPV-related vulvar squamous 
cell carcinoma (SCC). Histology of a biopsy of the commisura posterior showed a vulvar 
SCC with an invasion depth of 1.9 mm. (B) Multifocal SCC in a 47-year-old woman with a 
history of lichen sclerosus.
Normal
High-risk HPV
usual VIN vulvar SCC
Normal
? ?
Dierentiated
VIN vulvar SCC
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Centralisation of treatment
In many developed countries, centralisation of rare tumours such as VSCC is advised to 
increase survival and to decrease treatment-related morbidity. There is only scarce literature 
concerning centralisation of care for women with VSCC. It is believed there is a role for 
centralisation of the treatment of VSCC, because of the low incidence, the high complex 
surgery and the introduction of new techniques such as SLN procedure where learning 
curves are important. Therefore, centralising treatment has been advocated by the 
national guidelines of the Dutch Society of Obstetrics and Gynaecology in 2000. However, 
it remains to be proven if this policy indeed improves outcome with respect to prognosis 
and morbidity of patients. 
1.6  Prognosis
Inguinofemoral lymph node status at initial diagnosis is of critical prognostic importance 
for patients with VSCC.28 Overall 5-year survival in VSCC is around 70%29 and decreases by 
the number of positive lymph nodes and/or FIGO stage. More recent studies on prognosis 
in VSCC suggest that uVIN-related VSCC has a more favourable prognosis compared 
with dVIN/LS related HPV-negative vulvar cancer,8 although other studies on HPV as a 
prognostic factor have not been able to demonstrate a difference between the two 
pathways.30 
2.  LS and squamous premalignancies - nomenclature
Various terms have been used to define VSCC precursors. For a long time, VIN lesions were 
graded similar to CIN: VIN1, VIN2 and VIN3. In 2004, the International Society for the Study 
of Vulvovaginal Disease (ISSVD) decided to abolish the 3-grade system of VIN because 
clinicopathological data did not appear to support the concept of a continuous spectrum 
that we know from CIN and cervical carcinoma.31, 32 The abandonment of VIN1 and the 
consolidation of VIN2 and VIN3 into one category simply termed (high-grade) VIN, best 
fitted the studies that have been performed on grading of VIN so far.31 In the light of the 
two different types of VSCC the ISSVD clearly distinguishes: VIN usual type and VIN 
differentiated type.31, 33 uVIN can be subclassified into basaloid and warty subtypes, and 
cases with mixed features are common. In clinical practice, no difference is made between 
the two types of uVIN. Recently, the College of American Pathologists and American 
Society for Colposcopy and Cervical Pathology suggested a two-tier classification for all 
HPV related squamous lesions of the anogenital tract: low-grade squamous intraepithelial 
lesions and high-grade intraepithelial lesions, paralleling the terminology of the Bethesda 
System cytological reports.34 So far, no further classification for dVIN is suggested. 
enough experience of the multidisciplinary team (gynaecologic oncologist, nuclear 
physician and pathologist) are necessary to safely perform SLN procedures. Patients 
should be informed about the low risk of missing a positive SLN and patients are preferably 
treated within the protection of a clinical study such as GROINSS-V-II24 under strict protocol 
and follow-up.25 Women with a multifocal tumour or tumour >4 cm should undergo an IL. 
In case of microinvasive tumours (≤1 mm invasion and a maximum diameter of 2 cm, Table 1), 
patients are treated with a WLE only and treatment of the groins can be safely omitted26 
because only <1% of these superficially invasive VSCCs metastasise to the groins.27
In case of more than one intranodal metastasis and/or extranodal growth, postoperative 
radiotherapy on the pelvis is recommended. In case of close or positive margins, local 
reexcision or follow-up is advised. In these cases also adjuvant radiotherapy may be 
considered, although criteria for the application are not clearly defined because of a lack 
of robust evidence. 
Table 1  FIGO classification of VSCC (2009).
Stage I
Confined to the vulva or perineum; no nodal metastasis
A Lesions ≤ 2 cm in size with stromal invasion ≤ 1 mm*
B Lesions > 2 cm in size or stromal invasion > 1 mm*
Stage II
Adjacent spread to the lower urethra, the vagina, or the anus, no nodal metastasis
Stage III
Tumour confined to vulva or adjacent spread to the lower urethra, the vagina, 
or the anus and positive inguino femoral lymph nodes
A One lymph node metastasis ≥ 5mm or 1-2 lymph node metastases < 5 mm
B Three or more lymph nodes < 5mm or 2 or more lymph nodes ≥ 5mm
C Lymph nodes with extracapsular spread
Stage IV
A Tumour with fixed or ulcerated lymph nodes or tumour with spread into upper 
urethra/vagina, bladder, rectal mucosa, bone or fixed to pelvic bone
B Any distant metastasis, including pelvic lymph nodes
*  The depth of invasion is defined as the measurement of the tumour from the epithelial-stromal junction 
of the adjacent most superficial dermal papilla to the deepest point of invasion
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3.3  Histology
LS can be recognised by a thinned epidermis with loss of normal rete ridges, hyperkeratosis 
and basal layer vacuolor changes (Figure 4A). Furthermore, a wide band of homogenised 
collagen below the dermo-epidermal junction and a band-like lymphocytic infiltrate 
below the homogenised area are present. The dermis can show oedema or hyalinization 
and sometimes bullae are present.37
3.  Lichen sclerosus
3.1  Epidemiology
The true incidence of LS is unknown and difficult to establish as different specialists are 
providing care for LS patients. No recent studies of the incidence of LS in the general 
population are available. In 1971, Wallace calculated incidences of 1:300 to 1:1000 in new 
patients, referred to a general hospital.35 The rate of biopsy proven vulvar LS in one general 
gynaecology private practice was approximately 1.7% (one in 60 women).36 LS is diagnosed 
at different ages and has a bimodal peak incidence in prepubertal girls (5–15%) and 
women aged 50–70 years.36 
3.2  Clinical characteristics
Typically, the lesions are white plaques and papules, often with areas of erythema, ecchymosis, 
hyperkeratosis, pallor, fissuring, telangiectasia, hyperpigmentation, bullae, excoriation, oedema 
and/or ulceration. The clinical appearance can vary from subtle (Figure 3A) to advanced 
(Figure 3B). Presenting symptoms of LS may include intense pruritus, soreness, pain, burning, 
dyspareunia, dryness, irritation, urinary complaints, constipation/bowel pain, bleeding and 
blistering. Painful skin fissures can occur with or after sexual intercourse and defecation.
Figure 3  Clinical pictures of patients with lichen sclerosus. (A) Lichen sclerosus in a woman 
showing subtle loss of architecture and white plaques on the labia minora. (B) Advanced 
lichen sclerosus in a postmenopausal woman, showing loss of architecture, erythema, 
hyperkeratosis, fissuring and ulceration.
Figure 4  Histological pictures of lichen sclerosus, differentiated vulvar intraepithelial 
neoplasia and usual vulvar intraepithelial neoplasia. (A) Lichen sclerosus with loss of rete 
ridges, hyperkeratosis and a hyalinised zone of oedema beneath the basement membrane 
with a band-like infiltrate of lymphocytes (magnification ×50). (B) Differentiated vulvar 
 intraepithelial neoplasia (dVIN), characterised by a thickened epithelium associated with 
elongation and anastomosis of rete ridges, dyskeratosis and parakeratosis. There is 
formation of keratin pearls. The most superficial layers show normal maturation without 
atypical cells (magnification ×50). (C) Detail of dVIN in which the nuclei have prominent 
nucleoli (predominantly in the (para)basal keratinocytes). Atypical mitotic figures (arrow) 
are seen mainly in the lower layers (magnification ×200). (D) Usual VIN with hyper- and 
parakeratosis and atypia throughout the entire epithelium.
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4.  Differentiated VIN
4.1  Epidemiology
dVIN accounts for a small proportion (<2–5%) of all VIN lesions.32, 50 Because of the difficult 
clinical and histological diagnosis, it is probably considerably underdiagnosed. In a retro -
spective study by van de Nieuwenhof et al, it was shown that after histopathologic revision of 
LS lesions that progressed to VSCC, 42% were reclassified as dVIN.9 dVIN characteristically 
occurs in postmenopausal women and is associated with LS. As dVIN is seldom found in 
an isolated form, some authors believe it is actually part of the adjacent VSCC.49 
4.2  Clinical characteristics
dVIN can present as an area of grey-white discoloration with a roughened surface, an 
ulcerative red lesion, an erythematous red lesion, or as an ill-defined raised white plaque 
(Figure 5A & B). It may be difficult to distinguish dVIN from LS.10 Patients are, due to the 
underlying LS, often symptomatic with a long-lasting history of itching and other LS- 
related symptoms.10 
4.3  Histology
The histological diagnoses of dVIN is difficult as atypia is only confined to the basal 
epidermal cell layers. Therefore it is often confused with squamous hyperplasia or lichen 
sclerosus,9 though no data on reproducibility of the diagnosis exist. dVIN is characterised 
by a thickened epithelium that is typically associated with parakeratosis, dyskeratosis and 
elongation and anastomosis of rete ridges (Figure 4B and 4C).51 Dyskeratosis is characterised 
by disturbed maturation and premature keratinisation of squamous cells that are located 
deeper in the epithelium. In the parabasal layers of the epithelium, individual and clusters 
of cells show premature maturation, with large cells that show eosinophilia of the 
cytoplasm and even formation of keratin pearls. The nuclei have prominent nucleoli, 
usually predominantly in the (para)basal keratinocytes. Atypical mitotic figures may be 
seen mainly in the lower layers. The most superficial layers show normal maturation 
without atypical cells. 
4.4  Treatment
dVIN is treated by surgical excision preferably with a few millimetre margins of healthy 
tissue. dVIN lesions are usually confined to nonhair-bearing areas or the external sides of 
atrophic labia minora. Recurrent lesions are common and so far, there is no place for 
medical therapy.32
3.4  Treatment
In general, LS has no cure and follow-up is required to treat symptomatic flare-ups of the 
disease and possibly diminish anatomical changes. In some cases, especially prepubertal 
girls, spontaneous resolvement of LS has been described.38 It is not known whether 
successful control of the disease reduces the long-term risk of malignancy, although a 
protective effect from malignant evolution has been suggested.39, 40 The symptomatic 
treatment with the best evidence of efficacy is the use of topical potent corticosteroid 
ointments. Corticosteroids have anti-inflammatory, antipruritic and vasoconstrictive 
effects. Various studies show good clinical response and even histological improvement 
with the use of these drugs. British Association of Dermatologists guidelines advocate 
their use, and give specific guidance on length of initial treatment and on maintenance 
treatment. 41 There is no convincing evidence that corticosteroid treatment of LS influences 
its prognosis. Maintenance therapy is often advised, as symptoms can recur in women 
who terminate therapy.39 
3.5  Malignant potential
There are different reasons to link LS to the development of VSCC.42 First, the majority of 
VSCCs has LS, squamous cell hyperplasia or dVIN in the adjacent epithelium.43, 44 Second, 
in series of LS patients that underwent long-time follow-up, 4.5% has been reported to 
develop VSCC.11 Until now, it is not clear which LS patients are at risk of developing dVIN 
and eventually SCC. In a retrospective case review, Jones. compared clinical parameters of 
46 women with LS and VSCC with 213 women with LS but without VSCC.45 The women 
with VSCC were significantly older, had significantly more hyperplastic skin changes and 
showed squamous hyperplasia and cellular atypia more often. There were no differences 
in the presence and duration of symptoms or loss of vulvar architecture. Although the 
term ‘leukoplakia’ was rejected by the ISSVD because of inconsistency of clinical and 
histological features, several studies described leukoplakia in preceding 60–100% of the 
cases with vulvar cancer.35, 46 Therefore, areas of LS that become thickened and do not 
respond to frequent application of topical steroids should be biopsied in order to exclude 
malignancy. Several studies have tried to find molecular markers in LS, which are an 
indication of a higher risk of developing SCC. High expression of or mutations in the 
tumour suppressor genes p53 has been postulated as a marker for increased likelihood in 
LS to progress to VSCC,47, 48 but has also been attributed to ischemic stress.49 Furthermore, 
parakeratosis, dyskeratosis, hyperplasia and basal cellular atypia are significantly more 
often seen in patients with LS that progressed to VSCC compared with LS without 
progression.9 Interestingly, these are all characteristics of dVIN, but in the days of most 
studies, dVIN was not regarded as a separate entity. Finally, little is known about the 
genetic alterations found in LS with and without progression into dVIN and finally SCC, 
these might act as markers for progression in patients with LS.
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5.  Usual VIN
5.1  Epidemiology
The incidence of uVIN is approximately five per 100,000 women per year and is increasing 
worldwide.4 It is more common in young women, often between the age of 30 and 40 
years. Risk factors are smoking and an immune compromised state. A reason for a recently 
described increased incidence in uVIN might be the more liberal use of vulvar biopsy, 
which contributed to earlier diagnosis of uVIN lesions that might have been missed in the 
past. The malignant progression in patients who have been treated for uVIN is estimated 
to be <5%, so only a limited number of uVIN lesions progress to invasive VSCC.54
5.2  Clinical characteristics
UVIN lesions can have a variety of clinical appearances. They often produce large whitish 
or erythematous plaques, while some lesions are pigmented (Figure 5C and 5D). The most 
frequently affected sites are the labia majora, the labia minora and posterior fourchette, 
but the entire vulva can be affected with >40% multifocal Involvement.55 Multicentric intra-
epithelial or invasive squamous neoplasia (of the cervix, vagina or anus) is also common, 
occurring in approximately 35% of the uVIN patients.16 Therefore a cervical smear and 
careful inspection of the entire anogenital area should always be performed, also when 
patients are not in a cervical screening program because of their age. The most common 
presenting complaint of uVIN is pruritus, present in about 60% of the patients. Other 
presenting symptoms can be pain, ulceration and dysuria. Approximately a fifth of the 
patients have no specific complaints, apart from the finding of an abnormal vulvar area 
by (self) examination.
5.3  Histology
In uVIN the epidermis is thickened and contains atypical cells from the basal membrane 
up to the surface (Figure 4D). Acanthose, dyskeratosis, hyper- and parakeratosis, a high 
nuclear-to-cytoplasmic ratio and koilocytes may be present.51
5.4  Treatment
There are several options for treatment of uVIN like cold knife surgery, laser surgery/
vaporization and the use of imiquimod (Aldara®). In the past, extensive surgery has been 
performed for uVIN. Nowadays, local excision, consisting of removal of all visible lesions, is 
the surgical technique of choice,56 especially since studies have shown that surgical 
margins are no predictor for the risk of invasive disease. Surgery can be performed either 
by cold knife or laser. Before treatment with laser vaporization, invasive disease must have 
been excluded. 
4.5  Malignant potential
It is suggested that dVIN is highly proliferative and therefore more likely to progress to 
an invasive VSCC than LS and uVIN.10, 52 The observation that most VSCCs are dVIN-related 
and most VIN lesions without concurrent invasion are of the usual type, combined 
with the frequent finding of dVIN adjacent to rapidly growing invasive VSCC, reinforces 
this presumption.10, 53 The median time of progression from a biopsy proven dVIN to VSCC 
is significantly shorter than the time of progression from LS to VSCC. It was shown in an 
observational retrospective study, that the overall percentage of dVIN patients later 
diagnosed with VSCC was 32.8%.9
Figure 5  Clinical pictures of patients with vulvar intraepithelial neoplasia. (A) Patient with 
differentiated vulvar intraepithelial neoplasia (dVIN) in the background of lichen sclerosus: 
on the left labium minora two red and erosive lesions can be seen. (B) Patient with dVIN 
in the background of lichen sclerosus, on the left labium minora a hyperkeratotic plaque 
can be seen, histopathologically confirmed as being dVIN. (C) Patient with multifocal 
usual vulvar intraepithelial neoplasia. (D) Detail of the patient with usual vulvar intra-
epithelial neoplasia.
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study of Vandborg et al, in which they looked for reasons for diagnostic delay in different 
gynaecological malignancies, showed that vulvar cancer had the longest delay of 170 
days, mainly caused by patient delay.68 Furthermore, a GP will only see a few patients with 
vulvar LS and very few patients with VIN/VSCC during his/her carrier which may also cause 
delay in diagnosis. Besides, these conditions are not or only little addressed during their 
medical (specialist) training. Nunns and Mandal. showed that only 56% of the GPs they 
questioned carried out genital examinations on patients with recurrent vulvar symptoms 
in their daily practice, because of lack of time or at the patients’ request.69 As a consequence, 
only 59% of patients with recurrent symptoms were investigated prior to treatment. 
Therefore, it is desirable to perform a gynaecological examination in all women with vulvar 
complaints. 
6.3  Self examination
Because of the increased risk of developing a (pre)malignancy in patients with LS and 
uVIN, instructions should be given for self-examination. When there are signs of a VSCC 
(nonhealing erosions, development of tumour(s) or ulcers, itching that changes towards 
pain), a patient should consult her doctor.70 It can be helpful to explain the signs of a VSCC 
to the patient by using a mirror, so patients can get familiar with their own anatomy and 
colour of their skin.
6.4  A multidisciplinary approach
Multidisciplinary vulvar clinics in which specialist expertise is combined are of great value71 
and are operating in many European countries and the USA. A specialist is defined as a 
consultant dermatologist and/or gynaecologist who has had additional specialised 
training in managing vulvar disease.72 Furthermore, there is an important role for 
supporting specialists. Collaboration with a sexologist and pelvic floor physiotherapist is 
vital. Also, there is a need for a trained (gynaeco-)pathologist as the diagnosis of dVIN in LS 
patients is often difficult to establish. 
6.5  Vaccination
Prophylactic
HPV vaccines have been introduced from 2007 onwards with the main goal to reduce the 
incidence of cervical (pre)malignancies and further to reduce the incidence of other 
HPV-related lesions like genital warts, oropharyngeal, anal, vaginal and vulvar (pre)
malignancies. Two prophylactic vaccines have been introduced (a quadrivalent vaccine 
against HPV 6, 11, 16 and 18 and a bivalent vaccine against HPV 16 and 18). As a result of 
the prophylactic vaccins, the estimated reduction of VSCC is 20%8 of all patients, while in 
patients with VIN the reduction will be larger, as the large majority is HPV-related. 
Imiquimod (Aldara, 3M Pharmaceuticals, MN, USA), an imidazoquinoline amine, is classified 
as an immune response modifier. It is widely used in the treatment of genital warts with 
proven efficacy in terms of clearance of the lesions, and a lower recurrence rate compared 
with conventional surgical treatments.57 By inhibiting viral replication, imiquimod directly 
treats the cause of uVIN and preserves the anatomy and function of the vulva.58 Several 
studies evaluated the effect of imiquimod on uVIN. Responses were reached after 6–30 
weeks of treatment.58 Follow-up of patients treated with imiquimod is still relatively short; 
long-term effects cannot yet be established. The results of imiquimod are promising, 
especially in smaller lesions59 but large randomized controlled trials are needed to obtain 
data on the long-term effects60 and to compare with other treatment modalities like 
surgery in small lesions. Considering the side effects of imiquimod, its use should be 
restricted to motivated patients. 
5.5  Malignant potential and risk of recurrence
Recurrence rates of uVIN lesions, even after extensive surgical procedures, are common. 
A number of studies have reported the influence of surgical margins status on recurrence 
rates. Surgical margins are often positive, irrespective of the type of operation performed32 
and the evidence whether free surgical margins prevent recurrence is lacking,61, 62 although 
a recent study showed recurrence was associated with positive margins. Furthermore, 
high rates of recurrences were found to be associated with smoking. The chance of 
malignant progression in uVIN has long been debated. The rate of invasion after various 
primary treatments ranges from 3.3 to 5.7%, as shown in three large studies.50, 61, 62 
Untreated patients have a significantly higher risk of malignant progression.61, 62 
6.  Impact, prevention and identification
6.1  Impact of vulvar LS and (pre)malignancies 
In general, both LS as well as VIN/VSCC are often long-term conditions causing significant 
morbidity and psychological distress. Many women feel embarrassed and have sexual 
problems. Patients may feel uncomfortable with their complaints and the disfiguring 
changes that may occur, which might result in avoiding sexual intimacy. Studies show that 
the majority of patients report an impact on Quality of live (QoL), especially with sexual 
functioning which causes significant sexual distress.63-66 
6.2  Diagnostic delay
In patients with LS, there was found to be a self-reported diagnostic delay (age at first 
symptoms compared with age at diagnosis) of 4.9 years.67 Furthermore, in these patients 
the number of symptoms was higher in the group with a worse QoL, which suggests that 
resolving one or more symptoms by treating the patient, leads to a better QoL. The cohort 
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role of dVIN as a precursor lesion. Although earlier studies provided some evidence that 
dVIN is the true precursor lesion of HPV-negative VSCC, studying the genetic profile may 
increase the evidence. Therefore, in chapter 2 we studied the corresponding genetic 
alterations that can be found in dVIN and VSCC with the use of a molecular inversion 
probe single-nucleotide polymorphism assay. 
Second, the (histopathological) identification of dVIN lesions is difficult due to a lack of 
knowledge and criteria. In order to optimise the identification of VSCC and its premalig-
nancies, we investigated the possibility of improving the methods of diagnosing lesions. 
In chapter 3 we examined the role of cytology as a triage instrument that may determine 
whether subsequent biopsy is necessary. In chapter 4 we evaluated the reproducibility 
of diagnosing dVIN by pathologists and investigated the possible improvement of the 
reproducibility after providing guidelines with criteria for recognition of dVIN. Finally, 
in order to find the most optimal method of measuring the depth of invasion in relation 
to the individual outcome in patients with VSCC, we compared the current and an 
alternative measuring method in chapter 5. 
Third, VSCC is a rare tumour and centralisation of care in oncology centres is advised. 
Furthermore, the treatment has become less radical. In order to evaluate the effect of 
these treatment changes and implementation of the advice to centralise care of women 
with VSCC, two large population-based studies in the Netherlands were performed. 
In chapter 6 we determined whether the advice to centralise has been adapted and has 
led to improved survival in the Eastern part of the Netherlands. In chapter 7 trends of 
incidence and survival of women with VSCC in the Netherlands are described.
In chapter 8, we propose hypotheses and future studies based on the results of the 
abovementioned research, to gain future insight in the development of HPV-negative 
VSCC and to further improve care for women with vulvar squamous (pre)malignancies.
Joura et al. showed that the quadrivalent vaccine was effective in preventing high-grade 
vaginal and vulvar lesions associated with HPV16 or HPV18 in women who were naive to 
these types before vaccination.73 Furthermore, they showed74 a 46% reduction of recurrent 
HPV-related disease after undergoing cervical surgery in women after vaccination compared 
with placebo. Looking more in detail to patients with vulvar and vaginal disease, only a 
significant reduction of CIN grade I or worse could be found but not of the incidence of 
recurrent vulvar or vaginal intraepithelial neoplasia grade II or worse (possibly due to lack 
of power).
Therapeutic
Besides the prophylactic use of the HPV vaccine, there might be a role for a therapeutic 
use in uVIN and SCC in the future. Current data show that HPV vaccination does not reduce 
progression to cervical precancers in women with ongoing infections at the time of 
vaccination.75 Therefore, it has been evaluated whether there is an effect of vaccination on 
the incidence of recurrent disease in women who underwent treatment for cervical, 
vulvar or vaginal diseases. Kenter et al showed that vaccination with synthetic long-peptide 
against the HPV-16 oncoproteins E6 and E7 is effective over a period of 12–24 months for 
the treatment of women with HPV-16-positive VIN.76 Fifteen out of 19 patients had a 
clinical response, nine out of 19 patients (47%) showed a complete response at 12 months 
follow-up and two patients developed an (micro) invasive carcinoma. Until now, the role 
of the therapeutic vaccination is promising but only experimental and needs to be further 
investigated.
Outline of the thesis
Proper identification of VSCC, its precursor lesions (uVIN and dVIN) and LS is vital, but 
diagnosing these lesions is sometimes difficult because of their rarity and variety of 
symptoms. In recent decades, progress has been made in order to improve care for 
patients with vulvar squamous (pre)malignancies; more insight has been gained in the 
oncogenesis of VSCC and the treatment of VSCC has become less radical and more 
individualised. 
Still, there are some important issues that need to be addressed in order to improve care for 
patients with vulvar squamous (pre)malignancies. In this thesis we will address some of 
these issues.
First, the mechanism behind the oncogenesis of HPV-negative VSCC, with special focus 
on the role of dVIN, remains to be unravelled. This might eventually lead to new treatment 
options or risk prediction. As dVIN is rarely found as a solitary lesion, some question the 
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Genome-wide copy number analysis 
suggests a clonal relationship 
between differentiated  
vulvar intraepithelial neoplasia and 
papillomavirus-negative vulvar 
squamous cell carcinoma
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Abstract 
Objective
Differentiated vulvar intraepithelial neoplasia (dVIN) is assumed to be the precursor lesion of 
vulvar squamous cell carcinoma (VSCC), but genetic evidence is currently lacking. To study 
the genetic relationship between dVIN and VSCC, we compared the copy number 
abnormalities between paired dVIN and VSCC lesions. 
Methods
Specimen of six patients with dVIN and VSCC were included in this study. High- resolution 
genome-wide copy number analysis was performed using a molecular inversion probe single- 
nucleotide polymorphism array on isolated DNA.
Results
Copy number alterations (CNA) were identified in all six VSCC samples, including loss of 
8p (present in all cases), gain of 8q (present in 5/6 VSCCs), gain of 7p and loss of 18q (present 
in 4/6 VSCCs). On average, we found 6 gains and 9 losses per VSCC sample. Copy number 
profiles of three dVIN lesions passed quality thresholds, and CNAs were identified in one dVIN 
lesion. In these patients at least three out of the 33 CNAs identified in the VSCC sample were 
also detected in the paired dVIN sample, including a high-level amplification on chromosome 
11q23. These findings suggest that the two lesions originate from a single precursor in 
which additional alterations may have resulted in the development of VSCC. 
Conclusion
Our study revealed several candidate genes and genomic regions that may be associated 
with VSCC pathogenesis. We have found the first genetic evidence for the clonal 
relationship between dVIN and VSCC in one patient, which supports the hypothesis VSCC 
can originate from dVIN precursor lesion. 
Introduction
Vulvar cancer is the fourth most common cancer affecting the female genital tract and 
has an incidence of 1-2/100.000 women per year.1 The median age of diagnosis is 70 years and, 
due to the ageing of the Western population, the incidence is increasing.2 Approximately 
80% of all vulvar cancers are of squamous origin and can develop following two different 
pathways.3, 4 The minority of vulvar squamous cell carcinomas (VSCCs) is caused by a 
persistent infection with high-risk human papillomavirus (HPV); its oncogenesis resembles 
the development of cervical cancer. The oncogenesis of the most common VSCC is still 
unclear. These HPV-negative tumours arise in a background of the chronic inflammatory 
vulvar skin disease Lichen Sclerosus (LS) and/or the premalignancy differentiated vulvar 
intraepithelial neoplasia (dVIN). The exact role of LS and dVIN in the development of VSCC 
is not yet known, but patients with LS have a lifetime risk of 4-5% to develop VSCC.5 
In one of our earlier studies we showed that of all VIN lesions diagnosed in the Netherlands 
between 1992 and 2005, only a minority were dVIN in comparison to the HPV induced 
usual VIN. Furthermore, dVIN is rarely found as a solitary lesion.1 Interestingly, in VSCC 
about 80% of the cases is HPV unrelated.6, 7 This discrepancy can be explained by dVIN 
being a difficult clinical and histopathological diagnosis8 and the assumed short intra-
epithelial phase which suggests that dVIN is possibly suffering from underdiagnosis.9 On 
the other hand, it has been hypothesised that dVIN is a border phenomenon of VSCC.10 
Though the carcinogenesis has not been fully clarified, there are strong indications that 
dVIN is a precursor lesion; in recent years the incidence of solitary dVIN is increasing1 and 
dVIN is more often found in revised biopsies previously diagnosed as LS in patients that 
later developed VSCC.9 
The upcoming techniques to search for genetic changes are promising to provide more 
information on the aetiology of (pre)malignant vulvar lesions. However, the literature on 
this topic is limited. In theory, tumours arise from a multistep process of accumulated 
genetic alterations.11 The identification of chromosomal regions most frequently affected 
by copy number alterations (CNA) may be relevant for determining the relationship 
between dVIN and VSCC. We hypothesise that dVIN is a precursor lesion already showing 
early neoplastic alterations which are also present in VSCC together with other accumulating 
events. In order to provide information on the mutations that can be found in VSCC and 
to provide more evidence for a clonal relation between dVIN and VSCC, we aimed to 
determine the genetic abnormalities that can be found in VSCC en dVIN tissues in the 
same patients with the use of single-nucleotide polymorphism-based copy number 
analysis.
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and B-allele frequency plots. To allow comparison of VSCC copy number profiles with 
those of the dVIN samples, which were of poorer quality, we performed smoothening of 
the dVIN probe intensity values using a 15x running smoothing of the median (R package). 
Copy number plots of VSCC and smoothened dVIN data per chromosome were made 
using GenomeGraphs library 1.28.015.
Results
Patient samples
In total 12 samples of 6 patients (6 VSCC, 6 dVIN) were hybridised to Oncoscan arrays. The 
median age of the patients was 52 years (range 47-83), four of six patients (67%) had a FIGO 
stage IB VSCC and two of six patients (33%) had a FIGO stage III VSCC (Table 1). Nine of the 
12 samples generated copy number profiles that passed quality control and could be 
further analysed, including all six VSCC samples and three dVIN samples, although the 
latter three were of poorer quality and showed higher levels of noise. 
Chromosomal alterations in VSCC
An overview of the distribution and number of gains and losses per patient per sample are 
displayed in Figure 1 and Table 2. In VSCCs we identified a total of 94 copy number 
alterations (Table 2 and supplementary Table S1). These alterations consisted of 55 losses 
and 39 gains, including 7 high-level amplifications. Overall, eleven genomic regions were 
affected by CNAs in three or more tumours (supplementary Table S2). The most frequently 
Patients and methods
Tissue samples
Six patients with a primary VSCC who were surgically treated in the Radboud university 
medical centre Nijmegen, the Netherlands, between 2008 and 2010 were included in this 
study. Inclusion criteria were: a history of LS, presence of dVIN in the slides after surgical 
excision and no previous treatment with radiotherapy or chemotherapy. Clinical data of 
these patients including age and stage were retrieved. 
Microdissection and DNA extraction
The haematoxylin & eosin stained slides of the surgical excision specimen were reviewed 
by a gynaecopathologist (HB); areas with dVIN and VSCC were identified. Formalin-fixed 
paraffin-embedded (FFPE) blocks were retrieved and re-cut at 5 µm. The last re-cut slide 
was H&E stained and compared with the original slide in order to confirm that the lesion 
was still present. Tumour cells were collected through removal of VSCC and dVIN tissue 
by scraping with a clean scalpel from several unstained slide sections. DNA was isolated 
with TET-lysis buffer (10 mmol/L Tris-HCl, pH 8.5; 1 mmol/L EDTA, pH 8; 0.1% Tween-20) 
containing 5% Chelex-100 (Bio-Rad, Hercules, CA). Protein digestion was performed by 
adding 20 µL of proteinase K to each sample following incubation at 56°C for 48 hours. 
Fresh proteinase K of 10 µL was added after 24 hours. Next, DNA was denatured by heat 
inactivation at 95°C for ten minutes. The samples were centrifuged for ten minutes at 
14.000 rpm (RT) and measured by Picogreen measurements (Invitrogen, Carlsbad, CA, 
USA).
Copy number profiling
Genome-wide copy number profiling was performed using FFPE-compatible Affymetrix 
Oncoscan arrays OncoScan FFPE Express v.2 (Affymetrix, Santa Clara, CA, USA), according 
to the protocol provided by the manufacturer.12-14 The data that passed quality control 
(MAPD value ≤ 0.6) were then analysed using Nexus Copy Number software Edition 7 
(Biodiscovery, El Segundo, CA, USA) with NCBI build 37 of the human genome. The 
SNP-FASST2 Segmentation Algorithm was used. The significance threshold was set at 
5.0E-7 with a minimum of 250 probes and a maximum contiguous spacing of 1000 kb to 
define a segment. Copy number gains and losses were set to 0.3 and -0.3, respectively. 
High-level amplifications and homozygous losses indicating greater than a single copy 
number change were set at 1.2 and -1.2 respectively. The homozygous frequency 
threshold was set at 0.85 and the homozygous value threshold was set at 0.8 with a 
minimum loss of heterozygosity (LOH) requirement of 500 kb. The heterozygous 
imbalance threshold was set at 0.4. Allelic imbalance and LOH was only scored when 
larger than 15 Mb, and adjacent sequential calls of allelic imbalance and LOH were merged 
as one region of uniparental disomy (UPD) upon visual inspection of the copy number 
Table 1  Patient demographics and clinical characteristics.
Patient Age FIGO stage Samples# Differentiation tumour
1 83 IB 01VSCC
01dVIN
Poor
2 81 IB 02VSCC Well 
3 54 III 03VSCC
03dVIN
Moderate
4 57 III 04VSCC Moderate
5 50 IB 05VSCC Well
6 47 IB 06VSCC
06dVIN
Well
FIGO stage: stage of tumour classified by the FIGO classification 2009. #The VSCC and dVIN lesion of each 
patient was collected at the same point of time.
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found alteration was loss of chromosome 8p, present in all tumours, followed by gain of 
chromosome 8q in five of six tumours, gain of chromosome 7p and loss of chromosome 
18q, both present in four of six tumours (Figure 1 and supplementary Table S2). Seven high- 
level amplifications were seen in three of six VSCCs (Table 3). Five of these encompassed 
large genomic regions (37-45 Mb), affecting many genes. The others were 1-8 Mb in size 
and contained known oncogenes including EGFR (7p21.1), FGFR1 (8p11.23), IL11-RA (9p13), 
and YAP1 (11q22.1). Furthermore, 12 regions of allelic imbalance were identified representing 
copy neutral homozygosity. These regions are known as acquired uniparental disomy 
(aUPD), and frequently contain mutations in tumour suppressor genes that have become 
homozygous as a result of mitotic recombination. The regions were not completely 
homozygous, suggesting it to be present in a subset of the tumour (supplementary Table S3). 
Chromosome 17p encompassing, among other genes, the tumour suppressor gene TP53, 
was affected by aUPD in three samples (supplementary Table S3). 
Clonal relationship between VSCC and dVIN
Next we analysed whether the chromosomal abnormalities detected in VSCC could 
already be detected in the paired dVIN samples. Three dVIN samples from patients 1, 3, 
and 6, passed quality control and could be further analysed. Due to the limited quality 
compared to VSCC, we first applied smoothing of the samples before detecting copy 
number alterations. Whereas the dVIN samples of patients 1 and 6 did not show any copy 
number alterations, three CNAs could be detected in the dVIN sample of patient 3. This 
Table 2   Overview of gains, losses and aUPD per patient per sample vulvar squamous 
cell carcinoma.
Patient Total 
CNAs
Gains1 Losses High-level 
amplifications
aUPD
1 21 11 10 2 2 (10p, 17p)
2 17 9 8 3 2 (5, 12q)
3 33 7 26 2 2 (11q, 17p)
4 9 4 5 0 4 (3q, 6p, 9p, 9q)
5 13 8 5 0 2 (13q, 17p)
6 1 0 1 0 -
Total 94 39 55 7 12
Average 15.7 6.5 9.2 1.2 2
1 including high-level amplifications. Abbreviations: CNA= Copy number alteration. aUPD= acquired uniparental 
disomy.
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patient was a 54-year old female with a unifocal lesion of 2.5 cm on the left labium minus 
localised 1.5 cm left from the clitoris. Histopathological examination showed that the dVIN 
was located in the immediate surroundings of a moderately differentiated VSCC with 
presence of lymphovascular invasion, an invasion depth of 9.5 mm and a sentinel node 
with some tumour cells (Figure 2). The copy number abnormalities in dVIN involved an 
amplification of 11q22 and a deletion at the telomeric region of 12q. Furthermore, 
chromosome 14 showed a higher median probe level, suggesting a gain of this entire 
chromosome. All three copy number alterations were also detected in the VSCC sample 
(Table 1 and Supplementary Table S1). Direct comparison between the dVIN and VSCC 
showed that these lesions were very similar, suggesting that they are indeed preserved 
from VSCC (Figure 3A-C). Importantly, the other copy number alterations detected in VSCC 
(five gains and 25 deletions) could not be detected in the dVIN sample. This could be 
partly due to the poorer quality of the dVIN copy number data, hampering the detection 
of low-intensity copy number changes. However, chromosome 8 in the dVIN sample also 
showed no signs of copy number abnormalities, whereas in the VSCC sample a high level 
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Figure 2  Histological overview of the epithelium of patient 3; the area on the left side 
shows VSCC, the area on the right side dVIN. Micro-dissection was performed in these 
areas, there is a distance of 2 mm (normal epithelium) between both areas (original 
magnification x50).
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8q22-q24.3 amplification was observed in the VSCC sample (Figure 3D and Table 3). These 
findings demonstrate that the dVIN of patient 3 is clonally related to the adjacent VSCC 
lesion, but contains lesser chromosomal abnormalities, illustrating a further progression 
towards malignancy in the VSCC compared to the dVIN.
Figure 3  Shared and different copy number abnormalities in differentiated VIN (dVIN) and 
vulvar squamous cell carcinoma (VSCC) of patient 3. Shown are the high-level amplification 
on chromosome 11 (A and B) and the deletion of 12p-ter (C), which is shared between the 
two samples, and the copy number gains on chromosome 8, which is absent in dVIN (D). 
Detail of the amplification on chromosome 11 (B) shows that its boundaries are identical 
between the two samples.
Figure 3  Continued. 
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Next generation sequencing approaches are expected to reveal this matter in much 
greater detail. 
 
Liegl and Regauer10 suggested that the rare identification of dVIN without VSCC in their 
patient group raised the question of whether dVIN should be considered a true precursor 
lesion of VSCC or whether it represents an in situ carcinoma component adjacent to an 
invasive SCC. They suggested that the interpretation of dVIN as a precursor lesion needs 
to be carefully reconsidered. In general, epithelial disorders are found adjacent to VSCC in 
70-80% of patients. However, evidence that some of these disorders are precursors of 
VSCC is circumstantial.19 Reason to question dVIN as being the precursor lesion is the low 
incidence of solitary dVIN compared to uVIN1, while the majority of VSCCs is not HPV 
associated. This low incidence can be explained by the difficulty of diagnosing dVIN 
which might result in an underdiagnosis8 or the existence of a shorter intra-epithelial 
phase compared to uVIN.1, 20 Though there are no recent studies concerning the incidence 
of dVIN, in daily practice we experience a higher incidence of solitary dVIN since clinicians 
and pathologists are more aware of the diagnosis. Molecular evidence in favour of dVIN as 
a precursor lesion can be found in expression profiles of immunohistochemical markers 
like p53 and MIB1. The typical staining pattern for p53 reported in dVIN is strong staining 
in the basal layer extending to nuclei in suprabasal layers of the epithelium,19, 21 whereas in 
reactive conditions, the staining trends to vary in intensity and remains confined to the 
basal epithelium. Furthermore, this is different from the pattern seen in VSCC in which the 
entire epithelium shows p53 expression.
The number of studies that did try to find genetic similarities between VIN and VSCC are 
small and mainly involve a low number of loci investigated. Furthermore, these studies do 
not differentiate between uVIN and dVIN-related VSCCs. Lin et al22 compared patterns of 
LOH between different locations of the tumour of one patient with a HPV-negative VSCC; 
the tumour itself scored positive for LOH in four of seven loci. Furthermore, one site of 
dVIN shared its locus with the invasive tumour whereas the other dVIN shared one of two 
loci with the cancer. Normal epithelium and stroma showed no abnormalities. These 
results are suggestive for dVIN being a precursor lesion, though this conclusion is based 
on a single case and only seven genomic loci. Pinto et al23 compared 11 identified loci 
which scored positive for AI in greater than 50% of cases from a prior study of VSCC (n=16)24 
to pre-invasive lesions (LS, uVIN, dVIN and hyperplasia). This comparison showed a lower 
percentage of AI in pre-invasive lesions, though in this comparison no distinction was 
made between HPV-positive and negative lesions. The advantage of our study is the high 
number of loci investigated, which allows us to compare the whole genome of dVIN and 
VSCC which provides more detailed information. 
Discussion
We present the first study which investigates the genome-wide copy number alterations 
of HPV-negative VSCC lesions and patient-matched dVIN lesions using high-resolution 
SNP array analysis. Gains of 7p and 8q and losses of 8p and 18q were found in most VSCC 
lesions, as well as aUPD of chromosome 17p. In one patient, three of the 33 CNAs found in 
VSCC were also detected in dVIN including a high-level amplification on 11q22 and a 
deletion of 12qter. These findings suggest that the two lesions originate from a single 
precursor cell in which a subset of the genetic alterations, possibly driving premalignant 
events, were present in an early stage, and additional alterations may have resulted in the 
progression towards VSCC.
In patient 3 a clonal relationship was found between VSCC and dVIN. Whereas the majority 
of CNAs, of which one high-level amplification, were found only in VSCC, three CNAs 
appeared to be present also in dVIN. The most pronounced aberration was a high gain of 
chromosome 11, which encompassed the BIRC and MMP gene clusters as well as the 
YES-associated protein 1 (YAP1) as a possible candidate gene. This latter gene is known to 
play a role in the development and progression of multiple cancers and may function as 
a potential target for cancer treatment.16 YAP1 expression seems to indicate a poor 
outcome in several cancer types.17, 18 Future studies should reveal whether these 
aberrations are more common in dVIN lesions and are involved in the progression from 
dVIN towards VSCC. 
One could question whether the CNAs we found in the dVIN lesions were actually CNAs 
present in a subset of VSCC cells that were present in the dVIN biopsy. However, although 
the samples were taken from the same surgical excision specimen (vulvectomy), cells for 
DNA were collected from a different site of the specimen. Furthermore, histological 
examination of the H&E stained slides showed there was a distance of 2 mm with normal 
epithelium between the dVIN lesion and VSCC lesion (Figure 2). It is important to note that, 
due to the low copy number intensities in the dVIN sample of patient 3, and the relatively 
low signal-to-noise ratio, it might be possible that other aberrations detected in the VSCC 
sample were simply missed in the dVIN sample. Nevertheless, it is unlikely that the 
high-level amplification at 8q has been missed in dVIN (Figure 3), which indicates that the 
dVIN and VSCC samples share genomic alterations, but are not identical, thereby making 
it less likely that VSCC-derived cells were present in the dVIN sample. 
Although we found CNAs in one patient that were shared between the dVIN and VSCC 
lesions, suggesting a clonal relationship, two other dVIN lesions did not show any CNAs. 
This, however, does not exclude that the dVIN lesions in these patients are clonally related 
to the VSCC, since the Oncoscan array identifies only a limited set of possible abnormalities. 
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Several studies have reported different patterns of chromosomal alterations with the use 
of lower resolution techniques in VSCC. Recently, Trietsch et al25 published a review of all 
studies concerning (epi)genetic alterations. Detection of somatic mutations was mostly 
focussed on TP53. Furthermore, they showed that HPV-negative tumours harboured 
more mutations than HPV-positive tumours, and the percentage of mutated samples 
increased with higher stages of (pre)cancerous lesions. Thomas et al26 showed in their 
review that the CNAs frequently observed with the use of comparative genetic 
hybridization (CGH) in high risk HPV-positive VSCC (n=33) were gain of 3q and loss of 3p 
and 11q.27-30 These CNAs were also most frequent observed in cervical SCC. In the 
HPV-negative VSCC (n=14) the picture is different; CGH analysis showed frequent gains at 
8q (12/14) and less frequent on 3q (4/14) and 11q (4/14), while most frequent losses were 
seen at 5q (4/14) and 11q (4/14).27, 28, 30 Gain of 8q was also frequently found in our study 
(5/6). Loss of 8p that was found in all cases in our study, is present in other studies though 
less frequent (3/14). Studies on VIN are scarce and mainly based on usual type VIN.28, 31 Only 
Aulmann et al addressed uVIN and dVIN separately. They analysed 3q26 gains using 
fluorescence in situ hybridisation and showed gains were present in most dVINs and in 
the minority of uVINs.32
In order to provide more evidence for our hypothesis that dVIN is the precursor lesion of 
VSCC by determining the genetic profile of these lesions, the method we used showed a 
clonal relationship in one patient. Nevertheless, retrieving enough DNA for analysis has 
shown to be challenging as only three of six dVIN samples contained enough DNA. 
Although the Oncoscan FFPE Expres v.2 (Affymetrix, Santa Clara, CA, USA) is especially 
designed for analysing FFPE, in vulvar tissue it remains difficult. In order to obtain more 
information on the correlation between dVIN and VSCC, exome sequencing in a larger 
number of lesions might contribute.
In summary, we have used high-resolution SNP array analysis to investigate the genome- 
wide aberrations in VSCC and its possible genetic relationship with dVIN. One patient 
showed accumulating events which points in the direction of our hypothesis that dVIN 
is the precursor lesion of VSCC. In order to collect more evidence for this hypotheses, 
a proof of concept study will be performed in a larger patient group using whole exome 
sequencing. 
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Cytology of the vulva:  
feasibility and preliminary results  
of a new brush
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Abstract
Objective
Taking a biopsy is a standard procedure to make the correct diagnosis in patients with 
suspicious premalignant vulvar lesions. The use of a less invasive diagnostic tool as triage 
instrument to determine whether biopsy is necessary may improve patient comfort 
especially in patients with chronic vulvar disorders that may warrant consecutive biopsies. 
This study was conducted to investigate whether vulvar brush cytology is feasible and 
may be used to detect (pre)malignant vulvar lesions.
Methods
A pilot study was performed with patients having clinically normal vulvar skin, lichen 
sclerosus (LS), usual or differentiated vulvar intraepithelial neoplasia or squamous cell 
carcinoma. A total of 65 smears were taken with the use of a vulvar brush and biopsies 
were performed for histopathological analysis.
Results
Out of 65 smears, 17 (26%) were discarded because of poor cellularity. A total of 28 of 
29 (97%) smears with a histological proven (pre)malignancy had a smear classified as 
‘suspicious’ or ‘uncertain’. Cytology classified 11 smears as ‘non-suspicious’, of which 10 
(91%) were indeed normal skin or LS. The accuracy, based on the presence of a lesion, 
for (pre)malignant lesions with the use of the brush showed a sensitivity of 97% and a 
negative predictive value of 88%.
Conclusion
Vulvar brush cytology is feasible and may be a first step in the development of a triage 
instrument to determine whether subsequent biopsy of a clinically (pre)malignant lesion 
is necessary.
Introduction
Vulvar squamous cell carcinoma (SCC) is a multifactorial disease following two separate 
and independent pathways. Each pathway has its own precursor lesion; usual VIN (uVIN) is 
the first precursor and is caused by the human papilloma virus (HPV).1, 2 Differentiated 
vulvar intraepithelial neoplasia (dVIN) is the second and most common precursor and 
often occurs in a background of lichen sclerosus (LS).3, 4 On the basis of our earlier studies 
we conclude that dVIN and not LS is the true precursor of SCC.5
Patients with LS have a lifetime risk of 4–6% to develop vulvar SCC.6, 7 Therefore, life-long 
follow-up is advised. In case of suspicion of a vulvar (pre)- malignancy, histopathological 
examination is required and considered to be the gold standard. Usually punch biopsies 
are conducted under local or general anaesthesia.8 After treating vulvar (pre)malignancies 
there is often residual disease and/or a high risk of recurrent lesions. In these patients, the 
vulvar examination can be difficult because of scarring due to a previous vulvectomy. 
Besides, the majority of these patients fear repeated biopsies making the development of 
a less invasive, accurate, diagnostic tool desirable to improve patient comfort. Brush 
cytology has been proven to be a reliable patient-friendly method to diagnose cervical 
(pre)malignancies. The accuracy of cytology largely depends on the presence of enough 
cells and the ability to recognise cellular and nuclear atypia. Various techniques for vulvar 
cytology have been described with disappointing results because of scarce cellularity so 
vulvar cytology is now far from being common practice.9-14
For the present pilot study, a new vulva brush (Rovers Medical Devices BV, Oss, The 
Netherlands; Figure 1) for obtaining vulvar cytology was introduced for a feasibility study 
at our department. A non-invasive tool was designed, resembling the cervex-brush, but 
with a brushing surface suitable for the vulvar skin and the ability to collect enough cells 
for cytology. Though histology still remains the gold standard, with this brush we want to 
make a first step in the development of a triage instrument that can determine whether 
subsequent biopsy of a clinically (pre)malignant lesions is necessary. This study was 
conducted to investigate whether vulvar cytology obtained by this brush is feasible and 
may be used in distinguishing benign from (pre)malignant vulvar lesions. 
Patients and methods
The pilot study was performed in patients from the vulvar clinic of the Department of 
Obstetrics and Gynaecology at the Radboud University Nijmegen Medical Centre, The 
Netherlands. Over a period of several months, 37 women were recruited having clinically 
LS, lesions suspicious of uVIN (raised, well-demarcated and asymmetrical lesions; varying 
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from white and condylomatouslike to brown lesions) or dVIN (raised white plaque, 
ulcerative or erythematous red lesion) or SCC (ulcerative lesions). All patients underwent 
cytological brushing and one or more vulvar punch or excisional biopsies were performed. 
A biopsy was not performed at the site of the brushing of the normal skin. 
Brushing was performed only at the site of the lesion; in patients with LS the most affected 
site was chosen to brush. Saline moistening was used before brushing, in order to remove 
debris, ointment and/or keratinised squamous cells as much as possible. All smears 
were prepared following our local standard Thin Prep protocol, using the Thin Prep 3000 
Processor (Cytyc Europe Benelux, Almere, The Netherlands), Papanicolaou stained and 
subsequently (blindly) assessed by both an experienced cytotechnologist (JV) and an 
expert cytopathologist (JG).
All smears were evaluated and scored for cellularity, presence of hyper and parakeratosis, 
presence of koilocytosis, atypia and squamous cell dysplasia. Regarding cellularity, a slight 
modification of the Bethesda 2001 guidelines for cervical cytology was followed.15 
In short, <5000 squamous cells and/or anucleate squamous cells per slide were considered 
inadequate, >5000 but <8000 were suboptimal and <8000 were considered sufficient. 
If cellularity was adequate, smears were classified as ‘suspicious for (pre)malignancy’, 
‘uncertain’ or ‘nonsuspicious’. Also the most likely corresponding histological disorder 
(uVIN or dVIN) was scored based on the cytological findings present in the slide (Table 1).
Histological features of uVIN are well recognisable. Atypical cells with increased nucleo- 
cytoplasmic (N/C) ratio are present at all levels of the epidermis and koilocytes may be 
numerous. In addition, the chromatin pattern is coarse and mitoses may be numerous 
(Figure 2A). Histological features of dVIN are more difficult to recognise. Atypia is confined 
to the (para)basal layers of the epithelium, in which the cells have abundant cytoplasm 
and may form abortive pearls. Prominent nucleoli are often present. Mitoses may be 
frequent, but are confined to the (para)basal cell layers. The superficial layers of the 
epithelium show a normal maturation and do not contain koilocytes. However, individual 
dyskeratotic cells may be seen. Furthermore, a thick hyper and sometimes parakeratotic 
layer is often present (Figure 2B). Invasive carcinoma will show a disrupted basement 
membrane with infiltrating nests of atypical squamous cells surrounded by a desmoplastic 
stroma reaction. Therefore, the following criteria for cytology were scored: if koilocytes, 
dyskeratotic squamous cells and cells with increased N/C ratio were present, smears were 
categorised as suspicious for (pre)malignancy, favour uVIN (Figure 3A and B): if large 
atypical epithelial cells with prominent nucleoli, eccentric nuclei and abundant non-kera-
tinising cytoplasm were present, in the absence of the above described characteristics, 
smears were categorised as suspicious for (pre)malignancy, favour dVIN (Figure 3C and D). 
If only a few atypical cells were present, or if cells showed only slight aberrations, smears 
were categorised as ‘uncertain’. No attempt was made to specifically diagnose invasive 
SCC, as this cannot be differentiated reliably from the precursor lesions dVIN and uVIN on 
cytological brush material.
Figure 1  Vulva brush (Rovers Medical Devices BV).
Table 1   Classification of cytological smears. 
Normal Uncertain Suspicious for (pre)malignancy:
Favour uVIN Favour dVIN
No atypical or 
dysplastic cells
Some atypical cells Evident dyskaryotic cells 
and cell groups.
Increased N/C ratio, 
irregular coarse 
chromatin, irregular 
nuclear membrane. 
Koilocytes present.
Large atypical cells, 
often isolated. 
Eccentric nuclei. 
Prominent nucleoli. 
Absence of koilocytes. 
Abbreviation: N/C ratio= nucleo-cytoplasmic ratio.
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All biopsies and excision specimens were routinely fixed (4% buffered formalin) and 
paraffin embedded. Standard 4-µm thick haematoxylin and eosin-stained sections were 
used for the classification of the lesions according to current WHO criteria and the recent 
modification of the ISSVD.16 Finally, cytological and histological findings were correlated. 
The study was conducted after obtaining local ethics committee approval from the 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and informed 
consent of all participants.
Statistics
Calculations were performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Descriptive 
statistics were used to reproduce study results as percentages, means and medians.
Results
A total of 65 smears with the vulva brush were taken from 37 patients; in 40 of 65 smears 
a vulvar punch or excisional biopsy was taken immediately adjacent to the brushed area 
and in 13 of 65 smears a biopsy was taken a median of 5 months before or after the 
smear. Additionally, in 12 of 37 patients a smear was taken of clinically normal vulvar skin 
far from the lesion. Brushing was feasible in the outpatient clinic and well tolerated by 
the patients.
A total of 17 smears (26%) were inadequate because of poor cellularity and excluded from 
further analysis. Of these excluded smears the diagnosis was LS in 7 of 17 smears (histologically 
confirmed; 41%) and clinically normal in 7 of 17 smears (41%); an overview of the exact 
diagnoses can be seen from Table 2. Besides, 18 smears (28%) had a suboptimal cellularity 
and 30 (46%) had sufficient cellularity.
The correlation between the cytological and histological diagnoses is shown in Table 2. 
Among the 48 smears when suboptimal or sufficient cellular smears were obtained, 29 
were biopsy proven (pre)malignancies; uVIN (n=14), dVIN (n=3) or vulvar carcinoma (n=12). 
A total number of 28 of 29 (97%) biopsy proven (pre)malignancies had a smear classified 
as ‘uncertain’ or ‘suspicious for (pre)malignancy’. Only one biopsy proven case of dVIN had 
a corresponding smear classified as ‘nonsuspicious’. However, the cellularity of this one 
false-negative smear was suboptimal and predominantly anucleated squamous cells 
were present.
Diagnosis of 19 of the remaining 48 smears were biopsy-proven LS (n=14) or samples of 
normal skin (n=5). In 10 of these 19 cases (53%) the corresponding smear was correctly 
classified as ‘nonsuspicious’. Seven smears were classified ‘uncertain’, of which six were 
Figure 2  Histology of uVIN and dVIN. (A) uVIN; atypia and mitoses are present in all levels 
of the epidermis, nucleo cytoplasmic (N/C) ratio is increased and koilocytes can be seen. 
(B) dVIN; normal N/C ratio, atypia confined to the (para)basal layers of the epithelium, the 
superficial layer shows normal maturation with a single dyskeratotic cell and prominent 
hyperkeratosis. No koilocytosis (H&E-stained, x20).
Figure 3  Cytological findings consistent with uVIN and dVIN. (A and B) uVIN: dyskeratotic 
cells and cell groups with increased N/C ratio, irregular coarse chromatin and irregular 
nuclear membranes. (C and D) dVIN: presence of large atypical cells with eccentric nuclei 
with prominent nucleoli and relatively abundant cytoplasm (Papanicolaou stained thin 
prep samples, x40).
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histologically diagnosed as LS. Two smears were ‘suspicious for (pre)malignancy’ and were 
diagnosed as LS and normal. 
Although we are aware of the effect the small sample size, we calculated the accuracy of 
cytology to diagnose a malignancy and/or premalignancy based on the presence of a 
lesion. Smears of normal skin were excluded for this calculation as it was our purpose to 
use vulvar cytology to distinguish between benign and (pre)malignant vulvar lesions. 
Accuracy is shown in Table 3. Cytology has a 100% sensitivity and negative predictive 
value of 100% in case of a malignancy. In case of premalignancies (uVIN and dVIN), 
sensitivity of 94% and a negative predictive value of 88% was obtained. For malignant and 
premalignant samples together 97% sensitivity and a negative predictive value of 88% 
was calculated. Specificity was 50% for both premalignancy and malignancy. The accuracy 
of only the smears taken immediately adjacent to the place of biopsy (n=52) showed 
comparable results.
Discussion
Obtaining a rapid and accurate diagnosis in women suspected of VIN or vulvar cancer 
generally leads to (repeated) punch biopsies and consequent patient discomfort. Though 
histology remains important as it is currently the gold standard, especially for the primary 
diagnosis of LS, our results indicate that cytology obtained by the new vulva brush is 
feasible. Moreover, it may be a possible first step in the development of a triaging 
instrument to determine which patients with the suspicion of a pre(malignancy) especially 
in the follow-up, should have a subsequent punch biopsy and in which patients a biopsy 
might be safely omitted.
In this study, 17 of 53 smears (26%) did not carry enough cells for interpretation. This 
difficulty in obtaining sufficient material has also been discussed in the previous literature.10, 
13, 14, 17, 18 Whether our brushing technique results in higher cellularity compared with other 
techniques with a spatula or blade is not clear because studies with different techniques 
do not use comparable analysing methods. Moreover, the cellularity in vulvar smears is 
much lower compared with cervical smears. This can be explained by the presence of a 
thick keratin layer that covers the vulvar epithelium, which requires vigorous brushing to 
obtain the underlying diagnostic cells for adequate sampling. Additionally, debris and/ or 
keratinous squamous cells may confuse the cytological appearance of the sample; in our 
study we tried to prevent this by cleaning the surface with saline before brushing. Low 
cellularity may also be explained by the type of lesion that was brushed; when looking 
more in detail to the diagnoses of the 17 smears with poor cellularity (Table 2), it is striking 
and reassuring that the histological findings of these smears are benign. The small 
proportion of (pre)malignancies with low cellularity (n=3), supports the hypothesis that 
(pre)malignant lesions may dissociate more easily compared with benign lesions. In this 
study, brushing was not performed according to a strict protocol, which may have led to 
a variation in cell collection. For optimising the brushing method a more standardised 
approach should be followed. This approach should first contain repeatedly firm brushing 
of the surface. In some patients this may be painful. Probably the use of local anaesthetics 
such as Xylocaine spray can be helpful in these cases. Second, in cases with remaining low 
cellularity the use of immunohistochemistry should be considered. There might be an 
important role for HPV testing and the use of markers such as p53 or p16 to make a 
distinction between benign, HPV-related (usual) VIN/SCC or HPV-non-related (differentiated) 
Table 2   Cytology - histology correlation (n=65).
Cytology
Histology
SCC uVIN dVIN Lichen 
Sclerosus
Normal 
skin*
Total
Suspicious for  
(pre)malignancy†
Favour uVIN
Favour dVIN
8
3
9
0
0
1
1
0
1
0
19 
4
Uncertain^ 1 5 1 6 1 14
Non suspicious 0 0 1 7 3 11
Poor cellularity 1 2 0  7 7 17
Total 13 16 3  21 12 65
* Based on clinical appearance, no histologic confirmation. †Atypical cells present; indicative of a (pre)
malignancy. ^Presence of atypical cells not conclusive.
Table 3   Accuracy of vulvar cytology.
Diagnosis Sensitivity 
(%)
Specificity 
(%)
Negative 
predictive 
value (%)
Positive
predictive 
value (%)
(Pre)malignancy* 97 50 88 80 
Malignancy† 100 50 100 63
Premalignancy^ 94 50 88 70
*Including uVIN, dVIN and SCC. ^Including uVIN and dVIN.
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VIN/SCC.2 Recently, an attempt was made to identify a new marker of specifically dVIN. 
Van de Nieuwenhof et al19 showed localisation of mast cells in dVIN, which could be a 
potential marker for this entity. We hypothesise that the use of markers may lead to 
adequately differentiation, also in the samples with poor cellularity. Whether this marker 
will be useful in liquidbased cytology, can be subject of future studies.
Only three prior studies with a limited number of samples, have evaluated whether results 
from cytology correlate with histological findings of VIN or SCC. Bae-Jump et al14 concluded 
that with the use of a spatula end for cytology collection, only 7 of 22 patients (32%) with 
biopsy proven (pre)malignancies had a vulvar Pap smear significant for VIN or vulvar 
carcinoma. They concluded that a negative Pap smear was not necessarily indicative for 
the absence of disease. Likewise, we found one smear with normal cytology, but with a 
histologically proven dVIN. This cytological misdiagnosis might be explained by 
suboptimal cellularity and the presence of predominantly anucleated squamous cells in 
the preparation. As it is known that the atypical cells in dVIN reside predominantly in the 
(para)basal cell layers, probably in this case brushing was not performed vigorously 
enough to obtain diagnostic atypical cells. Furthermore, vulvar brush material often 
contains many anucleated squamous cells. Therefore, in the future a cytological specimen 
should not only be analysed for cellularity before making a diagnosis, but also additionally 
be assessed for the presence of enough nucleated squamous cells.
Jimenez-Ayala and Jimenez-Ayala13 collected cells for cytology (n=563) by scraping with a 
scalpel blade. They reported that cytology can be used for the diagnosis of malignancy 
with a sensitivity of 98%, which is comparable to our results, although they also reported 
a high specificity of 95%. Their better results compared with ours may be due to a more 
vigorous scraping method in which they probably collected more cells from the deeper 
tissue layers, underscoring the remarks above. However, patient discomfort was not 
scored and the accuracy of detecting premalignancies was not investigated in the study.
The accuracy obtained with our vulvar brush is different from the accuracy that can be 
obtained with the cervical brush to diagnose cervical (pre)malignancies. The accuracy of 
routine cytology is highly variable in different studies. An overview of Cuzick et al20 showed 
that the overall sensitivity (53%, range 18.6–76.7%) is lower compared with the overall 
specificity (96.3%, range 84.2–99.6%) in detecting high-grade cervical intraepithelial 
neoplasia (2+). The primary aim of the coordinated screening programs for cervical cancer 
is early detection of (pre)malignancies of the cervix in healthy women. This aim is 
completely different from our study where brushing is used for patients with a suspicious 
lesion. In our study the sensitivity (97%) was higher compared with the specificity (50%), 
which is acceptable concerning the aim of triaging patients with suspicious vulvar lesions.
Levine et al12 used the cytobrush for cell collection and analysed 28 cytological samples of 
histologically benign or premalignant lesions. With dyskeratosis as the sole cytological 
criterion for VIN or anal intraepithelial neoplasia (AIN), all samples were consistent with 
histology except for one (4%) that was cytologically diagnosed as VIN, but no VIN was 
identified in the biopsy. Presumably, these were all HPV-related VIN or AIN cases; no 
attempt was made to differentiate between uVIN and dVIN. In contrast with Levine’s 
percentage of false positive smears (1 out of 28 smears; 4%), in our study 9 smears (19%) 
were classified as ‘uncertain’ (n=7) or ‘suspicious for (pre)malignancy’ (n=2). Cytological 
recognition of uVIN generally is easier because koilocytosis and dyskeratotic cells are 
present in the entire epithelium, whereas in dVIN atypical cells are only present in the 
basal layer. Because the aim was to diagnose uVIN and dVIN, the threshold of suspicion 
was lower with consequently more false positives in our study and therefore lower 
positive predictive value. However, compared with standard management of suspicious 
vulvar lesions, the amount of biopsies may decrease. We hypothesise that especially those 
patients, visiting the clinic on a regular basis with recurring premalignancies, may benefit 
from cytology as a triaging instrument. The experience in our vulvar clinic is in that 
patients with premalignancies such as uVIN, and in particular dVIN, lesions are difficult to 
distinguish from benign on the clinical findings. This implies that biopsies may be taken 
despite the absence of disease. Not seldom we performed a vulvar mapping where no 
(pre)malignant lesions can be found. In these patients we want to use cytology to safely 
exclude premalignancies. The next step is to perform a study in a larger group of patients 
to investigate whether cytology with our vulva brush indeed can function as a triage 
instrument.
This study shows that cytology obtained by the new vulva brush is promising as a possible 
first step in obtaining a diagnosis in patients with suspicious (pre)malignant vulvar lesions. 
By classifying the smear based on the presence or absence of a few parameters, it is 
possible to detect a (pre)malignancy. However, histology still remains the gold standard 
and the brushing technique needs to be improved and addressed in future studies to 
increase the cellularity, which is obligatory for the right diagnosis.
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Abstract
Objective
No published data concerning intraobserver and interobserver variability in the histo-
pathological diagnosis of differentiated vulvar intraepithelial neoplasia (dVIN) are available, 
although it is widely accepted to be a subtle and difficult histopathological diagnosis. 
In this study, the reproducibility of the histopathological diagnosis of dVIN is evaluated. 
Furthermore, we investigated the possible improvement of the reproducibility after 
providing guidelines with histological characteristics and tried to identify histological 
characteristics that are most important in the recognition of dVIN. 
Methods
A total number of 34 haematoxylin and eosin-stained slides were included in this study 
and were analysed by six pathologists each with a different level of education. Slides were 
reviewed before and after studying a guideline with histological characteristics of dVIN. 
Kappa statistics were used to compare the interobserver variability. Pathologists with a 
substantial agreement were asked to rank items by usefulness in the recognition of dVIN. 
Results
The interobserver agreement during the first session varied between 0.08 and 0.54, which 
slightly increased during the second session toward an agreement between -0.01 and 
0.75. Pathologists specialised in gynaecopathology reached a substantial agreement 
(kappa 0.75). The top five of criteria indicated to be the most useful in the diagnosis of dVIN 
included: atypical mitosis in the basal layer, basal cellular atypia, dyskeratosis, prominent 
nucleoli and elongation and anastomosis of rete ridges. 
Conclusion
In conclusion, the histopathological diagnosis of dVIN is difficult, which is expressed 
by low interobserver agreement. Only in experienced pathologists with training in gynae-
copathology, kappa values reached a substantial agreement after providing strict guidelines. 
Therefore, it should be considered that specimens with an unclear diagnosis and/or 
clinical suspicion for dVIN should be revised by a pathologist specialised in gynaeco-
pathology. When adhering to suggested criteria the diagnosis of dVIN can be made easier.
Introduction
Vulvar carcinoma is rare with squamous cell carcinoma as the most common histopatho-
logical subtype. Nowadays, we can distinguish two types of squamous cell carcinoma 
with their own premalignant lesions.1, 2 The first type of vulvar squamous cell carcinoma 
consists of mainly non-keratinizing carcinomas and is caused by an infection with high-risk 
human papilloma virus (HPV). This type of carcinoma is associated with warty and/or 
basaloid vulvar intraepithelial neoplasia (VIN; together grouped as usual VIN (uVIN)). The 
second and most common type of carcinoma is differentiated keratinizing squamous cell 
carcinoma, often occurring in the background of lichen sclerosus. Differentiated VIN 
(dVIN), which is an entity that has no relation with HPV, is believed to be the precursor 
lesion associated with this type of vulvar squamous cell carcinoma.3-5
Until 2003, a three grade system for premalignant VIN (VIN grades 1–3, Table 1) was used. 
As clinicopathological data did not appear to support the concept of a continuous spectrum 
of VIN lesions leading to vulvar carcinoma that does exist for cervical intraepithelial 
neoplasia and cervical carcinoma,6-8 this grading system was abolished. The abandonment 
of VIN 1 and the consolidation of VIN 2 and 3 into one category simply termed (highgrade) 
VIN, best fitted the studies that have been performed on grading of VIN so far.6 Nowadays, 
the concept of usual VIN and differentiated VIN has been accepted more and more by 
clinical pathologists around the world.
Histopathologically, usual VIN lesions are easy to recognise whereas the recognition of 
differentiated VIN is difficult as it is seldom diagnosed as a solitary lesion. DVIN is often 
found directly adjacent to squamous cell carcinoma and is characterised by a thickened 
epithelium that is typically associated with elongation and anastomosis of rete ridges 
(Figure 1a).4, 5, 9-12 Dys- and parakeratosis are usually present (Figures 1e and f), associated 
Table 1   Overview of the old and new nomenclature of VIN lesions.
Old nomenclature New nomenclature
VIN 1 No cancer precursor
Classic (VIN 2/3) Usual VIN (uVIN)
Warty VIN
Basaloid VIN
Mixed (warty-basaloid)
(Well-)differentiated VIN 3 Differentiated VIN (dVIN)
VIN terminology (ISSVD 20046).
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with prominent intercellular bridges. Dyskeratosis is characterised by disturbed maturation 
and premature keratinisation of squamous cells that are located deeper in the epithelium. 
In the parabasal layers of the epithelium, individual and clusters of cells show premature 
maturation, with large cells that show eosinophilia of the cytoplasm and even formation 
of keratin pearls (Figure 2). The nuclei have prominent nucleoli (Figure 1c), usually 
predominantly in the (para)basal keratinocytes (Figure 1e). Atypical mitotic figures (Figure 1d) 
may be seen mainly in the lower layers.4 The most superficial layers show normal maturation 
without atypical cells, although dyskeratosis may be present above the (para)basal layers 
with cells that have vesicular nuclei, prominent nucleoli and abundant eosinophilic 
cytoplasm. As the cytological atypia in dVIN is confined to the basal epidermal cell layers, 
it is often confused with squamous hyperplasia or lichen sclerosus. The recognition of 
dVIN is hindered by a high degree of cellular differentiation combined with an absence of 
widespread architectural disarray, nuclear pleomorphism and diffuse nuclear atypia.9 
Probably, this has led to a considerable underdiagnosis of dVIN. Although, it is of great 
importance to recognise this lesion properly because of its high malignant potential and 
rapid progression toward vulvar squamous cell carcinoma.4 Making the right pathological 
diagnosis is of utmost importance to assure proper treatment and follow-up.
Until now, there are no published data on intra and interobserver variability in the histo-
pathological diagnosis of dVIN, although it is widely accepted to be a subtle and difficult 
histopathological diagnosis.5 In this study, the reproducibility of the histopathological 
diagnosis of dVIN is evaluated in a group of six Dutch pathologists with different level of 
experience. Furthermore, we investigated the possible improvement in diagnosing dVIN 
Figure 1  Differentiated vulvar intraepithelial neoplasia (dVIN). Overview of dVIN with (A) 
elongation and anastomosis of rete ridges, (B) disorderly basal cell layer and acanthosis, 
(C) prominent nucleoli and disorderly basal cell layer, (D) atypical mitoses, (E) and (F) 
dyskeratosis (indicated by arrows). Original magnifications: x50 (A), x100 (F), x200 (B, C), x400 
(D, E).
Figure 2  (A) Overview of differentiated vulvar intraepithelial neoplasia with keratin pearl 
formation within the rete ridge (original magnification x50). (B) Detail of keratin pearl 
formation, dyskeratosis and basal cellular atypia (original magnification x100). (C) Detail of 
the basal layer with atypia and prominent nucleoli (original magnification x200).
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after providing guidelines with histological characteristics of dVIN. Finally, we tried to 
identify histological characteristics that are most important in the recognition of dVIN.
Patients and methods
Haematoxylin and eosin (H&E)-stained slides of vulvar biopsies taken before the diagnosis 
of vulvar squamous cell carcinoma of 60 patients were collected, all patients subsequently 
developed vulvar squamous cell carcinoma. All patients were treated at the Department 
of Obstetrics and Gynaecology of the Radboud University Nijmegen Medical Centre 
(RUNMC) or the University Medical Centre Groningen between 1990 and 2008. The slides 
were reviewed by two experts in the field of gynaecopathology from these two hospitals 
(JB and HH), independently and unaware of the course of the disease. Discrepancies in 
diagnoses were resolved in a consensus meeting with these two expert gynaecologic 
pathologists (further on named ‘consensus pathologists’). Consensus diagnoses were 
based on published criteria, which are shown in Table 24, 5, 7-15 and considered to be the 
golden standard.
Of 60 slides, 46 were diagnosed as lichen sclerosus or dVIN during the consensus meeting. 
Thirty-five corresponding formalin fixed paraffin embedded specimens could be retrieved, 
re-cut at 4 mm, and H&E stained. To quicken the process of analysis, for each specimen a 
total number of three slides were re-cut. One consensus pathologist (JB) compared the 
slides from each specimen to confirm that these were comparable. As one specimen lost 
quality after re-cutting, it was excluded from further analysis. Finally, three identical sets of 
34 slides were assessed for this study. 
Six pathologists (consensus pathologists not included) were asked to classify all 34 slides 
in two separate sessions. The group of pathologists consisted of two gynaecologic 
pathologists (pathologists that had special training in gynaecopathology), two general 
pathologists and two pathologists in training. During the first session, the pathologists 
were asked to diagnose the lesions as lichen sclerosus, dVIN, high-grade dysplasia and/or 
other. When squamous cell carcinoma (n=4) was present next to lichen sclerosus or dVIN, 
the pathologists were asked to score both. No information about age, clinical aspect of 
the lesions or original diagnosis was provided. In between the first and second session, 
the pathologists were asked to study a guideline. This guideline was developed by the 
consensus pathologists (HH and JB) and consisted of the descriptive categories (lichen 
sclerosus, uVIN and dVIN) with extensive description of the pathological features (Table 2), 
illustrated by low- and high-power field photographs. After a washing out period of at 
least 3 months, the six pathologists were asked to study the guideline and diagnose the 
lesions as lichen sclerosus, dVIN and/or high-grade dysplasia and score the histological 
characteristics (Table 2). To evaluate the reproducibility of the histopathological diagnosis 
of dVIN, interobserver variability was calculated. Furthermore, the effect of education in 
each individual pathologist was assessed. To identify histological characteristics that were 
most important in the recognition of dVIN, one of the consensus pathologists on behalf 
of the consensus pathologists (JB) and pathologists with a high level of agreement were 
asked to put criteria in order of usefulness for the diagnosis of dVIN.
Statistical Methods
All slides diagnosed with dVIN by each pathologist were compared with the golden 
standard to give a level of agreement among pathologists. The kappa statistic, often used 
in studies in order to test the interobserver variability, was used. Values of 0.4–0.6, 0.6–0.8 
and 40.8 were taken to reflect moderate, substantial or excellent correspondence, 
respectively.16 Analyses were performed using SPSS 16.0 (SPSS, Chicago, IL, USA).
Table 2   Histological characteristics of dVIN.
Hyperplasia/acanthosis
Hyperkeratosis 
Parakeratosis
Elongation and anastomosis of rete ridges
Basal cellular atypia (including disarray of the basal cellular layers, large pleiomorphic 
keratinocytes, enlarged vesicular nuclei)
Prominent nucleoli
Atypical mitosis in the basal layer
Dyskeratosis (keratin pearl formation)*
Hypermaturation of rete ridges
Based on published criteria (4-7, 9-13) *Dyskeratosis = disturbed maturation and premature keratinisation of 
squamous cells that are located deeper in the epithelium. In the parabasal layers of the epithelium, individual 
cells and clusters of cells show premature maturation, with large cells that show eosinophilia of the cytoplasm 
and even formation of keratin pearls.
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Results
Of the 34 slides assessed in this study, 20 (59%) were diagnosed as lichen sclerosus, 13 
(38%) as dVIN and 1 (3%) as normal skin during the consensus meeting of the consensus 
pathologists. The median time to development of vulvar squamous cell carcinoma was 44 
months (range 9–200); in patients with lichen sclerosus/normal skin this was 92 (range 
9–200) months and with a prior biopsy of dVIN 24 (range 8–64) months. The agreement 
between the consensus pathologists (HH and JB) was 88%; 30 of 34 slides were scored 
concordant, with a kappa value of 0.73.
The distribution of collected data is shown in Table 3. The median time between the first 
and second session was 4 months (range 3–5 months). Pathologists D, E and F scored dVIN 
more often during the first session in comparison with the consensus, while pathologists 
A, B and C were less likely to score dVIN. The latter more often scored a lesion as high-grade 
dysplasia and/or other diagnosis, like aspecific dermatitis (n=13) or lichen planus (n=5). 
During the second session, the over- and underdiagnosis of dVIN remained present, 
although less clear. Pathologists were less likely to score high-grade dysplasia during the 
second session.
The interobserver agreement between pathologists during the first session varied between 
0.08 and 0.54 (data not shown). The overall kappa that summarises in a single coefficient 
the κ values relative to the different pairs of pathologists, could not be calculated because 
of the heterogeneous κ values. The interobserver agreement between pathologists after 
studying the guidelines during the second session slightly increased with values between 
-0.01 and 0.75.
Table 4 shows the kappa value of the diagnosis dVIN of individual pathologists vs 
consensus of the first and second session, categorised according to experience of the 
pathologist. The values range between 0.27 and 0.54 in the first session and between 0.15 
and 0.75 in the second session. All pathologists increased in kappa value, except for 
pathologists B and C. Pathologists with training in the field of gynaecopathology 
(gynaecologic pathologists), could reach higher kappa values after studying the guidelines 
compared with general pathologists and pathologists in training.
Most important criteria in order of usefulness for the diagnosis of dVIN were scored by one 
of the consensus pathologists (JB) and pathologists with a high level of agreement 
(pathologist E and F) and are displayed in Table 5. The top five of these criteria included 
atypical mitoses in the basal layer, basal cellular atypia, dyskeratosis, prominent nucleoli, 
and elongation and anastomosis of rete ridges. A schematic overview of these criteria is 
Table 3   Diagnosis made by pathologists during the first and second session.
Pathologist A* B* C^ D^ E# F# Consensus
Diagnosis session 1:
  dVIN¹
  High-grade dyplasia NOS²
  Lichen Sclerosus
  Others~
7
3
17
7
7
5
6
16
3
4
12
15
24
1
9
0
19
0
9
6
16
0
12
6
13
0
20
1
Diagnosis session 2:
  dVIN
  High-grade dyplasia NOS
  Lichen Sclerosus
  None of the above
10
1
18
5
15
3
7
9
4
0
9
21
21
0
13
0
13
0
16
5
13
2
16
3
-
-
-
-
Values are given as N. ¹Differentiated vulvar intraepithelial neoplasia. ²Not otherwise specified. *Pathologist 
in training. ^General pathologist. #Gynaecologic pathologist. ~Including aspecific dermatitis (n=13), lichen 
planus (n=5), acanthosis (n=4), squamous cell carcinoma (n=4), polyp (n=2), condylomata (n=2), lichen 
simplex chronicus (n=1), hyperkeratosis not otherwise specified (n=1), epidermal cyst (n=1), radiation effect 
(n=1) and not otherwise specified (n=17).
Table 4   Kappa value of the diagnosis of dVIN of individual pathologists versus 
consensus dVIN (N=34).
Pathologist Session 1 Session 2
Agreement 
with 
consensus¹ 
N (%)
Kappa
(95% CI)
Agreement 
with 
consensus  
N (%)
Kappa
(95% Cl)
Pathologist in 
training
A 26/34 (77) 0.45 (0.16-0.75) 29/34 (85) 0.67 ( 0.42-0.93)
B 24/34 (71) 0.32 (0.00-0.63) 20/34 (59) 0.15 (-0.18-0.48)
General 
pathologist
C 24/34 (71) 0.27 (0.01-0.53) 23/34 (68) 0.21 (-0.07-0.49)
D 21/34 (62) 0.30 (0.06-0.55) 24/34 (71) 0.44 ( 0.18-0.70)
Gynaecologic 
pathologist
E 26/34 (77) 0.54 (0.28-0.80) 30/34 (88) 0.75 ( 0.52-0.98)
F 23/34 (68) 0.34 (0.03-0.66) 30/34 (88) 0.75 ( 0.52-0.98)
¹All slides were scored as ‘dVIN=yes’ or ‘dVIN=no’ and compared with consensus.
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displayed in Figure 3. All histological characteristics scored in slides with consensus of the 
diagnosis dVIN (n=22) of the pathologists with a substantial agreement (kappa value 0.7 
or higher; pathologist E and F) were scored. The top five histological characteristics were 
identified in nearly all slides.
Discussion
With this study, we show that the agreement on the histopathological diagnosis of dVIN 
is low and diagnosing dVIN is difficult. After providing guidelines with histological charac-
teristics to diagnose dVIN, agreement did improve but mainly in gynaecologic pathologists, 
probably due to their long learning curves in the past. Therefore, it should be considered 
that specimens with an unclear diagnosis and/or clinical suspicion for dVIN should be 
revised by an experienced gynaecologic pathologist.
Making the right diagnosis is of utmost importance to assure proper treatment and 
follow-up, as dVIN is known for its rapid progression toward squamous cell carcinoma.3, 4 
Various studies11, 17, 18 highlighted the difficulty in making the clinical and histopathological 
diagnosis of dVIN. Unfortunately, this study shows that the pathological reproducibility is 
low in patients that subsequently developed a vulvar squamous cell carcinoma, which 
corresponds with the difficulties in diagnosing dVIN by the clinician.
Little is known about how pathologists differ in their interpretation of dVIN. It is widely 
accepted to be a subtle and difficult histopathological diagnosis as it can easily be 
mistaken for a benign dermatitis or epithelial hyperplasia5 and may be difficult to 
distinguish from the often present background of lichen sclerosus.17 To our knowledge, 
only three prior studies have addressed the interobserver variability of VIN19-21 of which all 
used the abandoned nomenclature of VIN 1–3 to classify the specimens. Trimble et al20 
demonstrated moderate to good agreement among experienced gynaecological 
pathologists in making the distinction between those lesions related to HPV and those 
that are not. Unfortunately, these lesions included squamous cell carcinoma and VIN 1–3; 
no agreement was calculated for the non-HPV VIN3. Preti et al19 showed an overall 
agreement of 73.9% for VIN 2/3 lesions, although no cases of differentiated VIN were 
included. Van Beurden21 showed a good agreement of 40 specimens with normal skin 
and VIN 1–3, of which possibly some of the VIN cases may be of the non-HPV type 
although this is not further clarified. Apparently, there is no literature that focuses on the 
histopathological diagnosis of dVIN.
The results of this study show that the diagnosis of different pathologists after providing 
guidelines with histological characteristics to diagnose dVIN, could only reach a substantial 
agreement of 0.75 (CI 0.52–0.98) in gynaecologic pathologists. Obviously, in diagnosing 
dVIN, more practice leads to better skills as the highest agreement could be reached in 
pathologists with more experience. Likely, also continuous exposure of cases with 
differentiated VIN in daily practice is important to keep experience.
Figure 3  Five most important histological characteristics in the diagnosis of differentiated 
vulvar intraepithelial neoplasia (dVIN) according to the pathologists with κ>0.7 and the 
consensus pathologists. Schematic overview of: (A) normal epithelium and (B) dVIN with 
atypical mitosis in the basal layer, basal cell atypia, dyskeratosis, prominent nucleoli, and 
elongation and anastomosis of the rete ridges.
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Apparently, studying the guidelines developed by the consensus pathologists (JB and HH) 
based on literature was not sufficient enough to increase the level of agreement among 
pathologists during the second session. A different approach in teaching general 
pathologists in the recognition of dVIN, for example, with an interactive session with an 
experienced gynaecologic pathologist, may probably reach higher agreement. An 
interactive session, like a (virtual) workshop where clinically en pathologically doubtful 
dVIN lesions are being discussed may be helpful.
The low interobserver agreement indicates the need for some clarity in making the 
diagnosis dVIN properly. Therefore, we tried to identify the most important histopatho-
logical features by asking the consensus pathologists and pathologists with a substantial 
agreement, to rank the items that they thought were the most important in making the 
diagnosis of dVIN, which is shown in Table 5. We agree with Hart11 and Scurry15 that 
pathologists should not be focused on nuclear atypia alone, in the diagnosis of non-HPV 
premalignancy, but should also look for other supporting features. When some of the top 
five features listed in Table 5 are present, there has to be a concern and the diagnosis dVIN 
should be considered.
Besides the use of these histopathological criteria in making the right diagnosis, there may 
also be a role for immunohistochemistry.21-23 The use of MIB1 can be helpful to distinguish 
between normal vulvar epithelium and dVIN as the basal cell layer in dVIN shows a higher 
proliferation index (percentage of MIB1-positive cells), than normal vulvar epithelium, 
where the basal cell layer often is negative for MIB1.23 Furthermore, in dVIN a strong 
positive staining of the (supra)basal cell layers with p53 can be seen. Strong staining of all 
cell layers with p16 is suggestive for usual VIN and not for differentiated VIN.
An important and difficult problem, which we did not address in this study, is to decide 
whether one is looking at dVIN or invasive squamous cell carcinoma. Separated small 
nests of highly differentiated squamous cells may be seen in the dermis, raising the 
question of whether early invasion has taken place. In superficial biopsies, distinction of 
differentiated VIN from early invasive squamous cell carcinoma may be very difficult to 
make.11, 14 Therefore, it is important to keep to the classic criteria of invasiveness: small 
irregular nests of highly differentiated (atypic) squamous cells or individual strongly 
atypical cells with prominent nuceoli or/and a desmoplastic reaction around the invasive 
nests.
As most specimens with a suspicion of dVIN are seen by a general pathologist in daily 
practice, it is worthwhile considering revision of specimens with an unclear diagnosis and/
or clinical suspicion for dVIN by an experienced gynaecologic pathologist. Probably, 
interaction between the clinician and pathologist will also be helpful.
In conclusion, the histopathological diagnosis of dVIN is difficult as the interobserver 
agreement is low. Only among gynaecologic pathologists, kappa values showed a 
substantial agreement after providing guidelines. To increase agreement among general 
pathologists, a more extensive instruction like (virtual) workshops with dVIN cases and 
doubtful lesions may be helpful. The histopathological features: atypical mitosis in the 
basal layer, basal cellular atypia, dyskeratosis, prominent nucleoli and elongation and 
anastomosis of the rete ridges that are ranked by pathologists with a substantial 
agreement, may be helpful in the diagnosis of dVIN.
Table 5   Histological characteristics of dVIN
Histological characteristics of dVIN~ Order of usefulness* 
Atypical mitosis in the basal layer 1
Basal cellular atypia 2
Dyskeratosis 3
Prominent nucleoli 4
Elongation and anastomosis of rete ridges 5
Enlarged vesicular nuclei 6
Keratin pearl formation 7
Hypermaturation of rete ridges 8
Prominent intracellular bridges 9
Epidermal thickening (hyperplasia/acanthosis) 10
Parakeratosis 11
~Differentiated vulvar intraepithelial neoplasia. *According to the pathologists with K >0.7 (pathologists E 
and F) and one pathologist on behalf of the consensus pathologists (JB).
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 the depth of invasion of  
vulvar squamous cell carcinoma  
in relation to prognosis
Loes C.G. van den Einden, Leon F.A.G. Massuger, Johanna K. Jonkman, Peter Bult, 
Joanne A. de Hullu, Johan Bulten
Modern pathology. 2015;28:295-302
5
C
ha
p
te
r 
 5
Vu
lv
ar
 c
an
ce
r 
in
va
si
on
 d
ep
th
84 85
Abstract
Objective
Depth of invasion is an important prognostic factor for patients with vulvar squamous cell 
carcinoma. The aim of this study was to identify the most optimal method of measuring 
the depth of invasion in relation to the individual outcome in patients with vulvar 
squamous cell carcinoma. 
Methods
Data of 175 consecutive patients with a primary vulvar squamous cell carcinoma with 
known lymph node status, treated in the Radboud University Medical Centre, the 
Netherlands (2000–2010), were stored in a database. At pathology review of 148 (85%) 
cases, depth of invasion was measured using the conventional and alternative methods. 
Clinical and pathological characteristics of patients with a change in FIGO stage were 
compared with those without a change in stage. 
Results
In 148 vulvar squamous cell carcinoma patients, the median depth of invasion was shown 
to be decreased from 5.5mm (range 1.1–20) using the conventional method to 3.6mm 
(range 0.2–20) using the alternative method (P<0.05). This led to a change in the FIGO 
stage in 13 of the 148 (9%) patients and a change in depth of invasion from 3.5 to 0.2mm 
in one patient (1%) with FIGO stage IIIA. Of all 69 stage 1B patients, 13 (19%) were 
downstaged to stage IA. The downstaged patients developed less recurrences (15% vs 
39%) and had a higher disease-specific survival (100% vs 84%) compared with the patients 
who remained FIGO stage IB. 
Conclusion
Using the alternative method for measuring the depth of invasion in tumours of vulvar 
squamous cell carcinoma patients, 19% of the patients with a FIGO stage IB tumour might 
be treated without groin surgery resulting in less treatment-related morbidity. The results 
are promising but more prospective data on a higher number of patients are necessary.
Introduction
Vulvar squamous cell carcinoma is a rare disease that mainly affects elderly women.1 For 
decades, radical surgery (radical vulvectomy with bilateral inguinofemoral lymphadenec-
tomy) has been the standard treatment for the early-stage disease with a favourable 
prognosis but with the consequence of impressive morbidity such as wound-healing 
problems, lymph oedema, and psychosexual impact.2, 3
Over the past years, efforts have been made to individualise the treatment of patients 
with vulvar squamous cell carcinoma and define subgroups of patients who may be 
treated by less radical procedures. Until now, there are some generally accepted 
modifications for patients with macroinvasive tumours (>1-mm invasion): separate 
incisions instead of ‘en bloc’ approach; wide local excision instead of radical vulvectomy; 
unilateral lymphadenectomy in case of a lateralised tumour;4 and a sentinel lymph node 
procedure in patients with a unifocal tumour <4 cm without abnormal groin nodes at 
imaging.5 In case of microinvasive tumours (≤1-mm invasion and a maximum diameter of 
2 cm), patients are treated with a wide local excision only, and treatment of the groins can 
be safely omitted6 because only <1% of these superficially invasive vulvar squamous cell 
carcinoma metastasise to the groins.7, 8 This is in contrast to tumours with >1-mm invasion, 
which have a risk of nodal metastases of up to 34%.8, 9 So far, patients with a stage IA 
tumour are the only group of vulvar squamous cell carcinoma patients who will not need 
to undergo treatment of the groins. 
As the depth of invasion guides the mode of treatment of vulvar squamous cell carcinoma 
patients, it is important that pathologists use a uniform measuring method that reflects 
the best clinical outcome. In the past, several methods have been described by Wilkinson,8 
which are shown in Figure 1. 
In 1984 the International Society for the Study of Vulvo-Vaginal Disease (ISSVD) and the 
International Society of Gynaecological Pathologists (ISGYP) recommended to define the 
depth of invasion as follows: from the epithelial junction of the most superficial adjacent 
dermal papilla to the deepest point of invasion (Method A in Figure 1).10 Reasons for 
choosing this method are not scientific but are mainly based on the following practical 
issues: (1) the adjacent dermal papilla can be found in all sites of the vulva, (2) it is not 
altered by variations in the depth of rete ridges, and (3) the measurement is not significantly 
influenced by hyperkeratosis, tumour surface ulceration, or adjacent epithelial hyperplasia.8, 
10, 11 Only Kurzl et al12 compared several methods of measurement, searching for the 
clearest prognostic differentiation between groups of patients. They found that depending 
on the cutoff point used for the depth of invasion (2, 3, or 5mm), different measuring 
methods led to different (disease-free) survival. Unfortunately, tumours were not classified 
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up and over 1mm, and the lymph node status was not available in this study as all patients 
had undergone groin irradiation. 
On the basis of our experience with the clinical outcome of patients with vulvar squamous 
cell carcinoma and on the basis of the fact that there is no scientific basis for choosing the 
current measuring method for the depth of invasion, it can be argued whether an 
alternative method of measuring depth of invasion may give a better reflection of the 
prognosis. Therefore, the aim of this study was to identify the most optimal method of 
measuring the depth of invasion in relation to the individual outcome in patients with 
vulvar squamous cell carcinoma.
Materials and methods
Patients
All patients with a primary vulvar squamous cell carcinoma and known lymph node status 
(based on results of inguinofemoral lymphadenectomy or sentinel lymph node procedure, 
FIGO stage ≥IB) diagnosed between 2000 and 2010 in the Radboud University Medical 
Centre (RUMC) were included in this study. Data of the patients were collected from medical 
charts, electronic patient files, and pathology reports, and were stored in a database. 
Patient characteristics included age, date of diagnosis, FIGO stage (2009), treatment 
modality, and recurrences. Pathological characteristics included tumour size, depth of 
invasion of the tumour, multifocality, nodal status, and presence of lymphovascular 
invasion. Furthermore, information on vital status, date, and the cause of death was 
obtained until the 1st September 2013.
Pathologic assessment
Available haematoxylin and eosin (H&E) slides of surgical resections of all patients were 
retrieved and revised by an expert gynaecopathologist (JB), independently and unaware 
of the clinical course of the patients. The depth of invasion was measured using a 
measuring ocular and two different methods were addressed: the conventional method 
(measures from the epithelial junction of the most superficial dermal papilla to the 
deepest point of tumour invasion, method A Figure 1) and the alternative method 
(measures from the basement membrane of the deepest adjacent (dysplastic) tumour-free 
rete ridge to the deepest point of invasion, method B Figure 1). Reasons for choosing this 
particular alternative method were as follows: (1) it is also used in measuring invasion 
depth in other cancer sites (such as in cervical13 and larynx/trachea14), (2) logically, tumour 
cells will originate from the nearest rete ridges instead of the most superficial one, (3) 
besides the conventional method, it is the only method described by Wilkinson8 that is 
not altered by variation of rete ridges or influenced by hyperkeratosis, ulceration, or 
epithelial hyperplasia. In cases where the deepest rete ridge was deeper than the tumour, 
the most adjacent basement membrane of the rete ridge was used to measure. Besides 
depth of invasion, grade of differentiation and lymphovascular invasion were determined. 
In case the tumour was multifocal, the deepest lesion was selected and in case the depth 
of invasion was ≤1mm, all lesions were assessed. In cases where the depth of invasion was 
>1mm using the conventional measuring method but ≤1mm using the alternative 
method, the slides of the biopsies taken before primary surgery were retrieved and 
assessed using both measuring methods. On the basis of the depth of invasion measured 
with the alternative method and the characteristics known before (tumour of ≤2 cm 
diameter) and after groin surgery (groin metastasis yes/no), patients were given a new 
FIGO stage.15
Figure 1  Schematic drawing of the skin with different methods of measuring the depth 
of invasion of vulvar squamous cell carcinoma. Method A (conventional method in this 
study): measurement from the epithelial junction of the most superficial adjacent dermal 
papillae to the deepest point of invasion, method recommended by the ISSVD and the 
ISGYP. Method B (alternative method in this study): measurement from the most adjacent 
dysplastic abnormal rete ridge to the deepest point of invasion, modified from one of the 
measuring methods described by Wilkinson et al7. Method C: measurement from the 
surface to the deepest point of invasion=tumour thickness. Method D: measurement 
from the granular layer to the deepest point of invasion (modified from Wilkinson et al8).
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Patients who were included in this study underwent a sentinel lymph node procedure in 
case the tumour diameter was <4 cm and the inguinoferoral lymph nodes were clinically 
nonsuspicious. The pathologic assessment of the sentinel node(s) was performed 
according to the standard protocol used in the GROINSS-V study.5 In short, ultrastaging 
was performed by sectioning the lymph nodes at 2- to 3- mm intervals. In addition, pairs 
of sections were cut at 350-mm intervals and stained with H&E and immunostained with 
cytokeratin 1% AE 1/3 antikeratin solution (Boehringer Mannheim, Mannheim, Germany).
Statistical analysis
The median invasion depths measured using the conventional and alternative methods were 
compared using the Wilkinson-signed rank test. Clinical and pathological characteristics 
of patients with a change in the FIGO stage were compared with those without a change 
in the FIGO stage, using the Fisher’s exact test and the χ² test. Furthermore, for these 
patient groups the overall survival and disease-specific survival were calculated using the 
Kaplan–Meier method. All analyses were performed using the SPSS software, version 20 
(SPSS Inc, Chicago, IL, USA). P-values less than 0.05 were considered to be statistically 
significant.
Results
Population description
For this study, 175 patients met the inclusion criteria: 27 cases (15%) were excluded because 
the H&E slides could not be retrieved (n=26) or because of a low quality of the slides for 
review (n=1). Finally, data from the 148 patients were enrolled in the study. The median 
age of the study population was 72 years (range 36–91). The median time of follow-up 
was 54 months (range 2 weeks to 156 months). Tumour-related characteristics are listed in 
Table 1.
Comparative measurement of tumour invasion
Of all the 148 patients, the depth of invasion was measured using the conventional and 
the alternative method. The invasion depth of 13 patients (9%) did not change; of 80 
patients (54%) the depth decreased 0.1–1mm; of 20 patients (14%) the depth decreased 
1.1–2 mm; and of 35 patients (24%) the depth decreased 2.1–8.1mm. The median depth of 
invasion using the conventional method was 5.5mm (range 1.1–20); using the alternative 
method the median depth of invasion was 3.6mm (range 0.2– 20), which is significantly 
lower (Wilcoxon-signed rank test, P<0.05).
Table 1  Characteristics of 148 women diagnosed with vulvar squamous cell 
carcinoma treated in the Radboud University Medical Centre (2000-2010). 
Characteristics N %
FIGO stage (2009)                                                                                                                                    
I  IB 
   II 
   III 
   IV
  69
    3
  73
    3
47
  2
49
  2
Tumour grade
   I 
   II 
   III 
  24
  78
  46
16
53
31
Lymphovascular  invasion
   Yes 
   No 
  37
111
25
75
Multifocality
   No
   Yes
120
  28
81
19
Positive lymph nodes
   No   
   Yes
  72
  76
49
51
Treatment
   Local surgery 
Wide local excision
Radical vulvectomy
Posterior exenteration
   Groin surgery
Sentinel lymph node procedure
Dissection
Sentinel lymph node procedure + dissection 
   Adjuvant radiotherapy
101
  43
    4
  
52
  72
  24
  
47
68
29
  3
35
49
16
32
Recurrence during follow-up
None
Local
Local + groin
Groin
  92
  47
    1
    8
62
32
  1
  5
Died during follow-up
   No
   Yes
of intercurrent disease
of disease
of unknown cause
83
65
21
31
13
56
44
14
21
  9
N= number of cases
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On the basis of the depth of invasion measured with the alternative method and the 
tumour characteristics known before (tumour diameter) and after groin surgery (groin 
metastasis yes/no), patients were given a new FIGO stage. Table 2 displays the changes in 
the FIGO stage. Of 134 patients (91%), the FIGO stage did not change and of 14 (9%) it did 
change. Thirteen of sixty-nine (19%) patients with FIGO stage IB (lesions >2 cm in size or 
with invasion >1.0mm, confined to the vulva/perineum, with negative nodes) were 
downstaged to FIGO stage IA. In 1 of 44 (2%) patients with FIGO stage IIIA (tumour 
confined to the vulva or adjacent spread to the lower urethra, the vagina, or the anus, with 
one lymph node metastasis ≥5mm or one or two lymph node metastases <5mm) the 
depth of invasion changed from 3.5mm to <1mm (0.2mm). This single case showed 
isolated tumour cells in the sentinel lymph node.
Tumour and clinical characteristics of the patient with FIGO stage IIIA 
VSCC that showed a change in the depth of invasion
The patient was a 49-year-old female with a history of lichen sclerosus and a unifocal 
lesion on the right labium minus of 2 cm. Microscopic evaluation showed a well-differentiated 
tumour without presence of lymphovascular invasion. An H&E-stained slide of the tumour 
is displayed in Figure 2. The patient was treated with a wide local excision and a sentinel 
lymph node procedure of the right groin. Three lymph nodes were removed; in the im-
munohistochemical slides of one node two isolated tumour cells were found (Figure 3). 
Therefore, the patient underwent an unilateral inguinofemoral lymphadenectomy in 
which eight lymph nodes were removed that showed no metastases. After a follow-up of 
120 months, the patient is alive and there is no evidence of disease.
Tumour and clinical characteristics of patients who changed from 
FIGO stage IB to IA and those who remained FIGO stage IB
The median ages of the patients who remained FIGO stage IB (N=56) and who were 
downstaged (N=13) were 75 and 69 years, respectively. Other characteristics are displayed 
in Table 3; the patients who were downstaged had more often a well-differentiated 
tumour (62% vs 18%, P=0.003), less lymphovascular invasion (0% vs 16%), less recurrences 
(15% vs 39%), and died less frequently because of the vulvar squamous cell carcinoma (0% 
Table 2  Comparison of FIGO stages of 148 vulvar squamous cell carcinoma patients 
according to the depth of invasion measured with the conventional and the alternative 
method. 
FIGO stage – conventional method
IA IB II IIIA IIIB IIIC IV Total
FIGO stage
-
alternative 
method
IA - 13* 0 1* 0  0 0 14
IB 0  56 0   0 0  0 0 56
II 0    0 3   0 0  0 0 3
IIIA 0    0 0 43 0  0 0 43
IIIB 0    0 0   0 6  0 0 6
IIIC 0    0 0   0 0   23 0 23
IV 0    0 0   0 0  0 3 3
Total 0 69 3 44 6 23 3 148
*down-staged Figure 2  Microscopical slide of the case with FIGO stage IIIA vulvar squamous cell 
carcinoma in which the depth of invasion changed from 3.5 to 0.2mm because of the 
alternative measuring method. A: measurement of depth of invasion with conventional 
method; B: measurement of depth of invasion with alternative method.
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vs 13%). The median diameter of the tumours in downstaged patients was 6mm (range 
2–19 mm), in contrast to the patients who were not downstaged with a median diameter 
of 25mm (range 5–63 mm). The median depth of invasion in patients who were 
downstaged changed from 2.4mm (conventional method, range 1.1–5mm) to 0.7mm 
(alternative method, range 0.2–1.0 mm), and from 5.6mm (conventional method, range 
1.7–14mm) to 2.6mm (alternative method, range 0.3–13mm) in patients who remained 
FIGO stage IB. An example of the measurements in a tumour that was downstaged is 
displayed in Figure 4.
Overall survival and disease-specific survival of patients with the conventional FIGO stage 
IB at 5 years was 75% (95% confidence interval (CI): 64– 86%) and 88% (95% Cl: 79–96%), 
respectively. In the group of patients with the alternative FIGO stage IA, the 5-year disease- 
Figure 3  Microscopical slide of the sentinel lymph node of the case with FIGO stage IIIA 
vulvar squamous cell carcinoma in which the depth of invasion changed from 3.5 to 
0.2mm because of the alternative measuring method. Arrow: one immunohistochemically 
positive tumour cell.
Table 3  Comparison of characteristics between 13 women who were downstaged 
from FIGO stage IB to IA and 56 women who remained FIGO stage IB with the use of 
the alternative measuring method for the depth of invasion of vulvar squamous cell 
carcinoma. 
IBàIA
(N=13)
IB=IB
(N=56)
P-ValueCharacteristics N % N % 
Tumour grade
  I 
  II 
  III 
8
4
1
 61
 31
   8
10
33
13
18
59
23 0.003*
Lymphovascular  invasion 
  Yes 
  No  
  0
13   
    0
100
9
47
16
84 0.13#
VIN adjacent to the tumour
  No
  Yes, 
uVIN
dVIN
3
10
4
6
 23
 77
 31
 46
11
45
6
39
20
80
10
70
0.52#
Multifocality
  No
  Yes
10
3
 77
 23
39
17
70
30 0.44#
Location
  Central  
  Lateral^
11
  2
 85
 15
45
11
80
20 0.54#
Treatment
  Local surgery
Wide local excision 
Radical vulvectomy
  Groin surgery
Sentinel lymph node procedure 
Dissection
Sentinel lymph node procedure +dissection
  Adjuvant radiotherapy
12
1
9
4
0
0
 92
   8
 69
 31
    0
    
0
41
15
24
26
6
0
73
27
43
46
11
  0 NA
Recurrences
  No
  Yes
Local
Groin
Local + Groin
11
2
2
0
0
 85
 15
 15
    0
    0
34
22
17
4
1
61
39
30
  7
  2
0.09#
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specific survival was 100% (95% Cl: 75–100%), which is higher compared with the 5-year 
disease-specific survival of the group of patients with the alternative FIGO stage 1B (84%; 
95% Cl 73–95%;P=0.15). The disease-specific survival is shown in Figure 5.
Discussion
This is the first study that focused on comparing the conventional with an alternative 
method of measuring the depth of invasion in order to find the method corresponding 
with the most optimal individual outcome in patients with vulvar squamous cell 
carcinoma. The results of this study show that with the use of the alternative measuring 
method, from the basement membrane of the deepest adjacent tumour-free rete ridge to 
the deepest point of invasion, 19% of the patients with a FIGO stage IB tumour were 
Table 3  Continued. 
IBàIA
(N=13)
IB=IB
(N=56)
P-ValueCharacteristics N % N % 
Died during follow-up
  No 
  Yes 
of intercurrent disease
of disease
unknown cause of disease
9
4
4
0
0
 69
 31
 31   
  0
  0
37
19
5
7
7
66
34
  9
12.5
12.5
0.61#
Abbreviations: FIGO= International Federation of Gynaecology and Obstetrics. NA= not applicable. 
*χ²test. #Fisher’s exact test. ^More than 1 cm of the midline.
Figure 4  Microscopical slide of a case which was downstaged because of the alternative 
measuring method of the depth of invasion in vulvar squamous cell carcinoma. A: measurement 
of depth of invasion with conventional method; B: measurement of depth of invasion with 
alternative method.
Figure 5  Disease-specific survival of vulvar squamous cell carcinoma patients* with FIGO 
stage IA vs stage IB after using the alternative measuring method for the depth of invasion, 
in months. *Five patients were excluded from analysis because the cause of death was 
unknown. 
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downstaged to FIGO stage IA. These patients showed less recurrences and a higher 
disease specific survival compared with the remaining FIGO stage IB tumours. This 
downstaged group might be treated without groin surgery. A change in the depth of 
invasion from 3.5 to 0.2mm occurred in one patient (1%) with FIGO stage IIIA who is alive 
without any evidence of disease 10 years after treatment. The alternative method of 
measuring the depth of invasion of tumours in vulvar squamous cell carcinoma patients is 
a promising alternative that needs to be a subject of more extensive research before 
implementation.
The conventional measuring method was chosen mainly based on practical issues11; the 
adjacent dermal papilla can be found in all sites of the vulva, is not altered by variations in 
the depth of rete ridges, and the measurement is not significantly influenced by 
hyperkeratosis, tumour surface ulceration, or adjacent epithelial hyperplasia. Wilkinson et 
al16 considered different measuring methods in one of his first studies about microinvasive 
carcinomas of the vulva and states that the difficulty in measuring from the deepest rete 
ridge (the alternative method used in this study) is that the overlying epithelium at the site 
of the neoplasm may itself be neoplastic and would be a variable site of measurement. 
The problem of variability can be argued; in our study no cases with the invasive overlying 
epithelium were seen. No disadvantages are described about the conventional measuring 
method by Wilkinson; however, often it turns out to be difficult to choose the most 
adjacent superficial rete ridge. In some cases the rete ridge is far from the tumour, and 
logically it is not likely that the tumour will originate from a point that is far away. Maybe, 
this difficulty is one of the reasons for the recent findings of Abdel-Mesih et al17; they 
showed that the interobserver reliability between 11 gynaecologic-orientated pathologists 
for diagnosing vulvar squamous cell carcinoma as invasive is fair (Kappa=0.24) and for 
measuring depth of invasion moderate (Kappa=0.51). When using the conventional 
method, interpretation of the location of the most superficial dermal papilla varied among 
pathologists. Pathologists used a different measuring method, similar to those displayed 
in Figure 1, other than the conventional one in 0–39% of the cases for reasons not 
mentioned. The question arises that how reliable is the use of the alternative method in 
our study. The recognition of differentiated VIN, which was in the surrounding of the 
tumour in 50–58% of the cases, is another difficulty in this study. We showed in one of our 
earlier studies that the interobserver agreement on the diagnosis of differentiated VIN is 
not high (Kappa 0.08–0.54);18 therefore, it may be more difficult to recognise the most 
adjacent rete ridge.
When using the alternative measuring method, 19% of the patients were downstaged. 
This subgroup of patients showed more often a well-differentiated tumour, had less 
lymphovascular invasion, less recurrences, and a disease-specific survival of 100%. In this 
group no groin recurrences were identified. Probably this subgroup of patients may be 
treated without groin surgery, with less morbidity as a result. In our study population, four 
inguinofemoral lymphadenectomy procedures and nine sentinel lymph node procedures 
could have been prevented. Although the morbidity of the sentinel lymph node 
procedure is limited, it might be of great advantage to prevent any surgical procedure of 
the groins to save the sentinel lymph node procedure for a possible future de novo 
tumour at follow-up. One should keep in mind that ±25% of the vulvar squamous cell 
carcinoma patients will develop local recurrences, requiring complete lymphadenectomy 
in case of an earlier sentinel lymph node procedure as part of the primary treatment.
There is a chance of <1% of positive lymph nodes in patients with a depth of invasion of 
<1mm measured with the conventional measuring method.7, 8, 19 This is substantially lower 
compared with the 7% when the case with FIGO stage IIIA, which had a depth of invasion 
of 0.2mm (instead of 3.5mm) with the alternative measuring method, would be included 
within the group of 13 cases that were downstaged from FIGO stage IB to IA. However, this 
single case showed only two solitary immunohistochemically detected tumour cells in 
the sentinel lymph node, and the patient is alive without any evidence of disease 10 years 
after treatment. Although the finding of the isolated tumour cells in the sentinel lymph 
node seems to be an important disadvantage of using the alternative measuring method, 
the value of this finding is questionable. In 2000, the sentinel lymph node procedure was 
introduced with ultrastaging and the use of immunohistochemistry as a routine procedure. 
This technique allows a more extensive pathological examination of the lymph nodes 
compared with that of the conventional lymph node dissection, which will result in an 
increase in the detection of small tumour deposits such as isolated tumour cells and mi-
crometastases.20, 21 In a study of van der Zee et al5 sentinel lymph nodes were examined by 
routine pathological examination, and only when no metastases were found, ultrastaging 
was performed. A total number of 163 positive nodes were detected, of which 95 (58%) 
were detected by routine pathological examination and 68 (42%) by ultrastaging. Oonk et 
al22 showed that the risk of nonsentinel node metastases increases with the size of the 
sentinel lymph node metastases; one of 24 patients (4%) with isolated tumour cells had 
non-sentinel lymph node metastases. Furthermore, they showed that the prognosis of 
patients with a positive sentinel lymph node based on isolated tumour cells is similar to 
patients with a negative sentinel lymph node.5, 22 However, firm conclusions are difficult to 
draw because of the lack of power, and therefore Oonk et al22 recommend additional 
groin treatment for all patients with vulvar SCC with sentinel lymph node metastases, 
regardless of the size of the lymph node metastases. Besides, the therapeutic effect of this 
procedure, which was part of the routine treatment, is undefined. More is known about 
the role of isolated tumour cells in patients with breast cancer. De Boer et al23 showed that 
isolated tumour cells or micrometastases in the sentinel lymph node were associated with 
a reduced 5-year disease-specific survival for women with favourable early-stage breast 
cancer who did not receive adjuvant hormonal therapy or chemotherapy. In patients with 
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isolated tumour cells or micrometastases who did receive adjuvant therapy, disease- 
specific survival was improved. In the study of Pepels et al24 the relevance of isolated 
tumour cells with respect to the risk of regional recurrence is considered to be of uncertain 
significance, not supporting the routine use of axillary treatment (in contrast to recom-
mendations in sentinel lymph node micrometastases). However, other large studies on 
isolated tumour cells in patients with breast cancer have not shown any effect on disease- 
specific survival.25 An important issue when comparing vulvar squamous cell carcinoma 
patients with breast cancer patients is the difference of receiving adjuvant therapy. In 
vulvar squamous cell carcinoma patients, no adjuvant therapy is given (only radiotherapy in 
case of more than one intranodal groin lymph node metastasis or extranodal growth), 
whereas in breast cancer patients (neo)adjuvant systemic therapy and/ or locoregional 
radiation therapy is given in a substantial number of patients. This may result in the 
eradication of possible (micro)metastases. Another difference is the observation that a 
recurrence in the groin in a patient with vulvar squamous cell carcinoma is nearly always 
fatal and is an important reason to be reluctant in omitting treatment of the groin. Further 
study is needed to establish the prognostic significance of isolated tumour cells in sentinel 
lymph nodes of patients with vulvar squamous cell carcinoma.
In conclusion, using the alternative method for measuring the depth of invasion in vulvar 
squamous cell carcinoma, 19% of patients with a FIGO stage IB tumours might be treated 
less radically, resulting in less treatment-related morbidity. Only one patient with FIGO 
stage IIIA with microinvasive vulvar squamous cell carcinoma based on the alternative 
measuring method had isolated tumour cells in the sentinel lymph node. On the basis of 
our result, it seems reasonable to further explore the introduction of the alternative 
measuring method in a prospective study with a higher number of patients before 
implementation in daily clinical practice.
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Abstract
Introduction
In general, centralisation of care for patients with rare malignancies is advised in order to 
improve outcome with respect to prognosis and treatment related morbidity. Therefore, 
centralisation of women with vulvar squamous cell carcinoma (SCC), which is an extremely 
rare tumour, has been advocated by the national guidelines of the Dutch Society of 
Obstetrics and Gynaecology in 2000. The objective of this study was to determine whether 
this advice has been adapted and has led to improved survival.
Methods
All patients diagnosed with vulvar malignancies between 1989 and 2008 in the Eastern 
part of the Netherlands were retrieved from the population-based cancer registry held by 
the Comprehensive Cancer Centre, The Netherlands. Patient- and tumour characteristics 
and vital status until January 2011 were retrieved. Data of patients diagnosed in two 
periods (before and after release of the guideline; 1989–1999 and 2000–2008) were 
compared. Relative survival rates were calculated as a good approximation of cause-specific 
survival.
Results
A total number of 382 patients with vulvar SCC with invasion >1 mm, who had an indication 
for groin surgery, were included in the analysis. In the first decade 62% (123 of 198 patients) 
were treated in a specialised oncology centre, which increased to 93% (172 of 184 patients) 
in the more recent period. Overall, the 5 year relative survival improved slightly from 68% 
(95% confidence interval (CI) 59–76%) to 72% (95% CI 63–81%). After adjustment for age 
and stage, being treated in a specialised oncology centre was an independent prognostic 
factor for survival.
Conclusion
Centralisation of care for vulvar SCC patients has been well adopted in the Eastern part of 
the Netherlands. Being treated in a specialised oncology centre was associated with a 
better survival after adjustment for age and stage.
Introduction
Vulvar carcinoma is a very rare gynaecologic malignancy with a yearly incidence of 1–2 per 
100,000 women.1 In the Netherlands 320 new cases of vulvar carcinoma are diagnosed 
each year.2 The majority of patients have a squamous cell carcinoma (SCC); only a minority 
of patients suffers from basal cell carcinoma, melanoma or adenocarcinoma.3 Vulvar SCC 
spreads mainly via lymphatics, primarily to the inguinofemoral lymph nodes.
The cornerstone of the treatment of vulvar SCC is surgery which offers an excellent chance 
of cure. Current standard treatment entails a wide local excision (WLE) with uni- or bilateral 
inguinofemoral lymphadenectomy via separate incisions.4 To decrease treatment related 
morbidity such as wound healing problems and lymphoedema, patients with an early 
stage disease may be managed by a WLE and a sentinel lymph node dissection (SLND) 
preferably within the setting of a clinical trial.5-8 Radiotherapy is only indicated when a 
patient is not eligible for surgery or postoperatively when lymph node metastases and/or 
narrow local resection margins are present. The most important prognostic factor is the 
inguinofemoral lymph node status.  In patients without groin node metastases the 5-year 
disease specific survival (DSS) is 80–90%7, 9 whilst in patients with nodal disease the DSS 
approaches only 50%.10 The recurrence rate is high, up to 30%.11 Whilst local recurrences 
can mostly be cured with surgery, groin recurrences are nearly always fatal.
In other rare malignancies, such as oesophageal and pancreatic carcinoma, an association 
exists between volume and/or specialisation of a hospital on the one hand and better 
survival on the other hand. Studies in these malignancies showed that the outcome of 
patients treated in a high-volume specialised centre was significantly better compared to 
outcome of patients treated in low volume hospitals.12-17 Benefits of centralisation of care 
are the development of expertise, the opportunity to give patients an appropriate 
treatment from experienced clinicians using new techniques that may improve prognosis 
and/or lower the treatment related morbidity, and the facilitation of training and research.
Because vulvar carcinoma is a rare tumour and the technical skills to perform surgery are 
no part of the training for general gynaecologists in the Netherlands, centralisation to 
specialised oncology centres has been advocated by national guidelines of the Dutch 
Society of Obstetrics and Gynaecology in 2000.18 However, it remains to be proven if this 
policy indeed improves outcome with respect to prognosis and morbidity of unselected 
patients in the general health care environment.
To our knowledge, this is the first population-based study in the Netherlands evaluating 
the centralisation of vulvar cancer patients as recommended by the Dutch guidelines.
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Patients and methods
Patient selection
Patients diagnosed with a primary vulvar malignancy in the period 1989–2008 in the 
Eastern part of the Netherlands were retrieved from the population-based cancer registry 
held by the Comprehensive Cancer Centre, The Netherlands (IKNL). This region has 
approximately 1.3 million inhabitants and is served by one specialised oncology centre 
and seven community hospitals. Eligible patients fulfilled the following criteria: primary 
invasive vulvar tumour diagnosed between 1st January 1989 and 31st December 2008 
and ICD-O-3 topography code C510-512, C518-C519.19
Data
Standard cancer registry data were retrieved from the database. These data were collected 
by trained registration staff through consulting pathology reports and medical files. Data 
concerning patients age, date of diagnosis, tumour characteristics (topography, histology, 
invasiveness, stage and treatment), type of hospital (community hospital or specialised 
oncology centre) and follow-up (vital status, date of emigration and date of death) were 
obtained. Two periods were identified: before (between 1989 and 1999) and after 
(between 2000 and 2008) the introduction of the guideline in 2000. The follow-up of all 
patients was completed until the 1st January 2011 by the IKNL.
All pathologically confirmed carcinomas were staged according to the FIGO surgicopath-
ological classification system of 1992.7 Tumours diagnosed before 1992 that were staged 
according to an earlier FIGO classification system were converted to the classification 
system of 1992. Pathology records of stage I tumours without known differentiation into 
stage IA (61 mm invasion) or IB (>1 mm invasion) (N = 82) were reviewed retrospectively 
through PALGA, the nationwide network and registry of histo- and cyto-pathology in the 
Netherlands. When possible, the differentiation into stage IA and IB was made. When 
insufficient information was available for pathological staging, the clinical stage was used 
in the analyses.
Statistical analyses
Descriptive analyses were performed to give insight in the differences in patient and 
tumour characteristics. Furthermore, the number of patients treated in a specialised 
oncology centre or community hospital in the period 1989–1999 and 2000–2008 was 
described. In order to evaluate the effect of the introduced guideline, the proportion of 
patients treated in an oncology centre versus community hospital in both time periods 
was evaluated by using the χ2 test.
Secondly, relative survival analyses were performed to evaluate the effect of being treated 
in a specialised oncology centre versus community hospital on survival. For these analyses, 
a subgroup of patients with vulvar SCC stage IB or higher was selected. Reason for this is 
that especially patients with stage IB or higher are appropriate candidates for treatment in 
a specialised oncology centre because they need groin surgery (elective inguinofemoral 
lymphadenectomy or SLND), that preferably should be performed by a fully trained 
gynaecologic oncologist in a specialised oncology centre. Patients with stage 1A vulvar 
SCC, basal cell carcinoma, and melanoma were excluded from further analysis, because in 
these patients elective inguinofemoral lymph node dissection can be safely omitted. 
Therefore, for these patients no strict need for specialised care with respect to the groins 
exists. Relative survival rates were calculated as a proximation of cause-specific survival. 
This method adjusts crude survival rates amongst patients with malignancies for the 
expected mortality according to annual life tables of the general population matched on 
age, gender, calendar period and geographic area. Besides computing the 1-, 5-, and 
10-year relative survival rates (RSR) before and after introduction of the guideline, 1-, 5-, 
and 10-year RSRs were calculated by stage, age and type of hospital. The follow-up used 
in the analyses was calculated as the time between date of diagnosis and date of death or 
1st January 2011 (end of follow-up). Univariable and multivariable relative survival models 
were estimated using a generalised linear model with an assumed Poisson distribution for 
the observed number of deaths.20 Analyses were performed using the software package 
SAS version 9.2 (SAS Institute, Cary, North Carolina, United States of America (USA)) and 
SPSS 16.0 (SPSS Inc, Chicago, IL, USA).
Results
Between the 1st January 1989 and the 31st December 2008 in the Eastern part of the 
Netherlands a total number of 549 patients were diagnosed with a primary vulvar 
malignancy. Of all patients, 295 (54%) were diagnosed between 1989 and 1999 and 254 
(46%) between 2000 and 2008.
See Table 1 for an overview of the patient- and tumour characteristics before and after 
introduction of the guideline. No difference in age at diagnosis between the two periods 
was found. SCC was the most common histopathological tumour type found in both 
periods. The proportion of patients treated in the specialised oncology centre increased 
over time (p < 0.0001, χ2 test). When addressing histopathological subtypes without 
taking into account the period of diagnosis, SCC was the most common tumour type 
found in the specialised centre (n = 318, 84.9%) and community hospitals (n = 102, 59%). 
The percentage of patients with a basal cell carcinoma was higher in community hospitals 
(n = 49, 28.3%) compared to the specialised oncology centres (n=17, 4.5%).
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After excluding all non-SCC vulvar malignancies and stage IA SCCs of the vulva, data of a 
total number of 382 patients with a vulvar SCC stage IB or higher were analysed; 198 
before and 184 after introduction of the guideline. For 347 patients (91%) the pathologically 
based FIGO stage was available. In Table 2 the stage distribution by period is presented. 
The percentage of patients with an advanced stage SCC (stage III and IV) increased over 
time; 26.7% in the first time period versus 37.0% in the second time period. The proportion 
of patients treated in a specialised centre increased significantly over time (p < 0.0001, 
χ2 test); in the first period 123 of 198 patients (62%) were treated in a specialised centre 
compared to 172 of 184 patients (93.5%) during the second period. This is also displayed in 
Fig. 1. Since 2000 only 12 of 184 patients (6.5%) with vulvar SCC were treated in a community 
hospital. The median age of these 12 patients was 80 years of age and 6 of 12 patients did 
not receive any treatment.
The 5 year RSR of patients with stage IB or higher vulvar SCC (n = 382) was 70% (95% CI 
64–77%). Table 3 shows the RSRs of patients with SCC stage IB or higher by stage, age, 
type of hospital, and period of diagnosis. The 5- and 10- year RSR of patients with an early 
FIGO stage (IB and II, which means absence of lymph node metastases) were significantly 
better compared to patients with an advanced stage tumour (III and IV). Because the type 
Table 1  Description of patient and tumour characteristics of all patients with vulvar 
cancer before and after release of the guideline. 
Total 1989-1999 2000-2008
Number of patients 549 295 254
Median age at diagnosis (range)   73 (18-99)   73 (18-90)   73.5 (20-99)
Place of treatment
Specialised oncology centre (%) 376 159 (53) 217 (85)
Community hospital (%) 173 136 (47)   37 (15) <0.0001 d
Histopathological subtype N % N % N %
Squamous cell carcinoma 421 76.6 220 74.6 200 78.7
Basal cell carcinoma   66 12.0   38 12.9   28 11.0
Melanoma   24   4.4   11   3.7   13   5.1
Adenocarcinoma   15   2.7   12   4.1     3   1.2
Carcinoma NOS a     8   1.5     6   2.0     2   0.8
Others   15   2.8     8 b   2.7     7 c   2.8
aNOS = not otherwise specified. bIncluding: vulvar sarcoma (n=4, 1.4%), Pagets disease (n=1, 0.3%), lymphoma 
(n=2, 0.7%) and adenosquamous carcinoma (n=1, 0.3%). cIncluding: vulvar sarcoma (n=4, 1.6%) and Pagets 
disease (n=3, 1.2%). dχ² test.
Table 2  Description of patient and tumour characteristics of patients with SCC stage 
IB or higher; before and after release of the guideline. 
Total 1989-1999 2000-2008
Number of patients 382 198 184
Median age at diagnosis (range)   73 (17-98)   73 (17-92)   73 (39-98)
Place of treatment
Specialised oncology centre (%) 295 123 (62) 172 (93.5)
Community hospital (%)   87   75 (38)   12 (6.5) <0.0001 c 
FIGO stage N % N % N %
Stage I   99 25.9 47 a 23.7 52 b  28.2
Stage II 116 30.4 72 36.4 44 23.9
Stage III   97 25.4 45 22.7 52 28.3
Stage IV   24   6.3   8   4.0  16   8.7
Stage unknown   12   3.1  11   5.6   1   0.5
Clinical stage only   34   8.9 15   7.6 19 10.3
aIncluding stage IB (n=41) and TI with unknown  stage (IA or IB; n=8). bIncluding stage IB (n=19) and TI with 
unknown stage (IA or IB; n=1). cχ² test.
Figure 1  Number of patients with squamous cell carcinoma stage IB or higher treated in 
a specialised oncology centre and community hospital, 1989-2009.
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of hospital and the period of diagnosis are closely correlated, the RSRs of the type of 
hospital by period were calculated as well which is presented in Table 3.
Table 3 shows that the 5 year RSR of all patients has improved from 68% (95% CI 59–76%) 
in 1989–1999 towards 72% (95% CI 65–83%) in 2000–2008, which is also displayed in Fig. 2A. 
Patients treated in a specialised oncology centre in the period 2000–2008, appeared to 
have a comparable 5- year RSR compared to patients treated in a specialised centre in the 
first time period, as can be seen in Fig. 2B.
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Figure 2  (A) Relative survival of patients with SCC stage IB or higher by period of diagnosis. 
(B) Relative survival of patients with SCC stage IB or higher by type of hospital and period 
of diagnosis.
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In Table 4 the results of the uni- and multivariable survival analyses are presented. Disease 
stage and being treated in a specialised oncology centre were univariably associated with 
a better survival. In the multivariable analysis these variables remained independent 
prognostic factors. Advanced stage and not being treated in a specialised centre both 
were associated with a dismal prognosis.
Discussion
This population-based study demonstrates that centralisation of care of patients with 
vulvar malignancies, as recommended by the Dutch guidelines in 2000, has been well 
adopted in the Eastern part of the Netherlands. Being treated in a specialised oncology 
centre was associated with better survival even after adjustment for age and stage.
In comparison with the period before introduction of the guideline, when 53% of the 
patients were treated in a specialised oncology centre, the number of patients treated in 
a specialised oncology centre increased until 85% in the more recent period. Even more 
important, amongst patients with vulvar SCC with invasion >1 mm who had an indication 
for groin surgery (inguinofemoral lymphadenectomy or SLND) the number of patients 
treated in a specialised oncology centre increased from 62.0% during the first period 
towards 93.5% in the second period. A group of only 12 (of 184, 6.5%) patients was treated 
in a community hospital in the second time period. As the median age of these 12 patients 
was 80 years of age and six patients did not receive any treatment, these patients may 
have had a poor performance status or were suffering from multiple co-morbidities. It can 
be assumed that these patients were more likely to stay in a community hospital for 
palliative care because of patients’ or gynaecologists’ preference. Unfortunately, detailed 
information about performance status was not available in this study. Apparently, a clear 
trend towards centralisation is observed in women with the need for groin surgery (SCC 
with >1 mm invasion). Only a minority (12 patients in 9 years in the whole region) of 
patients with vulvar SCC was not referred to a specialised oncology centre.
To evaluate whether the policy of centralisation indeed improved outcome of patients 
with vulvar malignancies, we compared the RSR of patients with vulvar SCC stage IB or 
higher (>1 mm invasion) before and after introduction of the guideline. Overall, the 5-year 
RSR increased from 68% before towards 72% after the introduction of the guideline which 
is not significant possibly due to lack of power. The rise in RSR is not likely to be caused by 
a difference in age as the age distribution was equal in both time periods. Furthermore, 
FIGO stage either causes this difference as in the first time period the percentage of 
patients with a FIGO stage III or IV is lower (26.7%) compared to the second time period 
(37.0%). However, one needs to realise that this observed difference may be caused by the 
introduction of the SLND as a result of which pathologic analysis enhanced, such as 
multiple sectioning and application of specific immunohistochemical staining. This has 
led to a more sensitive detection of micro metastases in the SLN which resulted in an 
upstaging of patients with early stage vulvar cancer.5, 9 Although the overall RSR of patients 
with vulvar SCC improved over time for the whole region (Fig. 2A), the RSR of patients 
being treated in a specialised centre was almost the same before and after centralisation 
(Fig. 2B). This can probably be explained by the fact that patients with a bad prognosis 
because of advanced disease stage and/or low performance status were treated in 
community hospitals in the first period (which resulted in a 5-year relative excess risk (RER) 
of 56%, see Fig. 2B), whereas almost all these patients were treated in a specialised centre 
during the second time period. Therefore, in this period the case mix in the oncology 
centre was probably less favourable, but the survival remained similar which indicates an 
overall improvement of survival. Moreover, we hypothesise there may be an additional 
role for the absence of improvement by the introduction of the SLN procedure. Although 
morbidity decreases, it might have a slightly decrease of prognosis, due to the learning 
curve and missing a positive SLN. Important mentioning is that there are some limitations 
of the use of survival as an end-point to evaluate the outcome of vulvar malignancies, as 
different aspects can have an effect on survival (e.g. treatment delay). This implicates that 
the results should be interpreted carefully. 
Table 4  Cox Proportional Hazards regression analyses (univariable and multivariable) 
of all patients with SCC stage IB and higher, diagnosed before (1989-1999) and after 
release of the guideline (2000-2008).
Univariable 
RERa (95% CIc)
Multivariable 
RERa (95% CIc)
Age 
 Younger than 65 yearsb
 65 years and older 1.52 (0.94-2.45)
Period
 1989-1999b
 2000-2008 0.87 (0.54-1.40)
Stage
 Stage I-IIb
 Stage III-IV
 
5.17 (2.89-9.28) 6.41 (3.62-11.34)
Specialised oncology centre
 Yesb
 No 2.51 (1.57-4.00) 3.63 (2.15-6.11)
 aRER= Relative Excess Risk. bReference category. c95% CI= 95% Confidence Interval
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Besides an improvement in survival, another advantage of more patients being treated in 
a specialised oncology centre might be less morbidity after the treatment. In recent years, 
during the second decade of our study, the treatment of patients with early stage vulvar 
SCC shifted from inguinofemoral lymphadenectomy into the SLND procedure. Patients 
benefit from less treatment-related morbidity like wound breakdown, cellulitis, lymphoedema 
and erysipelas after SLND. It is suggested that surgeons should perform this type of 
surgery at least 5–10 times per year to meet quality standards. In a rare tumour such as 
vulvar SCC, this will require centralisation.5
In conclusion, the present study showed that centralisation of the treatment of patients 
with vulvar SCC who need groin surgery has been well adopted in the Eastern part of the 
Netherlands. Being treated in a specialised oncology centre is associated with a better 
survival.
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Abstract
Introduction
Previous studies showed an increase in incidence of vulvar intraepithelial neoplasia (VIN), 
the premalignant lesion of Vulvar Squamous Cell Carcinoma (VSCC). Furthermore, during 
the last decades treatment of VSCC became less radical. Considering these changes the 
aim of this study was to describe trends of incidence and survival of patients with VSCC in 
the Netherlands.
Methods
All patients with VSCC diagnosed between 1989 and 2010 (n = 4614) were selected from 
the Netherlands Cancer Registry. Trends in age-adjusted incidence rates were evaluated 
by calculating the estimated annual percentage change (EAPC). Joinpoint regression 
analysis was used to detect changes in trends. Five-year relative survival rates were 
calculated for four time periods.
Results
The incidence of VSCC has increased since 2002 (EAPC 5.0; 95% confidence interval (CI): 
2.7–7.7%). In women aged <60 years incidence rates increased significantly during the 
whole study period (EAPC 3.5%; 95% CI: 2.0–4.9), while in women aged P60 years only an 
increase has observed from 2004 onwards (EAPC 5.0; 95% CI: 1.5–8.6). Survival rates did not 
change over time.
Conclusion
The incidence rate of VSCC has increased from 2002 onwards in all women. Over the 
whole study period the increase was strongest in women aged <60 years. The introduction 
of less radical surgery did not affect survival. 
Introduction
Vulvar carcinoma is a rare malignancy. In the Netherlands it is accounting for six to eight 
percent of all gynaecological malignancies. Annually, approximately 360 new cases of 
vulvar carcinoma and over 100 deaths are reported1. A two to fourfold increasing incidence 
of the premalignant lesion of vulvar carcinoma, vulvar intraepithelial neoplasia (VIN), is 
observed in several countries.2-6 Until now, only few studies showed a tendency towards 
an increasing incidence in vulvar carcinoma.3, 4
About 80 percent of all vulvar malignancies are squamous cell carcinomas (SCCs) of which 
20 percent is related to the human papilloma virus (HPV) and associated with the precursor 
lesion usual VIN (uVIN). This type of vulvar carcinoma primarily affects younger women. 
The majority of SCCs is non HPV related and occurs in elderly women, often in the 
background of lichen sclerosus (LS) and/or differentiated VIN (dVIN).7-9
The last two decades, treatment of patients with vulvar SCC (VSCC) has changed.10. Until 20 
years ago radical vulvectomy with ‘en bloc’ bilateral inguinofemoral lymphadenectomy 
was the standard treatment for almost all patients with VSCC. Since the early nineties 
the surgical treatment of VSCC has become more individualised.11 Current treatment 
entails a wide local excision (WLE) with uni- or bilateral inguinofemoral lymphadenectomy 
via separate incisions. More recently, sentinel lymph node dissection (SLND) has been 
introduced in early stage VSCC as a safe technique with a very low false negative rate. 
Though it is the standard management of early stage VSCC, all SLND procedures in the 
Netherlands are performed within the setting of a clinical trial from 2000 onwards.12 
Compared to a complete lymphadenectomy, SLND is associated with less treatment-related 
morbidity without compromising prognosis.13 As the technical skills to perform surgery 
are not part of the training of general gynaecologists in the Netherlands and the incidence 
of VSCC is low, treatment in a specialised oncology centre has been advocated by national 
guidelines of the Dutch Society of Obstetrics and Gynaecology in 2000.14
With the intention to study the effect of the increase of patients diagnosed with VIN and 
the given recent changes in treatment modalities, the aim of this population- based study 
was to determine the incidence and survival of VSCC in the Netherlands in the period 
between 1989 and 2010.
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Patients and methods
Data collection
Patients diagnosed with a primary vulvar malignancy in the period 1989–2010 in the 
Netherlands were selected from the Netherlands Cancer Registry (NCR). This nationwide 
registry documents all newly diagnosed patients with cancer and has a nationwide 
coverage since 1989. The completeness of the NCR is estimated to be at least 95%.15
Standard cancer registry data were retrieved from the NCR. These data were collected by 
fully trained registrars from pathology reports and patient files. Data concerning patients’ 
age, date of diagnosis and tumour characteristics (topography, histology, invasiveness, 
stage and treatment) were obtained. Information on vital status and date of death was 
retrieved from municipality registries and from the database of deceased persons of 
the Central Bureau for Genealogy and the municipal demography registries (GBA). The 
follow-up data were completed until the 1st January 2011.
Topography and morphology are coded according to the International Classification of 
Diseases for Oncology (ICD-O).16 Tumour-node-metastasis (TNM) classification17 is used 
for tumour staging and converted to the classification of the Fédération Internationale de 
Gynécologie et d’Obstétrique (FIGO).18 To evaluate the centralisation to specialised oncology 
centres, place of treatment (community hospital or specialised oncology centre) was 
retrieved. A specialised oncology centre is defined as a centre that treats at least 20 patients 
with vulvar cancer per year, in this study eight academic centres and two large public 
hospitals were classified as specialised oncology centre. As the classification system of 
FIGO stage was changed in 2009, analyses considering FIGO stage were only performed 
until 2009. 
Statistical analyses
For the analyses concerning incidence and survival, only patients with VSCC were included. 
The study period was divided into four periods (1989–1994, 1995–1999, 2000–2004 and 
2005–2010). Descriptive analyses and Chi-square tests were performed to evaluate 
differences in patient and tumour characteristics between different time periods. Annual 
age-standardised incidence rates adjusted to the European standard population (ESR) 
were calculated. Changes in rates were evaluated by calculating the estimated annual 
percentage change (EAPC) and the corresponding 95% confidence interval. To calculate 
this, a regression line was fitted to the natural logarithm of the rates, using the calendar 
year as regressor variable (i.e. y = ax + b where y = ln(rate) and x = calendar year, then EAPC 
= 100 * (ea-1)). The Joinpoint Regression Programme (version 3.5.1.) from the Surveillance 
Research Programme of the US National Cancer Institute (http://surveillance.cancer.gov/
joinpoint/) was used to identify significant changes in trends.
Relative survival rates (RSR) were calculated as an estimation of cause-specific survival 
according to the Ederer II method.19 In relative survival analyses the ratio of observed 
survival to the expected survival is calculated. Survival time was defined as date of 
diagnosis to date of death. Five-year relative survival rates were calculated by period of 
diagnosis, age-category (<60 and ≥60) and FIGO classification. Multivariable relative 
survival analyses, using Poisson regression modelling were performed to calculate relative 
excess risk of dying (RER). Age, period of diagnosis and FIGO classification were entered in 
the model. To study the effect of place of treatment the variable treated in a specialised 
centre (yes/no) was added to the model. Analyses were performed using Stata statistical 
software package (version 12.0). A p-value of less than 0.05 was considered statistically 
significant.
Results
Between 1989 and 2010, a total number of 5680 women were diagnosed with a vulvar 
malignancy; 4614 (81%) women were diagnosed with SCC, 8% with basal cell carcinoma, 
6% with vulvar melanoma and 5% with other histological subtypes. The distribution of 
histological subtypes did not differ over the calendar periods (p = 0.2).
Further analyses were only performed in patients with VSCC. See Table 1 for an overview 
of patient and tumour characteristics by period of diagnosis. Between 1989 and 2010 the 
absolute number of women diagnosed with VSCC increased from 183 to 315, which is an 
increase of more than 70%. The incidence rate (ESR) of VSCC in 1989 was 2.0 per 100,000 
and increased to 2.7 per 100,000 in 2010 (Figure 1). This increase is statistically significant 
(EAPC: 1.4%; 95% confidence interval (CI): 0.6 to 2.1). Joinpoint analyses revealed a 
statistically significant annual increase in incidence of VSCC of 5.0% (95% CI: 2.7–7.7) 
between 2002 and 2010, while during 1989 and 2002 no increase was observed (Table 2). 
The incidence rate (ESR) of VSCC in women aged <60 increased statistically significantly 
between 1989 and 2010 (EAPC 3.5; 95% CI: 2.0-4.9). In women aged 60 years and older no 
increase was observed over the whole study period (EAPC 0.55; 95% CI: -0.1 to 1.2). 
Nonetheless for this group a statistically significant increase was observed between 2004 
and 2010 (EAPC 5.0; 95% CI: 1.5–8.6).
Figure 2 shows somewhat higher age-specific incidence rates (per 100,000 women) in 
women aged 30–70 years during the years 2000–2010 compared to 1989–1999. For all 
other age categories incidence rates were nearly equal between the two periods.
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FIGO stage distribution did change especially between the time periods 1995–1999 and 
2000–2004; the percentage of patients with FIGO stage II decreased from 31% to 25% 
while FIGO stage III increased from 20% to 26%. The percentage of patients with FIGO 
stage I increased slightly over the years while the percentage of patients with FIGO stage 
IV remained stable. Joinpoint analyses of ESR per FIGO stage did not reveal significant 
changes in trends. However, a continuously significant increase was observed for stages I 
(EAPC 2.1%; 95% CI: 0.9–3.2) and III (EAPC 2.2%; 95% CI: 0.9–3.5), while unknown stage 
decreased annually with 5.7% (95% CI: -8.5 to -2.7). No statistically significant trends in ESR 
of FIGO stages II and IV were observed (Table 2). 
Over time more women were diagnosed or treated in a specialised centre; the percentage 
increased from 50% to 79% (p < 0.01) between 1995–1999 and 2005–2010 (Table 1).
Table 3 shows the 5-year relative survival rates (RSR). Survival of VSCC varies between 70% 
and 72% and did not change over time. Women aged below 60 years had a considerably 
higher 5-year RSR compared to women aged 60 and older.
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Figure 1  Incidence of vulvar squamous cell carcinoma (VSCC) (European age-standardised 
incidence rate (ESR) per 100.000 women in the Netherlands by age-category, 1989-2010.
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Table 2  Observed trends (EAPC and 95% CI) in incidence rates (ESR) of VSCC  by 
age-category and stage in the Netherlands (1989-2010). 
Period EAPC (95%CI) Period EAPC (95%CI)
Totala 1989-2002  -0.4 (-1.5 to 0.7) 2002-2010  5.0* (2.7 to 7.7)
Age at diagnosis
<60 1989-2010   3.5* (2.0 to 4.9)
≥60b 1989-2004  -0.6 (-1.4 to 0.3) 2004-2010  5.0* (1.5 to 8.6)
FIGO stagec
I 1989-2009   2.1* (0.9 to 3.2)
II 1989-2009  -0.2 (-1.3 to 0.9)
III 1989-2009   2.2* (0.9 to 3.5)
IV 1989-2009   1.3 (-0.6 to 3.3)
Unknown 1989-2009  -5.7* (-8.5 to -2.7)
Abbreviations: EAPC= Estimated annual percentage change. ESR= European age-standardised incidence rate.
a Total EAPC 1989-2010 1.4 (0.6 to 2.1). b≥60 EAPC 1989-2010 0.55 (-0.1 to 1.2). cData on FIGO stage are available 
until 2009. *The APC is significantly different from 0 (P <0.05).
Figure 2  Incidence of vulvar squamous cell carcinoma (VSCC) per 100.000 women in the 
Netherlands by age-category and period of diagnosis (1989-2010).
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Table 4 presents the results of the multivariable survival analyses, which did not show a 
significant difference in relative excess rate (RER) of dying between the four time periods. 
Women aged 60 and older and women diagnosed with higher FIGO stages show statistically 
significant higher RERs. In univariable survival analyses treatment in a specialised centre 
did not reveal a statistically significant RER of dying (RER 0.9; 95% CI: 0.7–1.1) (data not 
shown). After adjustment for several factors treatment in a specialised centre was a 
favourable prognostic factor for survival; women who were treated in a specialised centre 
showed a statistically lower RER compared to women who were not (RER: 0.6, 95% CI: 
0.5–0.8). Furthermore, a higher RER of dying was observed for women diagnosed between 
2005 and 2010 compared to women diagnosed between 2000 and 2004 when adjusted 
for age, stage and treatment in a specialised centre (RER 1.3; 95% CI: 1.1–1.5).
Discussion
During the last 20 years the incidence rate of VSCC has increased, especially from 2002 
onwards. Over the whole study period the increase was strongest in women aged below 
60, while incidence of VSCC in women aged 60 years and older started to increase from 
2004 onwards. Despite several changes in surgical treatment, such as the introduction 
of wide local excision, inguinofemoral lymphadenectomy via separate incisions and 
the sentinel node procedure, no changes in survival rates are observed during the last 
20 years.
Incidence rates of vulvar carcinoma increase with age. More than 50% of the patients are 
at least 70 years old at time of diagnosis. This study shows that the incidence is rising in 
patients 60 years and older, but only from 2004 onwards. We also show an increasing 
incidence in women aged below 60 years during the whole study period. Bodelon et al.2 
and Judson et al.4 reported a rising trend in age-adjusted incidence of vulvar tumours (SCC 
and non-SCC) present among women of all ages in the USA, not specifically in younger 
women. In contrast, an increasing incidence with a trend towards younger women has 
also been observed in Denmark.3 Another population-based study in the USA20 and a 
study from Norway5 reported a more stable incidence but these studies consider an 
earlier or smaller study period. In contrast to the slightly increasing incidence of VSCC, VIN 
shows a clear increasing trend in most population based studies. The incidence rates 
increased two- to fourfold in the USA,2, 4, 6 Norway 5 and Denmark.3 We did not have data 
concerning VIN available, however, van de Nieuwenhof et al.21 showed that the incidence 
of uVIN in the Netherlands has doubled and the incidence of dVIN increased nine fold 
from 1992 to 2005. Only Watson et al.20 reported no trend in incidence between 1973 and 
2000 in the US population. The increasing incidence of uVIN might have led to a rise in 
incidence in VSCC. The question is whether there is a ‘real’ rise of incidence or whether a 
part of the rise can be explained by increased detection. Only since a few years, there is 
consensus about the nomenclature; the use of terminology ‘uVIN’ and ‘dVIN’ was 
introduced by the International Society for the Study of Vulvovaginal Disease (ISSVD) in 
2004 and it took some years before the nomenclature was generally accepted, possibly 
resulting in difficult interpretation of the literature.22 Moreover, dVIN is clinically and histo-
pathologically a difficult entity to diagnose and may be extremely underreported because 
it may easily be mistaken for other histopathologic entities.23 Furthermore, vulvar premalignant 
lesions have gained more public awareness, and a more liberal use of biopsies may have 
led to the observed increase.
It is striking that particularly the incidence of VSCC in women below the age of 60 has 
increased. This increase might be related to human papilloma virus (HPV) infection,4, 5 that 
is associated with changing sexual habits and smoking. This may have caused a rise in 
Table 4  Relative excess risk (RER) of dying for patients with VSCC in the Netherlands. 
Multivariable model 
without treatment 
in specialised centre 
variable (1989-2010)
Multivariable model  
with treatment  
in specialised centre 
variable  (2000-2010)
  RER 95%CI RER 95%CI
Period of diagnosis     
1989-1994 1.00 Reference   
1995-1999 1.09 0.89-1.32   
2000-2004 0.98 0.81-1.20 1.00 Reference
2005-2010 1.13 0.94-1.36 1.27 1.06-1.54
Age at diagnosis     
<60 1.00 Reference 1.00 Reference
≥60 2.04 1.68-2.45 2.16 1.66-2.79
FIGO stagea     
I 1.00 Reference 1.00 Reference
II 2.13 1.58-2.88 1.95 1.27-3.00
III 6.14 4.71-8.00 6.62 4.61-9.51
IV 14.31 10.95-18.70 15.61 10.83-22.50
Unknown 5.30 3.51-8.01 10.05 5.97-16.91
Treatment in specialised centreb     
No   1.00 Reference
Yes   0.62 0.51-0.76
Abbreviation: RER= Relative Excess Risk.
aData on FIGO stage is available until 2009. bData on centre of treatment available since 1995.
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HPV-related uVIN resulting in a higher incidence of HPV-related SCCs. Though HPV 
(especially HPV 16 and 18) is associated with VSCC in only 20% of all cases, this type of 
VSCC mainly affects younger women.24, 25 Possibly, this can explain the rise in incidence of 
SCC in women below the age of 60. Details about HPV status of VSCCs were not present 
in the database, though unpublished data of 371 VSCCs at our clinic showed that 21 of 264 
(8%) SCCs of patients aged 60 years or older had adjacent uVIN in comparison with 40 of 
105 (38%) SCCs of patients younger than the age of 60.
Furthermore, HPV infections are more likely to develop into anogenital (pre)malignancies 
in women that are immune compromised, like in women after organ transplantation, HIV 
seropositivity or autoimmune disorders. For example in patients after kidney transplanta-
tion there is a 50-fold increased vulvar cancer risk.26, 27 Several studies show that 100% of 
the vulvar (pre)malignancies among renal transplant recipients are HPV-positive, 
compared to 20% in the general population.28 The group of immunocompromised 
women is growing, as newer immunosuppressive regimens have extended the life 
expectancy of allograft recipients and effective antiretroviral therapy prolonged the 
survival of HIV-infected people.29 Probably, HPV might explain a part of the increase; the 
recent introduction of HPV vaccination may result in a reduction of HPV-related VSCCs and 
uVIN, but this will take some decades.
Other risk factors associated with the development of VSCC are smoking, young age at 
first intercourse, larger number of sexual partners and genital warts.30, 31 However, these 
factors are all related to HPV infection. Looking at these risk factors in more detail, smoking 
seems to be strongly associated with VSCC and also a synergistic effect between smoking 
and HPV has been suggested. However, mainly current smoking and not former smoking 
seems to be associated with VSCC and an increased prevalence of HPV.30-32 In the 
Netherlands the percentage of female smokers was highest during the 1960s and 1970s 
and the percentage of female smokers did not increase during our study period. Therefore, 
smoking probably cannot explain the observed trends in our study.33 Furthermore, several 
studies in different countries show a tendency towards earlier sexual debut and more 
sexual partners during lifetime.34 In the Netherlands age at first intercourse decreased 
slightly from 17.7 to 17.3 years between 1995 and 2005 and remained stable until 2011.35 
The number of women with more than five sexual partners during lifetime increased 
considerably from 14% in 1991 to 35% in 2006.36 Finally several studies observed a 
substantial increase in the number of women who were diagnosed with genital warts 
during the last few decades.37, 38 Also in the Netherlands an increase in diagnosis during 
the last decade has been observed.39 Women with genital warts have a strongly elevated 
risk for developing HPV-related malignancies.
Increases in incidence rates of FIGO I and FIGO III were observed. An explanation for the 
increase in FIGO I is not clear; perhaps increased awareness among women and health 
professionals or changes in help-seeking behaviour have contributed to this increase. The 
increase in FIGO III might be related to the increasing use of SLND in the treatment of 
VSCC. Sentinel lymph node dissection with ultrastaging allows a more extensive pathology 
examination of the lymph nodes compared to lymph nodes removed during a complete 
lymphadenectomy, which can result in an increase in the detection of micrometastases.40, 
41 In a study of van der Zee et al.13 sentinel lymph nodes were examined by routine 
pathological examination and only when no metastatic sentinel nodes were found 
ultrastaging was performed. In total 163 positive nodes were detected of which 95 (58%) 
were detected by routine pathological examination and 68 (42%) by ultrastaging. This can 
also explain the shift from FIGO II to FIGO III seen between 1994–1999 and 2000–2004, as 
the SLND with ultrastaging was introduced in the Netherlands in 2000. So far, we did not 
find previous studies evaluating the impact of the implementation of SLDN on stage 
distribution at population-based level.
Furthermore, we studied the 5-year survival rate of VSCC patients, which was stable during 
the whole study period and was similar to rates reported in the literature5, 42 in spite of the 
changed surgical treatment during the last two decades. This was also observed by 
Ramanah et al.43 in women with late stage VSCC in the United States between 1988 and 
2007. The advice of treating women with SCC in a specialised oncology centre advocated 
by the Dutch national guidelines, has been followed; more patients have been treated in 
a specialised oncology centre, which was found to be an independent prognostic factor 
for survival in this study, which is in line with our earlier study.42
The multivariable survival analysis showed higher RERs for older women and for women 
with a higher stage at diagnosis, as expected. A remarkable finding is the higher RER for 
women diagnosed between 2005 and 2010 when compared to women diagnosed 
between 2000 and 2004 in the model including treatment in a specialised centre. In the 
model without treatment in a specialised centre which includes two earlier time periods 
we did not observe statistically significant RERs for period of diagnoses. We do not have 
an explanation for this higher RER, it would be interesting to evaluate whether a higher 
RER can still be observed when data of more recent years are available.
In this study we focused on trends in incidence and survival. Adding mortality data to this 
study could be valuable but unfortunately mortality rates are not available for VSCC 
specifically but only for all histologic subtypes together. However as the vast majority of 
all vulvar malignancies are SCCs this might provide an estimation for mortality rates of 
VSCC. Mortality rates of vulvar cancer in the Netherlands increased annually with 0.9% 
between 1989 and 2010 (95% CI: 0.0–1.9) but is still less than 1 per 100,000 women (ESR). 
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The increase is most prominent in the most recent years but no statistically significant 
changes in trends were observed (data not shown). A higher mortality rate could suggest 
a higher prevalence of risk factors for more aggressive tumours. However, the increase in 
mortality rate of vulvar malignancies is slighty lower than the increase in incidence rate of 
VSCC thus an increase in mortality seems to be due to the increased incidence.
This study presents trends in incidence and survival of VSCC in the Netherlands. Major 
strengths of this study are the nationwide population-based data and the long observation 
period of 22 years. Unfortunately, we did not have data about various risk factors of VSCC.
In conclusion, an increase in incidence in VSCC is observed with the strongest increase in 
younger patients. This might suggest HPV attribution to the observed increase. It is 
expected that incidence of vulvar malignancies will slightly decrease in a few decades due 
to the prophylactic HPV vaccination programme which started in 2009; however, this 
decrease will only be limited as only a minority of VSCC is caused by HPV. Finally, despite 
the introduction of more individualised treatment in VSCC with the aim to reduce 
morbidity, no changes in survival rate are observed during the last 20 years.
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It is generally accepted that there are two separate pathways leading to vulvar squamous 
cell carcinoma (VSCC): the HPV-related pathway with usual vulvar intra-epithelial neoplasia 
(VIN) as precursor and the more frequent pathway related to lichen sclerosus (LS) and 
differentiated VIN (dVIN). This thesis focuses on possibilities to improve clinical care for 
women with vulvar squamous (pre)malignancies in each step from diagnosis to treatment. 
In this chapter, these steps are discussed and future perspectives are suggested.
The role of dVIN and LS in the oncogenesis of vulvar squamous  
cell carcinoma
Patients with LS have a lifetime risk of 4-5% to develop VSCC. However, it still has to be 
clarified how VSCC exactly arises from LS and dVIN in the HPV-negative pathway. Evidence 
that dVIN is the true precursor lesion of HPV-negative VSCC is growing: although dVIN is 
rarely found as a solitary lesion, it is often found in revised biopsies previously diagnosed 
as LS in patients who later developed VSCC.1 A reason for the low number of published 
solitary dVIN lesions in studies might be explained by the idea that dVIN has a short intra- 
epithelial phase that rapidly progresses into VSCC. Difficulties with the clinical and 
 histopathological recognition of dVIN might be a second reason underlying the relative 
under- reporting of dVIN. Further evidence for dVIN being a precursor lesion can be found 
in DNA aneuploidy and p53 expression. Both occur in the earliest stages of malignant 
transformation and were found in dVIN lesions.2 
The field of (epi)genetics is largely unexplored in linking dVIN to VSCC as true precursor 
lesion. A first attempt to provide information about the genome-wide changes in vulvar 
(pre)malignancies has been made in chapter 2 by using a high resolution array. We found 
identical copy number alterations in dVIN and concurrent VSCC in the same patient, which 
indicates a clonal relationship. This finding should be further explored by expanding the 
number of samples. Retrieving enough DNA for analysis has turned out to be challenging. 
This is a known problem in vulvar lesions, especially when DNA is isolated from formalin- fixed 
paraffin-embedded blocks. In future research, somatic mutations and possible recurrent (driver) 
mutations should be identified in VSCC lesions using whole exome sequencing. 
Afterwards, these somatic mutations may be identified in patient- matched dVIN lesions 
using backtracking. To prove a clonal relationship, VSCC lesions should be compared with 
a histologically confirmed dVIN diagnosed several months before VSCC diagnosis, 
preferably at the same localisation within the vulva. An attempt to identify genetic 
alterations associated with malignant transformation was made in oral cancer research. 
Cervigne et al3 conducted an array comparative genomic hybridization analysis in 25 
samples from five patients; 20 progressive leukoplakia and five same-site carcinomas (with 
a time-interval of 2 to 9 years between the dysplasia and SCC). Specific genetic alterations 
were mapped in the progressive dysplasia, and in their corresponding oral SCCs in 70% 
of patients, indicating that these alterations may be associated with disease progression. 
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Considering dVIN as the early stage of HPV-negative VSCC on genetic grounds, the next 
question emerges how the precise relationships are between LS, dVIN and VSCC. Based 
on clinical and histopathological characteristics, it is impossible to predict which patients 
with LS will develop a VSCC and who will not.4 Although not all women with LS seem to 
have the same risk of malignancy,5 nowadays all patients with LS have at least yearly 
follow-up6-8 based on national and international guidelines. However, frequent follow-up 
results in more discomfort and high health care costs. Therefore, being able to predict the 
risk of LS to progress to VSCC might help to select patients who do need at least yearly 
follow-up. For patients at low risk of VSCC, a personalised follow-up schedule can be 
proposed, consisting of longer time intervals and/or patient-initiated contact in case of 
any changes. Possibly, results of (epi)genetic research might help finding differences 
between LS that progresses towards VSCC and LS that does not. However, there is limited 
literature on this topic. Furthermore, it might be of additional value to explore (epi)genetic 
differences between genital and extra-genital LS, because the latter never progresses to 
an invasive lesion. Until now, there is no explanation for this difference in progression 
towards a malignancy. Remarkably, dVIN or a comparable lesion is never found in 
extra-genital LS, which corresponds with the absence of development of malignancy. 
 Histopathologically, genital and extra-genital LS cannot easily be distinguished as classic 
histopathological features of LS are seen in both lesions. Only some minor features differ: 
genital LS contains less atrophy and more often a thin epidermis with a lymphocytic 
infiltrate in the suprabasal layer.9, 10 
In conclusion, we have gained genetic evidence which points in the direction that dVIN is 
the precursor lesion of VSCC, but the exact role still has to be further clarified. Identification of 
genetic alterations can help clarifying this role and might help predicting which patients 
with LS will progress towards VSCC and which do not. A challenge in the interpretation of 
results will be the concept of intra-tumour heterogeneity, i.e. different clones in one 
tumour.11 Another issue is the concept of field cancerisation; it is possible that several 
subtypes of LS with different malignant potentials are present within the vulvar area of 
one patient. This may explain why VSCC develops in some areas, whereas LS does not 
change for years in other areas.
How to improve the histopathological detection of dVIN?
Diagnosing vulvar (pre)malignancies is challenging with often a delay in diagnosis by 
patients as well as doctors.12, 13 As mentioned before, difficulties with the histopathological 
recognition of the lesion might contribute to the relative under-reporting of dVIN. In 
chapter 4, we have shown that the interobserver agreement was low, and even written 
guidelines with histological characteristics to diagnose dVIN did not increase agreement 
among general pathologists. The question is how the recognition can be improved. First, 
specimens with an unclear histopathological diagnosis and/or clinical suspicion for dVIN 
should be revised by a pathologist specialised in gynaecopathology. Second, international 
agreement on the histopathological criteria to diagnose dVIN is urgently needed. Recently, 
the ISSVD took a survey amongst experts in the field of diagnosing dVIN in order to reach 
consensus on the usefulness of histopathological criteria. The results of this survey will be 
presented on the next meeting of the ISSVD (2015 World Congress). Third, besides the use 
of histopathological criteria to diagnose dVIN, there may be a role for immunohisto-
chemical markers like MIB1, p16 and p53.14, 15 Last, when the clinical impression and histo-
pathological diagnosis disagree, the clinician should discuss the case with the pathologist. 
Not only the histopathological diagnosis of dVIN is difficult, but also the clinical diagnosis; 
in daily practice it is challenging to distinguish dVIN from LS. As a continuation of our 
research into making the histopathological diagnosis dVIN, it appears meaningful to 
investigate possibilities to establish criteria for the clinical diagnosis dVIN. DVIN appears 
mostly as a subtle erosive lesion in a background of LS, although there are various 
presentations. Improvements are already made by taking digital photos of the vulvar and 
perianal area as a standard routine, facilitating comparison of the anogenital area over 
time in much more detail. Another point of action to improve clinical recognition, is education 
of gynaecologists, dermatologists and pathologists in training because the subject ‘vulva’ 
is receiving very little attention during medical school and in educational programs. Therefore, 
we developed a digital education program for medical students which was recently 
introduced in their curriculum. Currently, we are developing an advanced version of the 
program for general practitioners, gynaecologists and dermatologists in training. A multi-
disciplinary approach for vulvar pathology is important to improve the understanding of 
vulvar disease, making correct diagnoses, and prescribing optimal treatment. Attending a 
multidisciplinary vulvar clinic is associated with improved quality of life of patients.16, 17 
Furthermore, centralisation of care that increases doctors’ exposure may be a factor of 
influence. Also patient factors may play a role.12, 13, 18 Improvements can be made by 
educating women about their vulvar disease in case of LS and/or VIN, and involve patients 
in the diagnostic and follow-up process. Regular self-examination of the skin should be 
advised6, 7 and patients with vulvar (pre)malignancies should be instructed to contact 
their doctors/nurses in case of complaints. 
What is the role of cytology in clinical care for patients with vulvar 
(pre)malignancies?
Cytology might be used as a triage instrument for LS patients with suspicious and unclear 
vulvar lesions and, as a consequence, may decrease the number of biopsies needed. 
In chapter 3, we investigated whether vulvar brush cytology was feasible in detecting LS, 
VIN and VSCC. In this study 26% of the smears were discarded because of poor cellularity. 
In the samples with sufficient cellularity, a sensitivity of 97% and a negative predictive 
value of 88% could be achieved when cytology was compared to histology. In the group 
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of LS without clinical suspicion of a premalignancy, performance of cytology was poor 
since the specificity was found to be low (50%).8 Although the results seem promising, 
histology remains the gold standard until the brushing technique is improved. The main 
problem of vulvar cytology is that cellularity is often too low. Besides, dVIN lesions mainly 
show dysplastic cells in the basal layer which might be difficult to reach with cytology. In 
order to overcome these problems, the most optimal brushing method with respect to 
cellularity should be addressed. Immunocytochemical markers like p16, mast cells and p53 
could improve the usefulness of cytology. Furthermore, there might be an additive role 
for epigenetic alterations in cytology material in the future. For example, in the cytological 
detection of CIN2 or worse, DNA methylation markers recently have been shown to be of 
value.19 Combined methylation marker analysis of two genes on HPV positive cervicovaginal 
lavage material has shown to be non-inferior to cytology triage in the detection of CIN2 
or worse. In vulvar lesions a limited number of studies are available on epigenetic 
changes;20 the true landscape of epigenetic alterations in VSCC still needs to be determined 
before the value in the diagnostic process can be set.
Organisation of care for patients with VSCC and individualisation  
of treatment
The evidence for the relation between high surgeon/hospital volume and improved 
patient outcome is increasing for certain tumour types like in breast cancer, lung cancer 
and colorectal cancer.21 It is well established that centralisation can improve patient 
outcome and limits health care costs, especially in low incidence cancers that require high 
complex treatment policies such as vulvar cancer. In chapter 6, we showed that the 
majority of patients with VSCC from the Eastern part of the Netherlands is treated in the 
specialised oncology unit of the Radboudumc nowadays. Treatment in a specialised 
oncology centre was found to be an independent prognostic factor for a favourable 
outcome. This finding suggests that we should continue centralisation as recommended 
by the Dutch Inspection of Healthcare (IGZ) and Dutch Society of Obstetrics and 
Gynaecology (NVOG).22, 23 High-volume centres may lead to better opportunities for mul-
tidisciplinary cooperation, research and education.24 In the Netherlands, the IGZ has 
established a minimum of 20 cases per centre per year for VSCC under the condition that 
surgeries should be performed by a fixed team of surgeons with supporting staff such as 
nurses and pathologist.25 However, caseload/experience of the individual surgeon mat be 
more important than the total caseload per centre. Structured multidisciplinary care may 
also increase the knowledge of vulvar diseases and improve diagnostic abilities to 
diagnose and recognise difficult vulvar lesions such as dVIN (chapter 4). A systematic 
review performed by Chowdhury et al21 in which 163 studies of 43 surgical procedures (of 
high and low incidence cancers) were analysed, showed that surgeon volume and 
specialisation are associated with improved patient outcome, while high hospital volume 
is of limited benefit. Currently, the only advice concerning surgeon-threshold values in the 
treatment of VSCC is that gynaecologic oncologists should perform at least 5-10 sentinel 
lymph node (SLN) dissections per year to meet the quality standards.26 However, it needs 
to be realised that this number of surgeries is chosen experience-based instead of 
evidence-based. To ensure that each individual gynaecological oncologist retains 
sufficient expertise for the treatment of vulvar cancer, further reduction in the number of 
specialised oncology centres for the treatment of vulvar cancer may be necessary.
Effort has been put in individualising treatment of patients with VSCC and in defining 
subgroups of patients that may be treated less radical. While patients were treated with 
standard radical vulvectomy with inguinofemeral lymphadenectomy in the past, the 
wide local excision and SLN procedure have acquired a permanent place in the treatment 
of early-stage vulvar cancer. Given the high local recurrence rate of VSCC, it is advantageous 
to avoid groin surgery as much as possible. In order to reduce the (slight) morbidity of the 
SLN procedure in cases where it is not necessary and to keep the option of SLN procedure 
for the future. Currently, the invasion depth of VSCC determines the need for groin surgery. 
Groin surgery is omitted in VSCCs with less than 1mm invasion depth (FIGO stage IA), 
based on the negligible risk of lymph node metastases from these tumours. Given our 
experience with clinical outcome of patients with VSCC and given the lack of scientific 
basis for the current measuring method, we questioned whether the invasion depth of 
VSCC measured by this current method is accurate in predicting the risk of lymph node 
metastases. In chapter 5 we showed that using an alternative measuring method, 19% of 
patients with originally FIGO stage IB tumour without node metastases were restaged to 
FIGO stage IA. As a consequence, these patients would have been treated without groin 
surgery with less treatment related morbidity. In a greater scope, 400 new VSCC patients 
are diagnosed in the Netherlands each year,27 approximately 200 of them have a FIGO 
stage IB tumour (based on the FIGO 2009 classification28). Using the alternative measuring 
method, nearly 40 (19% of 200) of these women will be down staged and will not need 
any groin surgery. One should keep in mind that missing a groin metastasis is nearly 
always fatal. Therefore, further studies with a higher number of patients should be 
performed before this alternative measuring method can be implemented. First, (inter)
national consensus should be reached between pathologists on how to determine the 
depth of invasion. Further research is needed to study the relation between depth of 
invasion and risk of lymph node metastases. Extra attention is warranted for difficult cases, 
for example when an ulcer is present. A national prospective trial in which the invasion 
depth is measured using both the alternative and conventional methods will provide 
information on the feasibility and accuracy of the alternative measuring method. One 
point that needs to be critically addressed is the clinical consequences of isolated tumour 
cells (ITC) in the SLN found after ultrastaging. In chapter 5, we found one patient that was 
restaged to FIGO stage 1A based on depth of invasion but with ITCsin the SLN. Up until 
now, the consequence of this finding is unknown. Further data are needed to learn about 
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the clinical significance of these isolated tumour cells and to establish their role in clinical 
decision making. How often are ITCs present and what is the consequence of ITCs with 
respect to disease specific survival? Results from GROINSS-V-I showed that ITCs were 
present in SLNs of 24 of 403 patients (6.2%). In an in-depth analysis, it was shown that the 
proportion of patients with non-SLN metastases increases with the size of the SLN 
metastasis. Only one of 24 patients with ITCs in the SLN had non-SLN metastases (4%). 
Furthermore, the prognosis of patients with a positive SLN based on ITC is similar to 
patients with a negative SLN,29, 30 although firm conclusions are difficult to draw because 
of the lack of power. Currently, GROINS-V-II is prospectively evaluating the safety of 
primary groin radiotherapy instead of full inguinofemoral lymphadenectomy for women 
with micrometastases (deposits ≤ 2 mm) detected in SLNs.31 Moreover, there is a 
registration of all patients with early-stage (4 cm or smaller lesions) VSCC without SLN 
metastases. As a consequence of the study design of GROINS-V-II we will not get additional 
information about the clinical value of ITCs because these patients will undergo additional 
radiotherapy. Though data from this study might be used to study the relation between 
depth of invasion and lymph node metastases. In contrast to VSCC, more is known about 
the role of ITCs in SLNs in breast cancer. Submicrometastases (metastases no larger than 
0.2mm) are classified as N0 and these patients are treated the same way as SLN-negative 
patients.32 However, results of SLNs of breast cancer patients are difficult to compare with 
results of VSCC patients. Firstly, because the pattern of metastasizing of breast cancer is 
completely different from VSCC. Secondly, because an increasing number of breast cancer 
patients receive (neo)adjuvant systemic therapy and/or locoregional radiation therapy, 
which may result in the eradication of possible ITCs. In order to further individualise the 
treatment of VSCC, a next GROINS-V study should be considered with an observational 
arm for patients with micrometastases (after finishing inclusion of patients in GROINS-V-II 
at the end of 2015). In theory, omitting treatment for possible ITCs might lead to groin 
metastases and thereby possibly to worse survival rates in a subset of patients. 
Trends in incidence, prevalence and prognosis of vulvar  
(pre)malignancies
Since 1989, all cancer patients in the Netherlands are registered in the database of the 
Netherlands Cancer Registry (NCR). This gives the opportunity to study trends in incidence, 
prevalence and survival of patients with various types of cancer in the population. The 
Dutch system is rather unique, as it has a high coverage rate decreasing the risk of selection 
bias. For recent years, more detailed data about either surgery/pathology results and 
co-morbidity are registered, making future population-based studies much more relevant. 
In chapter 6 and 7, we used the NCR database to study the incidence of VSCC and effect 
of changes in its treatment during the last two decades. Although earlier studies indicate 
that the incidence of VSCC is increasing, we were the first to confirm these results with our 
population-based data. An increase of absolute numbers of VSCC was expected because 
of the growing group of elderly. However, even after correction for changes in the 
composition of the population using the European age standardised incidence rates, an 
increasing incidence was observed especially in patients below the age of 60. Exact 
reasons for this increase are unclear. We hypothesize that this might be a consequence of 
an increased number of HPV infections as HPV-associated VSCCs mainly affect younger 
women. A study of the HPV VVAP study group33 confirmed our hypothesis by showing 
that the HPV-DNA detection and p16 over-expression in VSCC significantly increased 
between 1980-1999 and 2000-2011: HPV and p16 positivity was consistently higher 
amongst younger women. Analyses of antibody seroprevalence of high-risk HPV types 
between Nationwide Surveillance Studies from 1995-1996 and 2006-2007 in the 
Netherlands showed an increase in seropositivity in the general population.34 Besides, an 
increase in the incidence of genital warts35 and the proportion of HPV-positive samples is 
observed in other types of cancer such as anal cancer and oropharyngeal cancer.36, 37 The 
increasing contribution of HPV might be due to higher virulence of HPV but the 
involvement of multiple HPV types makes this hypothesis unlikely. Explanations for 
increased attribution of HPV in these cancers are probably linked to risk factors such as 
younger age at first intercourse, a higher number of sexual partners during lifetime, 
smoking habits and the higher number of immune-compromised patients due to more 
organ transplantations and broader indication area for the use of immunosuppressive 
medication for autoimmune disorders such as rheumatic diseases and inflammatory 
bowel diseases. Two commercial vaccines (Cervarix™ and Gardasil™) are available in many 
countries worldwide; these have been found to be highly efficient in preventing persistent 
HPV infections and lesions from the lower genital tract. It is expected that the incidence of 
HPV-associated VSCC and uVIN will decrease in a few decades as a consequence of the 
Dutch prophylactic HPV vaccination program with the use of Cervarix™ (HPV 16 and 18) for 
girls of 12 years old which started in 2009. With the use of the 9-valent HPV vaccine 
(includes types 6, 11, 16, 18, 31, 33, 45, 52 and 58), which is investigated at this time, it is 
expected that even a higher percentage of women can be prevented from infection and 
subsequent anogenital HPV-related diseases.38
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Summary
Vulvar squamous cell carcinoma (VSCC) is a rare gynaecological malignancy: in the 
Netherlands, 400 new cases are diagnosed yearly. There are two different types of VSCCs, 
both with their own associated premalignant lesions. The majority of VSCCs develop in 
elderly women and often arise in the background of lichen sclerosus (LS) or/and differentiated 
vulvar intraepithelial neoplasia (dVIN), but the exact oncogenesis is not known. HPV-related 
VSCCs are mainly seen in younger women and include the minority of VSCCs with usual VIN 
(uVIN) as precursor lesion. VSCC, VIN and LS have a large impact on quality of life in affected 
women and their partners. Lesions are sometimes difficult to diagnose by clinical doctors 
such as GPs, dermatologists, gynaecologists and pathologists because of the rarity of vulvar 
squamous (pre)malignancies with a  variety of symptoms. Proper and timely treatment is 
important in order to minimise the morbidity and mortality caused by these lesions. In this 
thesis, we describe opportunities for the further improvement of clinical care of women 
with vulvar (pre)malignancies with the focus on the diagnostic process and treatment. 
In chapter 1 an overview of the oncogenesis, clinical presentation, diagnostics and the 
treatment of VSCC, VIN and LS is given.
DVIN is assumed to be the precursor lesion of  the majority of HPV-unrelated VSCCs, but 
genetic evidence that supports this theory is currently lacking. In order to study the genetic 
relation between dVIN and VSCC, in chapter 2 we compared the copy number abnormalities 
between paired dVIN and VSCC lesions using a molecular inversion probe single-nucleotide 
polymorphism array on DNA isolated from these lesions. Copy number alterations (CNA) 
were identified in six VSCC samples, including loss of 8p (present in all cases), gain of 8q 
(present in 5/6 VSCCs), gain of 7p and loss of  18q (present in 4/6 VSCCs). Copy number 
profiles of three dVIN lesions passed quality thresholds, and CNAs were identified in one of 
them. In these patients at least three out of the 33 CNAs identified in the VSCC sample, were 
also detected in the paired dVIN sample, including a high-level amplification on chromosome 
11q23. These findings suggest that the two lesions originate from a single precursor in which 
additional alterations may have resulted in the development of VSCC. Furthermore, it 
supports the hypothesis that VSCC originates from dVIN precursor lesions. 
Taking a biopsy is a standard procedure to make the diagnosis in patients with suspicious 
premalignant vulvar lesions. The use of a less invasive diagnostic tool as triage instrument to 
determine whether biopsy is indeed necessary may improve patient comfort. In chapter 3 
we investigated whether vulvar brush cytology is feasible and may be used to detect (pre)
malignant vulvar lesions. We took 65 smears of normal skin, LS, uVIN, dVIN and VSCC with a 
vulvar brush and compared the findings with histology. Out of 65 smears, 17 (26%) were 
discarded because of poor cellularity. A total number of 28/29 (97%) smears with a histological 
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proven (pre)malignancy had a smear classified as ‘suspicious’ or ‘uncertain’. Cytology 
classified 11 smears as ‘non-suspicious’, of which 10 (91%) were indeed normal skin or LS. The 
accuracy for (pre)malignant lesions with the use of the brush showed a sensitivity of 97% 
and a negative predictive value of 88%. Based on these results we concluded that vulvar 
brush cytology is feasible and may be a first step in the development of a triage instrument 
to determine whether subsequent biopsy of a clinically suspicious lesion is necessary.
The histopathological diagnosis of dVIN is difficult, though no published data concerning 
the reproducibility of the diagnosis are available. In chapter 4, we evaluated the interobserver 
variability of the histopathological diagnosis of dVIN. Six pathologists, each with a different 
level of education, analysed haematoxylin and eosin-stained slides with LS and dVIN. The 
interobserver agreement varied between slight (kappa (κ)=0.08) and moderate (κ=0.54). In 
order to increase the agreement, guidelines with histological characteristics of dVIN were 
provided after which the pathologists were asked to analyse the slides again. The 
interobserver agreement increased slightly toward an agreement between slight (κ=-0.01) 
and substantial (κ=0.75). Only pathologists specialised in gynaecopathology reached a 
substantial agreement (κ=0.75). Therefore, it should be considered that specimens with an 
unclear diagnosis and/or clinical suspicion for dVIN should be revised by a pathologist 
specialised in gynaecopathology. Furthermore, we present five criteria (atypical mitosis, 
basal cell atypia, prominent nucleoli, dyskeratosis, elongation and anastomosis of rete ridges) 
that were ranked to be the most useful in diagnosing dVIN. When adhering to these criteria 
the diagnosis of dVIN might be made easier and earlier.
Depth of invasion is an important prognostic factor for patients with VSCC and guides the 
treatment plan; in case of a microinvasive tumour (depth of invasion ≤1mm, FIGO stage IA) 
patients are treated with a wide local excision only, while in case of a macroinvasive tumour 
(depth of invasion >1mm, FIGO stage IB or higher) patients will undergo treatment of the 
groins. It would be of advantage to prevent any surgical procedure of the groins to decrease 
treatment related morbidity, although one should be reluctant in omitting treatment of the 
groin because a recurrence in the groin is nearly always fatal. Based on the fact that there is 
no scientific basis for choosing the current measuring method, we hypothesised that an 
alternative method of measuring depth of invasion may give a better reflection of the 
prognosis of VSCC. In chapter 5 we aimed to identify the most optimal method of measuring 
the depth of invasion in relation to the lymph node status and survival in patients with VSCC. 
Depth of invasion of 148 VSCC cases was measured using the conventional (measures from 
the epithelial junction of the most superficial dermal papilla to the deepest point of tumour 
invasion) and an alternative (measures from the basement membrane of the deepest 
adjacent tumour-free rete ridge to the deepest point of invasion) method. The median 
depth of invasion decreased significantly with the use of the alternative method. This 
resulted into a change in FIGO stage from stage IB to IA in 19% of the patients. These 
down-staged patients developed less frequent recurrences (15.4% versus 39.3%) and had a 
higher disease specific survival (100% versus 84.2%) compared to the patients who remained 
FIGO stage IB. These patients might be treated without groin surgery resulting in less treat-
ment-related morbidity. Furthermore, a change in depth of invasion from 3.5 mm to 0.2 mm 
in one patient with FIGO stage IIIA (based on two isolated tumour cells in the sentinel lymph 
node (SLN)) was observed. Although the results are promising, the value of isolated tumour 
cells in a SLN and more prospective data on a higher number of patients using the alternative 
method of measuring are necessary. 
Centralisation of care for women with VSCC has been advocated by the national guidelines 
of the Dutch Society of Obstetrics and Gynaecology in 2000. In chapter 6, we determined 
whether this advice has been adapted and has led to improved survival. Therefore, all patient 
and tumour characteristics of women diagnosed with VSCC between 1989-1999 (n=198) 
and 2000-2008 (n=184) in the Eastern part of the Netherlands were retrieved from the pop-
ulation-based cancer registry and compared. The percentage of women treated in a 
specialised oncology centre increased from 62% to 93%. Overall, the 5-year relative survival 
improved slightly from 68% to 72%. After adjustment for age and stage, being treated in a 
specialised oncology centre was an independent prognostic factor for survival.
During recent decades the treatment of VSCC became less radical. Furthermore, previous 
studies showed an increase in the incidence of VIN. In order to study the effect of these 
changes, in chapter 7 the incidence and survival of patients with VSCC in the Netherlands 
were studied. Therefore, all patients with VSCC diagnosed between 1989 and 2010 (n=4614) 
were selected from the Dutch Cancer Registry. Data from these patients showed that the 
incidence of VSCC has increased significantly since 2002. In women aged <60 years incidence 
rates increased significantly during the whole study period, while in women aged >60 years 
only an increase was observed from 2004 onwards. Survival rates were not affected by the 
introduction of less radical surgery such as the introduction of a wide local excision with 
uni- or bilateral inguinofemoral lymphadenectomy via separate incisions and the SLN 
dissection, as the survival rates remained stable over time.
In chapter 8, clinical implications and future perspectives based on the results of the 
abovementioned studies are discussed with the aim to improve the care for women with 
vulvar squamous (pre)malignant lesions. 
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Samenvatting 
Het vulvacarcinoom is een zeldzame gynaecologische kanker en wordt in Nederland jaarlijks 
400 keer gediagnosticeerd. Er zijn twee typen vulvacarcinoom, beide met een ander voor-
loperstadium. De meerderheid van de vulvacarcinomen komt voor bij oudere vrouwen, 
vaak patiënten met Lichen Sclerosus (LS) of/en gedifferentieerde vulvaire intra-epitheliale 
neoplasie (dVIN). Hoe deze vorm van kanker exact ontstaat, is echter onbekend. Bij jongere 
vrouwen worden met name HPV-gerelateerde vulvacarcinomen gezien. Dit betreft een 
minderheid van de vulvacarcinomen. Het voorloperstadium van dit type vulvacarcinoom 
wordt usual VIN (uVIN) genoemd. Het vulvacarcinoom, VIN en LS hebben grote invloed op 
de kwaliteit van leven van patiënten en hun partners. De afwijkingen zijn soms moeilijk te 
diagnosticeren door de huisarts, dermatoloog, gynaecoloog en de patholoog vanwege 
hun zeldzaamheid en de variëteit aan symptomen. Om de ernst van de ziekte en de sterfte 
hieraan te minimaliseren is het belangrijk dat tijdig een adequate behandeling wordt gestart. 
In dit proefschrift worden verschillende mogelijkheden beschreven om de zorg voor 
vrouwen met een (voorloperstadium van het) vulvacarcinoom te verbeteren, met name 
gericht op de diagnostiek en het behandelproces.
In hoofdstuk 1 wordt een overzicht gegeven van de ontstaanswijze, het klinische beeld, de 
diagnostiek en behandeling van het vulvacarcinoom, VIN en LS. 
Over het algemeen wordt aangenomen dat dVIN het voorloperstadium van het niet- 
HPV-gerelateerde vulvacarcinoom is, maar genetisch bewijs dat deze theorie ondersteunt is 
er tot op heden niet. Met het doel de genetische relatie tussen dVIN en het vulvacarcinoom 
te bestuderen, hebben we in hoofdstuk 2 het DNA van dVIN vergeleken met het DNA van 
het vulvacarcinoom. Dit hebben we gedaan met behulp van een DNA-array waarmee 
chromosoom afwijkingen gevoelig in kaart kunnen worden gebracht. Het gaat  hierbij om 
numerieke afwijkingen (extra kopieën of verlies van chromosomen), of (kleine) deleties of 
amplificaties op een chromosoom. Aan de hand van de aan- of afwezigheid van deze 
afwijkingen konden we het genoom van het vulvacarcinoom van zes patiënten nauwkeurig 
in kaart brengen, en konden we een vergelijking maken met de afwijkingen die we 
aantroffen in de dVIN van dezelfde patiënt. Vulvacarcinomen hadden veelal een verlies van 
chromosoom 8p (de korte arm van chromosoom 8), een extra kopie van chromosoom 8q 
(de lange arm), en een verlies van 18q. Van drie dVIN-laesies waren de chromosoom profielen 
van voldoende kwaliteit voor beoordeling, waarbij in één sample afwijkingen werden 
geïdentificeerd. Hier vonden we het belangrijke bewijs waar we naar op zoek waren: drie 
chromosomale afwijkingen van het vulvacarcinoom troffen we ook aan in de dVIN, maar 
een groot aantal andere afwijkingen was afwezig.  Deze bevindingen suggereren dat dVIN 
en het vulvacarcinoom uit dezelfde voorlopercel voortkomen, waarbij de extra afwijkingen 
die werden gevonden in het vulvacarcinoom geleid kunnen hebben tot de verdere 
ontwikkeling van een vulvacarcinoom uit de dVIN. Dit ondersteunt de hypothese dat het 
vulvacarcinoom voortkomt uit dVIN. 
De standaardprocedure om te onderzoeken of vulvaire afwijkingen mogelijk een (voorlop-
erstadium van het) vulvacarcinoom zijn, is het nemen van een biopt. Het patiëntcomfort 
zou verbeterd worden als eerst een minder invasieve methode zou kunnen vaststellen of 
een biopt noodzakelijk is. In hoofdstuk 3 werd onderzocht of cytologie verkregen met een 
vulvabrush gebruikt zou kunnen worden om een (voorloperstadium van het) vulvacarcinoom 
te detecteren. We namen 65 cytologische uitstrijken van de normale huid, LS, uVIN, dVIN en 
het vulvacarcinoom met een vulvabrush en vergeleken de resultaten met histologie. Van de 
65 uitstrijken werden er 17 (26%) afgekeurd vanwege onvoldoende celopbrengst. In totaal 
werden 28 van de 29 (97%) uitstrijken met een histologisch bewezen vulvacarcinoom of 
voorloperstadium geclassificeerd als ‘verdacht’ of ‘mogelijk verdacht voor een (voorloper-
stadium van het) vulvacarcinoom. Elf uitstrijken werden als ‘niet verdacht’ geclassificeerd, 
waarvan 10 (91%) inderdaad van normale huid of LS waren genomen. Met cytologie 
verkregen via de vulvabrush kon een sensitiviteit van 97% en een negatief voorspellende 
waarde van 88% worden bereikt voor het diagnosticeren van een (voorloperstadium van 
het) vulvacarcinoom. Op basis van deze resultaten werd geconcludeerd dat cytologie 
afgenomen met een vulvabrush mogelijk een eerste stap is in de ontwikkeling van een 
triage- instrument om te bepalen of een biopt wel of niet nodig is.
Het stellen van de histopathologische diagnose dVIN is lastig en er zijn geen gepubliceerde 
data over de reproduceerbaarheid van de diagnose. In hoofdstuk 4 werd de variatie in de 
histopathologische diagnose van dVIN door verschillende pathologen (de interobserver 
variabiliteit) geëvalueerd. Zes pathologen (pathologen in opleiding, algemene pathologen 
en gespecialiseerde pathologen) analyseerden hematoxyline-eosine gekleurde coupes met 
LS en dVIN. De interobserver overeenkomst varieerde tussen ‘gering’ (kappa (κ)=0.08) en 
redelijk (κ=0.54). Om de overeenkomst te vergroten werden richtlijnen verstrekt met 
histologische karakteristieken van dVIN. De pathologen werd na bestudering hiervan 
gevraagd de coupes opnieuw te beoordelen. De interobserver overeenkomst verbeterde 
minimaal en varieerde tussen ‘slecht’ (κ=-0.01) en ‘voldoende tot goed’ (κ=0.75). Alleen 
pathologen gespecialiseerd in gynaecopathologie konden een overeenkomst bereiken die 
‘voldoende tot goed’ was (κ=0.75). Derhalve moet overwogen worden dat bij coupes met 
een onduidelijke diagnose en/of een klinische verdenking op dVIN een revisie door een 
gynaecopatholoog moet plaatsvinden. Naar aanleiding van dit onderzoek werden vijf 
criteria opgesteld (atypische mitosen, basale celatypie, prominente nucleoli, dyskeratose, 
verlenging en anastomose van de retelijsten) die het meest van belang zijn voor het 
diagnosticeren van dVIN. Wanneer men zich aan deze criteria houdt, kan de diagnose 
mogelijk makkelijker en eerder worden gesteld.
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Invasiediepte is een belangrijke voorspellende factor voor patiënten met een vulvacarcinoom 
en is leidend voor het behandelplan; in het geval van een microinvasieve tumor (invasiediepte 
≤1mm, FIGO stadium IA) worden patiënten alleen behandeld met een ruime lokale excisie, 
terwijl in het geval van een macroinvasieve tumor (invasiediepte >1mm, FIGO stadium IB of 
hoger) patiënten tevens een chirurgische ingreep in de liezen moeten ondergaan om 
lymfeklieren te verwijderen. Deze ingreep veroorzaakt vaak klachten, daarom zou het 
wenselijk zijn deze ingreep niet uit te hoeven voeren. Anderzijds kan in liesklieren die niet 
verwijderd zijn de kanker terugkeren, wat bijna altijd een fatale afloop kent. De gemeten 
invasiediepte bepaalt of een patiënt in de liezen geopereerd wordt of niet. Er zijn geen 
wetenschappelijke gronden voor de keuze van de huidige methode om de invasiediepte te 
meten. In hoofdstuk 5 onderzochten wij of een alternatieve methode om de invasiediepte 
te meten een betere weergave geeft van de prognose van vrouwen met een vulvacarcinoom. 
Het doel was om de optimale meetmethode te identificeren in relatie tot de lymfklierstatus 
en overleving van patiënten met een vulvacarcinoom. De invasiediepte van 148 vulvacarci-
nomen werd gemeten met de conventionele methode (gemeten vanaf de meest 
oppervlakkige dermale papil tot het diepste punt van de tumor) en met de alternatieve 
methode (gemeten van de diepste en meest dichtbij gelegen, tumorvrije papil tot het 
diepste punt van de tumor). De gemiddelde invasiediepte werd significant minder na het 
meten met de alternatieve methode. Hierdoor veranderde het FIGO-stadium bij 19% van de 
patiënten van stadium IB naar IA. Deze patiënten ontwikkelden minder frequent een recidief 
(39.3% versus 15.4%) en hadden een hogere ziektespecifieke overleving (84.2% versus 100%), 
vergeleken met patiënten bij wie het FIGO-stadium IB met de alternatieve methode niet 
veranderde. De groep patiënten waarbij het FIGO-stadium veranderde van IB naar IA zou 
mogelijk behandeld kunnen worden zonder liesklierchirurgie, met minder klachten als 
gevolg. Echter bij één patiënt met een FIGO stadium IIIA (gebaseerd op twee geïsoleerde 
tumorcellen in de schildwachtklier) werd een invasiediepte verandering van 3.5 mm naar 0.2 
mm gemeten. Ook al lijken de resultaten veelbelovend, de betekenis van geïsoleerde 
tumorcellen in de schildwachtklier moet verder worden uitgezocht. Eveneens is meer 
prospectieve data nodig van een grotere patiëntengroep waarbij gemeten is met de 
alternatieve meetmethode. 
De Nederlandse Vereniging voor Obstetrie en Gynaecologie adviseert sinds 2000 centralisatie 
van zorg voor vrouwen met een vulvacarcinoom. In hoofdstuk 6 werd bekeken of dit advies 
werd opgevolgd en of het heeft geleid tot een verbetering van de overleving. Hiervoor 
werden uit de Nederlandse Kankerregistratie patiëntgegevens en tumorkarakteristieken 
verkregen van alle vrouwen met een vulvacarcinoom in het oosten van Nederland, 
 gediagnosticeerd tussen 1989 en 1999 (n=198) en tussen 2000 en 2008 (n=184). Deze karak-
teristieken werden met elkaar vergeleken. Het percentage vrouwen dat behandeld was in 
een gespecialiseerd oncologisch centrum steeg van 62% naar 93%. De relatieve 5-jaars 
overleving steeg minimaal; van 68% naar 72%. Na correctie voor leeftijd en stadium bleek 
behandeling in een gespecialiseerd oncologisch centrum een onafhankelijke prognostische 
factor te zijn voor overleving.
De afgelopen decennia is de behandeling van het vulvacarcinoom minder radicaal 
geworden. Tevens lieten eerdere studies een stijging van het aantal gediagnosticeerde 
gevallen van VIN zien. In hoofdstuk 7 werd bestudeerd of dit effect heeft gehad op het 
aantal gediagnosticeerde gevallen van vulvacarcinoom en de overleving van patiënten met 
deze vorm van kanker. Alle patiënten met een vulvacarcinoom gediagnosticeerd tussen 
1989 en 2010 (n=4614) werden geselecteerd uit de Nederlandse Kankerregistratie. Data van 
deze patiënten lieten zien dat de incidentie van het vulvacarcinoom significant is toegenomen 
sinds 2002. Bij vrouwen onder de 60 jaar steeg de incidentie significant gedurende de 
gehele studieperiode, bij vrouwen boven de 60 jaar werd alleen een stijging vanaf 2004 
gezien. De overleving bleek stabiel gedurende de gehele tijdsperiode, ondanks de 
introductie van minder radicale chirurgie zoals de invoering van de ruime lokale excisie met 
liesklierchirurgie en de schildwachtklier procedure. 
In hoofdstuk 8 worden klinische implicaties en toekomstige perspectieven gebaseerd op 
de resultaten van bovengenoemde studies bediscussieerd, met als doel om de zorg voor 
vrouwen met een (voorloperstadium van het) vulvacarcinoom nog verder te verbeteren. 
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Dankwoord
Wat een heerlijk gevoel, het is klaar! Vanaf de start van mijn onderzoek volgden er vijf 
bewogen jaren. Ik heb veel geleerd, ben trots op wat we hebben bereikt en dankbaar. 
Een aantal belangrijke mensen in dit ‘laatste hoofdstuk’ van mijn proefschrift verdienen 
het om speciaal genoemd te worden. 
In het bijzonder mijn promotieteam prof. dr. Leon Massuger, dr. Joanne de Hullu en dr. 
Hans Bulten.
Leon Massuger, bedankt voor je begeleiding de afgelopen jaren. Jij bewaakte de grote 
lijnen en stuurde bij waar nodig. Jouw kritische en verhelderende blik zorgde ervoor 
dat het onderzoek alleen maar beter werd en er vele nieuwe ideeën ontstonden. Dank 
daarvoor! 
Joanne de Hullu, als ik iemand dankbaar ben, ben jij het. Je bent de motor achter vele 
goedlopende projecten, waaronder dat van mij. Je bent laagdrempelig benaderbaar, 
bent zeer efficiënt en lijkt voor elk probleem een oplossing te hebben. Daarnaast is er nog 
altijd tijd (of eigenlijk maak je tijd) voor een persoonlijk praatje. Bedankt dat je me wegwijs 
hebt gemaakt in de wereld van de vulvapathologie en het onderzoek. Ook bedankt voor 
je persoonlijke interesse en steun, dit waardeer ik enorm. Je bent een voorbeelddokter 
voor velen! 
Hans Bulten, als expertpatholoog was jij was de afgelopen jaren een onmisbaar persoon 
in mijn team. Tijd vinden om samen naar de vele coupes te kijken was af en toe een 
uitdaging met zo’n drukke agenda. Maar als die coupes onder je microscoop lagen, wist ik 
wel dat het goed was. Jouw kundigheid in en enthousiasme voor de gynaecopathologie 
zijn enorm. Bedankt voor het delen van die kennis en de tijd die je samen met mij achter 
de microscoop hebt doorgebracht!
Voor het tot stand komen van een aantal hoofdstukken was intensieve samenwerking 
met de afdeling pathologie essentieel. Medewerkers van het coupearchief en secretariaat, 
bedankt voor het opvragen en zoeken van de vele honderden coupes en blokjes. Peter 
Bult, Judith Vedder, Ilse van Engen-van Grunsven, Bart Sturm, Steven Bosch, Anne Wiersma, 
Annemarie Grefte, Harry Hollema en Leon van Kempen, bedankt voor alle input en 
prettige samenwerking gedurende de afgelopen jaren.
Dank aan het IKNL voor het aanleveren van gegevens en de dataverzameling. Speciale 
dank aan Katja Aben, Bart Kiemeney, Maaike van der Aa en Melinda Schuurman voor de 
vruchtbare samenwerking die heeft geleid tot twee hoofdstukken in dit proefschrift. 
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Roland Kuiper en Angela van Tilborg, zonder jullie input was het ‘geneticahoofdstuk’ 
nooit tot stand gekomen. Ik begaf me ver buiten mijn comfortzone, maar met jullie hulp 
is het goedgekomen. Ik heb veel van jullie geleerd, dank voor de fijne samenwerking. 
Mede-auteurs Dick Johan van Spronsen en Anneke Jonkman, dank voor jullie hulp en 
input!
De laatste jaren was ik onderdeel van de ‘vulvameisjes uit Nederland’, zoals we op menig 
congres werden genoemd. Irene, Hedwig, Kim en Floor, bedankt voor de samenwerking 
en de vele (gezellige) congressen samen. Michelle, succes met het voortzetten van de 
onderzoekslijn!
Lenno Dukel en Carine van der Vleuten, tijdens mijn werk op de vulvapoli heb ik veel 
geleerd van jullie expertise. Bedankt voor de fijne samenwerking! Lenno, naast mijn 
onderzoek waren wij samen ook druk met het ontwikkelen van de digitale module over 
vulvapathologie voor studenten geneeskunde. Ik zorgde voor de voortgang en grote 
lijnen, jij voor het finetunen. We waren een goed team samen en het resultaat mag er 
wezen, bedankt daarvoor!
Lieve bewoners van de tuin! We hebben een leuke tijd gehad; koffie drinken, taart eten, 
vrijdagmiddagborrel in Anneke, onderzoekersweekendjes en congressen. Voor een fijn 
werkklimaat zijn leuke collega’s essentieel. Ik had het geluk veel fijne collega’s te hebben 
de afgelopen jaren. Myrtille, Remko, Marjanka, Floor, Kim, Pleun, Sanne, Rafli, Marieke, 
Karin, Yvette, Sabine, Helga, Sophieke, Thijs, Bianca en nog vele anderen, bedankt voor de 
samenwerking en de vriendschappen die zijn ontstaan.
Dames van het secretariaat; Ans Bakker, Yvonne Lawson en Wilma Roest. Een praktisch 
probleem en jullie weten raad. Bedankt voor alle ondersteunende hulp! Poliverpleegkun-
digen Anja Benen en Karlijn Wijers, bedankt voor jullie hulp op de vulvapoli en andere 
onderzoeksgerelateerde ‘klusjes’.
Tijdens mijn werk op de (toenmalige) afdeling A20, op de vulvapoli, in de kantoortuin en 
in het ziekenhuis Rijnstate in Arnhem heb ik samengewerkt met vele gynaecologen en 
arts-assistenten. Dank voor de leuke samenwerking en jullie belangstelling voor mijn 
onderzoek. 
Lieve familie en vrienden. Om goed te kunnen functioneren zijn jullie van essentieel 
belang. Bedankt voor jullie interesse en steun de afgelopen jaren op wat voor manier dan 
ook. 
Lieve vriendinnetjes van het eerste uur, Anne-will, Ellen, Fanny en Yvonne. Bedankt voor 
jullie humor, creativiteit en adviezen. Ik waardeer onze vriendschappen enorm en hoop 
dat ze nog lang mogen duren. 
‘Vrienden van Dennis’, al jaren delen we lief en leed. Bedankt voor de vele leuke momenten 
samen die ervoor zorgden dat ik even kon ontspannen om daarna weer met energie aan 
het werk te kunnen gaan. Judith en Roy, dank voor het geven van de goede adviezen 
onder het genot van een wijntje of de zoveelste barbecue.
Lieve Maud, Anita en Anja, wat ben ik blij met jullie als vriendinnen! Het is fijn om bij jullie 
te kunnen ventileren. Zeker omdat we elkaar als de beste begrijpen, aangezien we als 
jonge vrouwelijke dokters zowel aan onze professionele carrière maar ook aan ons 
privéleven willen werken. Lieve Anja, met je positieve en relativerende blik help je me met 
elk probleem een stapje verder. Bedankt dat je er altijd voor me bent. Ik ben blij dat je als 
paranimf naast me wil staan!
Lieve Kim, paranimf. Soms kom je mensen tegen waarvan het lijkt alsof je ze al jaren kent. 
Jij bent zo iemand. Dank dat je de afgelopen jaren voor me hebt klaargestaan, op 
werkgebied maar vooral ook als vriendin.
Lieve schoonfamilie. Lieve broers en zussen; Kelly, Suzan en Reinald, Kristel en Mathijs, 
Thomas. Familie hebben we allemaal hoog in het vaandel staan en daar ben ik blij om. Ik 
haal enorm veel energie uit onze gesprekken, uitjes met onze kinderen en de ontelbare 
keren dat we Kolonisten van Catan speelden. Bedankt dat jullie altijd voor ons klaar staan, 
jullie zijn me lief!
Lieve pap en mam. Zonder jullie onvoorwaardelijke steun en goede raad was ik nooit zo 
ver gekomen. Talloze keren hebben jullie op de kinderen gepast, omdat ik weer aan mijn 
proefschrift moest werken. Jullie zijn er altijd voor ons en geen vraag is te veel, bedankt! 
Ik hou van jullie. 
Allerliefste Sofie en Lars. Jullie zijn heerlijke kinderen. Niets is vanzelfsprekend, dus ik geniet 
ieder moment van jullie. Allerliefste Dennis. Zonder jou was het niet gelukt om dit proefschrift 
af te ronden. Jij zorgde voor de broodnodige ontspanning en mental support. Je hield het 
huishouden draaiende als ik voor de zoveelste keer achter de computer kroop. Dank voor 
je geduld, steun en liefde, je bent onmisbaar.
Bedankt!
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Loes van den Einden werd op 5 augustus 1982 geboren in het Brabantse Deurne. In 2001 
behaalde zij daar haar vwo-diploma aan het Peelland College, waarna zij geneeskunde 
ging studeren. Zij behaalde haar propedeuse aan het Leids Universitair Medisch Centrum, 
waarna zij haar studie vervolgde aan de Radboud Universiteit Nijmegen. Tijdens haar 
studie ging zij voor een ontwikkelingsstage naar het Misikhu Mission Hospital in Kenia en 
sloot zij haar coschappen af met een stage in Semarang, Indonesië. In 2008 behaalde zij 
haar doctoraalexamen. Na kortdurend op de spoedeisende hulp van het Jeroen Bosch 
Ziekenhuis gewerkt te hebben, startte zij in 2009 als arts-assistent gynaecologie in het 
Radboudumc. Na een jaar verliet zij de kliniek om te starten met haar promotieonderzoek 
onder leiding van promotor prof. dr. Leon Massuger en copromotoren dr. Joanne de Hullu 
en dr. Hans Bulten. Naast haar onderzoek was zij actief betrokken bij het ontwikkelen van 
digitaal onderwijs over vulvapathologie voor studenten geneeskunde in samenwerking 
met Lenno Dukel. Tevens was zij werkzaam als arts op de vulvapoli. Na het afronden van 
haar promotieonderzoek werkte zij vanaf 2014 als arts-assistent verloskunde en 
gynaecologie in het Rijnstate Ziekenhuis in Arnhem. Ondanks haar enthousiasme voor 
het vak gynaecologie, besloot Loes het roer om te gooien. Zij vond haar nieuwe uitdaging 
in het huisartsenvak en is vanaf september 2015 huisarts in opleiding in het cluster 
Nijmegen. Loes is getrouwd met Dennis Baens en is moeder van Sofie en Lars.
